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ABSTRACT 
JONATHAN D. URBAN: Dopamine D2 receptor functional selectivity as a mechanism of 
atypical antipsychotic drug action  
(Under the direction of Richard B. Mailman) 
 
This project sought to understand how novel receptor mechanisms might play a 
role in the atypicality of antipsychotic drugs (APDs). The specific focus was on D2 
receptor “functional selectivity,” the phenomenon by which some ligands selectively 
activate D2-mediated functional pathways. The first studies examined the effects of a 
group of chemically diverse atypical antipsychotic drugs on the D2L-mediated activation 
of MAP kinase phosphorylation and of arachidonic acid release. These studies indicate 
that only aripiprazole showed partial intrinsic activity at both functional endpoints, 
whereas all other atypicals were neutral antagonists. Further study of aripiprazole 
demonstrated unique D2 binding characteristics and no capacity to initiate D2 receptor 
internalization. Next, site-directed mutagenesis of three transmembrane 5 (TM 5) helix 
serines (i.e., S5.42A, S5.43A, and S5.46A) was used to study how these residues affected 
the actions of aripiprazole and other typical partial D2 agonists. These residues play key 
roles in catecholamine-receptor binding and activity at multiple D2-mediated pathways in 
CHO cells, and my data illustrate that non-catechols with partial intrinsic activity are 
uniquely regulated by these serines compared to classical agonists. Finally, a D2L receptor 
transfected-dopaminergic cell line (N27-D2L) was examined as an in vitro dopaminergic 
neuronal model. The goal was to use this cell line to study atypical APDs for 
characterization of their intrinsic activity at D2L-mediated functions (e.g., dopamine 
iv 
uptake and release) at which certain drugs have differential effects in situ. Although these 
cells initially appeared to be promising dopaminergic models (i.e., they synthesized 
dopamine, expressed the dopamine transporter, and the transfected D2L receptors coupled 
to adenylate cyclase), their utility was limited by the fact that dopamine uptake and 
release, as well as D2L receptor internalization, were not measurable using the 
methodologies we employed. My data support the hypothesis that at least one major drug 
(aripiprazole) has unique D2L receptor binding and activating properties that cannot be 
accommodated by traditional pharmacological theory. In addition, aripiprazole and other 
functionally selective compounds can be important probes to further our understanding of 
ligand-receptor interactions, and how this leads to functional changes. This work also 
suggests reexamination of some current philosophies for rational drug discovery. 
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CHAPTER 1. BACKGROUND AND SCOPE OF THIS WORK  
SCHIZOPHRENIA  
What is schizophrenia? 
Dementia praecox, or premature dementia, was a term first coined by Benedict-
Augustin Morel (Morel, 1860), and later used diagnostically by Emil Kraepelin 
(Kraepelin, 1893) to describe a mental illness that presented in young adults. At its most 
basic level this condition was defined by a rapid degeneration in cognitive function, 
although as the research of Kraepelin progressed so evolved his classification of this 
disease. Thus, dementia praecox became a major heading of mental illness classification 
under whose title many sub-categories took shape to incorporate more subtle differences 
demonstrated within this type of mental illness (Ban, 2004).  
In 1908 Eugene Bleuler replaced dementia praecox with the term ‘schizophrenia’ 
(literally meaning ‘split mind’) in an effort to describe more suitably the psychotic 
condition comprised of both psychoses and disordered affects (Bleuler, 1908). He 
described the fundamental symptoms of schizophrenia as loosening of associations, 
inappropriate affect, ambivalence and autism. These became the primary diagnostic 
criteria used by psychiatrists in the first half of the twentieth century (Ban, 2004). Since 
the 1950s, these criteria have been modified as more has been understood about the 
disease. Today the complex symptomology intrinsic to this disease has led many to 
believe that rather than being one diagnosable disorder, schizophrenia probably represents 
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a number of distinct neurological conditions (Kirkpatrick et al., 2001). Although 
originally conceptualized as a single clinical entity, it has become clear that there are 
several symptom domains. These include positive (paranoid delusions and 
hallucinations), negative (apathy, amotivation, withdrawal, and decreased socio-
occupational functioning), and cognitive (characterized by deficits in memory, attention 
and executive function) domains. 
As mentioned previously, one of the characteristics of schizophrenia is that 
patients generally present symptoms early on in life, usually between late adolescence 
and early stages of adulthood. Furthermore, it was observed that men tended to develop 
the disease earlier than woman, and were inclined to digress into a more severe form of 
the disease than women, although between the sexes schizophrenia presents itself in 
reasonably equal numbers (Hafner and Nowotny, 1995; Usall et al., 2001).  
During the nineteenth and early twentieth centuries, mental institutions were often 
establishments where many patients were incarcerated for the remainder of their lives, 
reflecting both the lack of treatments, and societal attitudes toward the mentally ill. 
Practices in many mental hospitals included caging, incarceration without clothing, 
painful restraints, as well as simple neglect. This eventually spurred a social movement 
that called for drastic reformation of mental institutions on a national level. Dorothea Dix 
is widely considered to have founded this movement in the late nineteenth century 
(Harshey-Meade, 2006). Yet even this movement offered little hope to patients because of 
an inadequate appreciation about the etiology of many of the serious psychiatric illnesses, 
coupled with a lack of effective treatments. Indeed, one of the only ways to control 
symptoms was sedation to the point of near anesthesia. As early advances were made in 
 3 
the neurosciences, some of the procedures that were introduced (like electrical shock 
treatment and psychosurgery) were often as horrific as the early approaches they 
replaced. It is interesting to note, however, that electrical shock treatment and 
psychosurgery have matured into extremely useful and effective treatments for specific 
conditions (e.g., electroconvulsive therapy for intractable depression and deep brain 
stimulation for Parkinson’s disease and extreme obsessive compulsive behavior).  
In the early 1950s just prior to the accidental discovery of the first phenothiazine 
antipsychotics, the number of patients admitted to state mental hospitals in the United 
States peaked at about 550,000; twenty-five years later (see Figure 1.1) that number had 
plummeted to just above 100,000 (Burke and Regier, 1987). Thus, although the number of 
patient care episodes concomitantly increased from 1.7 million to 6.9 million over this 
period of time, the discovery and development of relatively effective pharmacotherapies 
played a crucial role in decreasing the number of institutionalized patients, and improving 
the quality of life of many (Burke and Regier, 1987).  
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Figure 1.1. Institutionalized mentally ill people in the United States in the early and mid- 
twentieth century.(NIMH 1969)  
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Biological aspects of schizophrenia 
Prior to the modern era of genetics and molecular neurobiology, the primary 
approach for understanding schizophrenia was through neuropathological studies. The 
clinical course of the disease was observed to be progressive in many cases, and it was 
naturally assumed that, like other progressive neurological diseases, schizophrenia would 
demonstrate distinct neuropathology. There had been reports that there was ventricular 
enlargement and a slight but significant reduction in grey matter in a few regions of the 
brain (e.g. the hippocampus, amygdala, parahippocampus, frontal cortex and thalamus), 
but it appears that these are the only gross neurophysiological irregularities illustrated in 
schizophrenics (Harrison, 1999). Furthermore, these observations are confounded by a 
number of factors. One fact is that such neuropathologies are similar to those found in 
chronic alcoholics. Since those suffering from schizophrenia are four times more likely to 
develop a dependency on alcohol than the general population, it is not clear whether the 
pathology is associated with schizophrenia or the result of excessive alcohol consumption 
(Harper and Kril, 1990; Halliday, 2001). Other reports describe a significant loss of 
neuropil, tyrosine hydroxylase immunostaining, and axonal innervation within prefrontal 
cortical dopaminergic tracts in post-mortem schizophrenic brains (Selemon et al., 1995; 
Akil et al., 1999; Akil et al., 2000), observations which have been linked to the cognitive 
symptoms of the disease (Goldman-Rakic et al., 2004). There are even more recent 
reports that suggest that the more subtle restructuring mentioned above may be due to a 
controlled apoptotic process that affects axonal and dendritic processes and synapses 
specifically, without inducing major neuronal death (Jarskog et al., 2005). 
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Another issue that has confounded the research of defining distinct 
neuropathologies of schizophrenia is the observation that many antipsychotic drugs 
(APDs) alone can induce structural changes in the brain. Thus, a key concern is whether 
or not the observed neuropathology was primarily the result of the illness or the 
treatment. It has been reported that long term treatment with APDs can cause substantial 
changes in D2 receptor physiology. For example, the expression of these drug targets 
becomes up-regulated over an extended period of exposure to the antagonists (Burt et al., 
1977; Silvestri et al., 2000). It is also clear that treatment with typical APDs contributes 
to caudate putamen volume increases (Chakos et al., 1994; Keshavan et al., 1994), 
whereas it appears that atypical APD treatment decreases striatal volume (Chakos et al., 
1995; Corson et al., 1999) and even reverses the increase in volume associated with 
typical APDs (Scheepers et al., 2001), although such observations were not always 
consistent (Staal et al., 2000).  
A focus on drug-naïve individuals in the initial stages of the disease, including 
children demonstrating psychoses as well as adolescents and young adults experiencing 
“first episode” schizophrenia symptoms (Lieberman, 1999) has helped efforts to separate 
drug-induced versus psychoses-induced structural changes. By employing neuroimaging 
techniques such as magnetic resonance imaging (MRI), research on “first episode” 
subjects confirmed the presence of many of the neuropathologies observed in postmortem 
studies (reviewed in Jarskog et al., 2005).  
Animal models have been employed to unravel the problem of long term 
neuropathological effects of APD use and the long term consequences of the illness on 
brain structure. Although there are obvious limitations to the human correlations that can 
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be made from such studies (because of species differences in metabolism rates and brain 
structure), what seems to be clear from these models is that drug type and dose play an 
important role in determining potential changes in certain aspects of brain morphology 
(Andersson et al., 2002). What has yet to be determined is how some of these changes 
(such as striatal hypertrophy) affect APD efficacy and the clinical course of schizophrenia 
(Andersson et al., 2002). Investigating these issues also promises to elucidate why 
chronic administration of APD is required before optimal therapeutic responses are 
realized. 
Genetic aspects of schizophrenia 
With the advent of the modern era of genetics and molecular biology, a major 
worldwide research goal has been to determine if specific genes were responsible for 
some or all of schizophrenia. Much of this work has focused on genes related to 
dopamine neurotransmission, or to systems that communicate with dopamine systems. 
Among the genes that have been linked to the disease are RGS4 [variability of expression 
(Mirnics et al., 2001)], polymorphisms of dopamine inactivating genes such as 
monoamine oxidase and catechol-O-methyltransferase (COMT) (Hahn and Blakely, 2002; 
Craddock et al., 2005), D3 receptor homozygosity (Crocq et al., 1992), tyrosine 
hydroxylase (Meloni et al., 1995), amine transporters (Golimbet et al., 2003), among 
many others. In many cases, attempts to replicate genetic linkages to schizophrenia fail to 
reproduce the initial findings (Prasad et al., 2002). There are a few genes, though, that 
appear in these studies more consistently than others. A high rate of dopamine 
metabolism within the prefrontal cortex has been associated with abnormal cognitive and 
executive function, deficits also observed in schizophrenics. The Val108/158Met COMT 
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gene is an unstable variant that is much less efficient at metabolizing dopamine (Lotta et 
al., 1995). Since both COMT genes are codominant, a spectrum of dopamine metabolism 
efficiency in the prefrontal cortex is possible, such that individuals homozygous for the 
Met gene variant will have sustained levels of dopamine in this region of the brain 
(Weinshilboum et al., 1999). In fact, Egan et al. (2001) found that families in which 
schizophrenia was manifested were more likely to express the Val allele than the Met, 
and therefore concluded that the Val COMT allele represented a risk factor for 
schizophrenia. 
There have been a number of polymorphisms discovered within the genes of 
dopamine receptors, although most of these gene alterations have not been convincingly 
linked to any phenotype of schizophrenia. There are a few polymorphisms, such as the 
BalI polymorphism in the D3 receptor and the Ser311/Cys311 alteration found in D2 
receptors, that do appear to have some significant association with the disease (Crocq et 
al., 1992; Shaikh et al., 1994). There has been a more concerted focus, however, on how 
polymorphisms of the D2-like receptor family may play a role in the variability of APD 
response, because these gene products represent the primary target for many of the APDs 
currently in use. More specifically, the -141C insertion in the promoter region of the D2 
receptor, a single nucleotide polymorphism (SNP) that is not associated with the 
occurrence of schizophrenia (Glatt et al., 2004), has been associated with a shorter 
response time to some APDs (Scharfetter, 2004; Lencz et al., 2006). Also, the Ser9 versus 
Gly9 polymorphisms of the D3 receptor are related to more favorable responses to typical 
versus atypical APDs, respectively (Scharfetter, 2004). Many of these studies involved 
small sample populations and will require more thorough research before definite 
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correlations can be made. It is reasonable, however, that polymorphisms that affect the 
structure of a receptor can have consequences on drug response, as Roth’s lab has 
illustrated to be the case with 5-HT2A receptor polymorphisms and APD binding and 
functional traits in vitro (Davies et al., 2006). 
There is some evidence that suggest that a complex genetic interaction alone might 
be playing a role in the etiology of schizophrenia (Lewis et al., 2003), but the more 
common view is that most cases of schizophrenia involve a complex interaction of many 
genes that may lead to sensitivity to environmental factors, especially during development 
(Maki et al., 2005). It appears certain, therefore, that this complex disorder will not have 
a simple molecular etiology.  
ANTIPSYCHOTIC DRUGS AND THE DOPAMINE HYPOTHESIS 
Therapy in the pre-pharmacological era 
Until the mid 20th century, treatment of people with severe psychoses involved 
confinement, restraint, and/or sedation to the point of near-anesthesia. Indeed, the 
medical frustration with the disorder led to trials with many different therapeutic 
approaches, some of which today would be considered barbaric. The most primitive of 
these was the technique of prefrontal lobotomy (or leukotomy), in which cores were made 
deep into the white matter of the frontal lobes in order to sever the neural fibers 
connecting the lobes (Kucharski, 1984). The technique, for which Egas Moniz won the 
1949 Nobel Prize in Medicine and Physiology, was modified and popularized in the 
United States by the early 1940’s by Walter Freeman and James Watts (Jasper, 1995; 
Feldman and Goodrich, 2001). The “improved” lobotomy technique gained access to the 
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frontal lobe via an upward puncture of the orbital roof through the tear duct, using an ice 
pick-like tool. It was used on patients with a variety of psychiatric illnesses, and led to a 
range of clinical outcomes. Despite a few, highly publicized successes, there was the 
development of seizures, fatal hemorrhaging, and severe frontal lobe syndrome, the latter 
of which most notably was suffered by Rosemary Kennedy, the sister of President John F. 
Kennedy (Feldman and Goodrich, 2001). 
Although used primarily for intractable depression, electroconvulsive therapy 
(ECT) was another approach used in attempts to treat some of the symptoms of 
schizophrenia. This method, in which an electrical shock is applied to the patient to 
induce a temporary seizure, was commonly used in the 1940s and 1950s for a variety of 
psychiatric disorders. Using the early procedures, ECT produced a range of side effects, 
from extended memory loss to fractures (Anon.1985). Such controversial treatment 
methods ultimately generated serious examination into ethical considerations, as well as 
the informed consent of patients (Holden, 1985). It was also from this framework of 
desperation that the first major medical advance occurred in the early 1950’s.  
Chlorpromazine and the pharmacological revolution 
Chlorpromazine was the first of a long line of antipsychotic drugs introduced into 
the psychiatric field that ultimately revolutionized the treatment options for schizophrenic 
patients. Initially chlorpromazine was studied for potential sedative, anesthetic and 
antiemetic properties. Observations that chlorpromazine had unique CNS effects led to 
clinical trials in which psychiatrists administered the compound to patients that had been 
hospitalized with erratic behaviors (reviewed by Shen, 1999). These initial clinical trials 
demonstrated that chlorpromazine had promising antipsychotic properties that made it a 
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superior psychiatric treatment option than the pharmacotherapies of the time (which 
generally consisted of a range of sedatives). Thus, chlorpromazine was found to improve 
the mental functioning of some patients (“miraculous” in that the therapeutic effects were 
delayed and there was no mechanism of action known at the time), and with continued 
use the drug became more effective while not inducing the drug-patient dependency 
associated with the sedatives that they replaced (Barondes, 2003).  
The pharmaceutical industry built upon the success of chlorpromazine, and about a 
decade after the introduction of chlorpromazine there was rapid development and 
proliferation of other phenothiazine derivatives (e.g. thioridazine and fluphenazine). 
Around the same time, additional antipsychotics with chemical structures ranging from 
phenothiazine-related (e.g., thioxanthenes) to structurally unique (e.g., butyrophenones) 
became available. These early APDs are today referred to as ‘typical’ because they share 
many pharmacological properties. Many of these agents are still in use today. In 
particular, the butyrophenone derivative haloperidol (marketed as Haldol®) has been one 
of the most widely used of the typical APDs. As was mentioned previously, it was due to 
the advent of this antipsychotic armamentarium that led to a revolution in mental institute 
conditions and treatment approaches as many patients were now able to function outside 
the walls of psychiatric wards. 
Dopamine and antipsychotic drug action 
The dramatic medical impact of APDs led many researchers to attempt to 
understand the mechanism(s) of action of these drugs. This research became centralized 
around dopamine, first postulated by the Swedish researcher Arvid Carlsson to be a 
neurotransmitter integral to the ability to control movement. Carlsson would later receive 
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the 2000 Nobel Prize in Physiology or Medicine for this discovery and his contribution to 
our present understanding of the role of dopamine in Parkinson’s disease and 
schizophrenia.  
There are three major dopaminergic pathways that innervate the forebrain (see 
Figure 1.2). Arising from the substantia nigra and ventral tegmental area, dopamine 
containing neurons project via the mesostriatal pathway to innervate the striatum (caudate 
and putamen); via the mesolimbic pathway to innervate the nucleus accumbens, 
amygdala, and olfactory tubercle; and via the mesocortical pathway to innervate the 
prefrontal cortex. Dopamine neurotransmission in the basal ganglia plays a critical role in 
initiation and control of movement, and is important in Parkinson’s disease. The receptor 
and signaling mechanisms related to dopamine neurotransmission are inherent to this 
dissertation, and are discussed in detail below [see Dopamine receptor signaling 
beginning on page 16).  
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Figure 1.2. Major dopamine neuronal pathways in the human brain. 
Therapeutic limitations and neurotoxicity: the dark side of antipsychotic drugs 
Although the typical APDs did prove to be beneficial to many patients, numerous 
observations over the years indicated that the drugs were fraught with limitations both in 
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efficacy and side effect profile. Clinicians observed that the typical APDs failed to 
effectively reduce positive symptoms in 30-60% of diagnosed patients, while having no 
effect on negative symptoms and cognitive deficits (Iqbal et al., 2003). More troubling, 
however, were the movement disorders that were linked to the administration of these 
drugs. Although not much was understood about the mechanism of action of these 
compounds, a number of extrapyramidal side effects (EPS), such as parkinsonism, 
akathisia and dystonic reactions, were observed in patients on high doses of the drug and 
early on in the treatment regimen. The first clue into their mechanism of action was 
reported by Carlsson and Lindqvist (Carlsson and Lindqvist, 1963), who demonstrated in 
animals that exposure to haloperidol and chlorpromazine increased COMT-derived 
metabolites of dopamine and epinephrine. It was surmised that the increase in aminergic 
metabolites was due to the neuroleptics blocking catecholaminergic receptor activity that 
resulted in an increase in tyrosine hydroxylase activity (Carlsson and Lindqvist, 1963; 
Anden et al., 1970). This helped lay the foundation for further APD development, as 
researchers utilized dopaminergic rodent models in order to select for compounds able to 
block such biological endpoints as amphetamine-induced stereotypies and apomorphine-
induced vomiting (for review see Ban, 2004). The first direct evidence for 
antidopaminergic actions of the APDs was biochemical evidence (Kebabian et al., 1972), 
and shortly thereafter it was discovered that these compounds were exerting these 
antagonistic effects directly by blocking dopamine receptors (Creese et al., 1976; Seeman 
et al., 1976). Indeed, it was demonstrated that many of the APDs of the time were high 
affinity antagonists of what are now called D2-like receptors (Kebabian and Calne, 1979) 
(vide infra). Further research suggested that the EPS associated with these drugs were 
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probably due to their ability to significantly antagonize dopaminergic activity in the basal 
ganglia, whereas the efficacy of these drugs for treating the positive symptoms associated 
with schizophrenia was proposed to be the result of their ability to block abnormally high 
dopaminergic activity in the mesolimbic regions of the brain (Worrel et al., 2000). These 
initial observations laid the foundation for the dopamine hypothesis of schizophrenia that 
posits that abnormal dopamine activity within certain areas of the CNS are responsible for 
the symptoms associated with schizophrenia. 
Tardive dyskinesia is another neurological side effect associated with typical 
APDs, although this syndrome manifests itself in patients who have been chronically 
exposed to relatively high APD doses. These patients develop abnormal buccolingual 
thrusting and chewing movements as well as choreoathetotic behavior that can persist 
even after the individual has withdrawn from the neuroleptic therapy (Hodgson et al., 
1998). Still another of the side effects experienced by patients on the classic neuroleptics 
is that of a marked increase in prolactin levels in the body. This has been shown to result 
from dopamine receptor antagonism at the tuberoinfundibular neuron that controls 
prolactin levels thereby inhibiting the release of prolactin from the anterior pituitary 
(Goodnick et al., 2002). Due to the significant side effect profile of the traditional APDs, 
patient noncompliance eventually became a problem. Thus clinicians and researchers 
continued to search for potential APDs that would address the efficacy issues as well as 
the all important issue of neurotoxicity. 
Atypical APDs in the pre-aripiprazole era 
Investigators discovered the prototype ‘atypical’ APD clozapine in the early 
1980s, a breakthrough that initiated the dawn of a second generation of APDs. It was 
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initially pulled from the market amidst concerns that it was inducing agranulocytosis and 
life-threatening infections in some patients. Clozapine was returned to the market in the 
early 1990s because it showed a better efficacy for the positive and negative symptoms of 
schizophrenia without producing the incapacitating EPS associated with the typical 
antipsychotics. Clozapine is now primarily administered on a limited basis (e.g., to 
patients exhibiting predominantly severe negative symptoms or those patients resistant to 
other APDs) with patients on clozapine subject to frequent blood tests to monitor for the 
loss of white blood cells. 
New variants of clozapine (both structural and functional) have since entered the 
market that are less toxic but exhibit similar efficacy. A definition that roughly describes 
the atypical APD class is that they are neuroleptics that provide at least equal efficacy for 
positive symptoms as the typical APDs without inducing EPS or persistent prolactin 
elevation (Miyamoto et al., 2000).  
Along with clozapine, drugs such as olanzapine, risperidone, ziprasidone and 
quetiapine are the primary APDs marketed as “atypical” today. One factor that has 
hampered our understanding of the mechanisms of action of atypical APDs is that most of 
these drugs, such as clozapine, olanzapine, and quetiapine, demonstrate considerable 
affinities for a number of G protein-coupled receptors (GPCRs) other than dopaminergic 
receptors (e.g. serotonin, histamine, adrenergic and cholinergic receptors) along with 
lower D2 receptor affinity. Thus, while this ”rich” receptor pharmacology is thought to 
contribute to the favorable therapeutic attributes and lower risk for EPS associated with 
atypical APDs, it also appears to be responsible for many of the diverse side effects 
related to the administration of these compounds. Side effects include weight gain [a 
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common side effect with this class of drugs but primarily associated with clozapine and 
olanzapine treatment due to their high affinity for the H1 histamine receptor (Kroeze et 
al., 2003)], abnormal heart rhythms (QTc prolongation, a documented side effect 
primarily of risperidone and to a lesser degree ziprasidone and sertindole), and sedation 
(again, a side effect common to the atypicals and associated with CNS histamine receptor 
antagonism), among others (Miyamoto et al., 2000). 
Risperidone, on the other hand, has a high affinity for D2 and 5-HT2A receptors, 
and less of the overall “rich” pharmacology associated with the other atypicals. Due to the 
high D2 receptor affinity, risperidone is associated with an increased risk for EPS at high 
doses (thereby demonstrating “typical” APD qualities), while at lower doses this drug 
takes on more atypical attributes (Serretti et al., 2004). Furthermore, risperidone does not 
induce the cholinergic side effects that are commonly reported for other atypical APDs 
that tend to act as high affinity antagonists at M1 muscarinic receptors (Miyamoto et al., 
2000). Despite the assortment of side effects linked to the atypical antipsychotics, they 
are fast becoming the first choice in prescription drugs for those schizophrenic patients 
who can afford them because of the low incidence of EPS and prolactin elevation, 
ultimately translating to improved patient compliance (Naber and Karow, 2001). 
Recently, aripiprazole was approved as the newest atypical antipsychotic drug, bringing a 
third type of mechanism to the debate of therapeutic approaches that will be discussed in 
detail below (see Aripiprazole, functional selectivity, and the goals of this dissertation 
on page 29.)  
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DOPAMINE RECEPTOR SIGNALING 
Dopamine receptors and the brain 
The basis of typical APD action is thought to lie in their interactions with 
dopamine receptors. Dopamine receptors were first described by their ability to modulate 
levels of adenosine 3’,5’-cyclic monophosphate (cAMP), the second messenger molecule 
converted from adenosine triphosphate (ATP) by the enzyme adenylate cyclase 
(AC)(Missale et al., 1998). The idea that these receptors were comprised of two distinct 
types was fostered by pharmacological evidence which illustrated that the dopamine 
antagonist sulpiride was unable to block dopamine activity in every brain region (Garau 
et al., 1978; Kebabian and Calne, 1979; Missale et al., 1998). Thus two distinct families 
of dopamine receptor were hypothesized: D1 receptors (those that stimulate AC) and D2 
receptors (those that inhibit AC) (Kebabian and Calne, 1979). With the advent of gene-
cloning procedures and the discovery of more selective dopaminergic compounds, this 
initial receptor dichotomy became even more complicated when it became clear that there 
were multiple types of dopamine receptor within two pharmacological groups: D1-like 
(D1 and D5) and D2-like (D2short, D2long, D3, and D4, the latter of which is comprised of 
D4.2, D4.4, and D4.7 alternate splice variants) receptors (van Tol et al., 1992).  
D1-like receptors generally signal through stimulatory G protein isoforms (Gαs and 
Gαolf), while D2-like receptors inhibit AC by coupling to and activating pertussis toxin-
sensitive Gαi/o subtypes (Chern, 2000). The last two decades of dopamine receptor 
research has illustrated that D2-like receptors are able to regulate more than just cAMP 
levels, but also certain potassium, sodium, and calcium channels, multiple kinases as well 
as the generation of such polyunsaturated fatty acids as arachidonic acid (Missale et al., 
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1998). While the evidence for D1-like receptors being coupled to multiple signaling 
pathways is not as well defined, it does appear that there is also more to D1-like signaling 
than AC stimulation (Missale et al., 1998). 
Dopamine receptors are present in both the CNS and certain areas of the periphery 
(Gerfen et al., 1990; Weiner et al., 1991; Le Moine and Bloch, 1991; Le Moine et al., 
1991). D1-like receptors are highly expressed in the medial prefrontal cortex (mPFC), the 
basal ganglia (e.g., striatonigral and striatopallidal projections and nucleus accumbens), 
amygdala, and olfactory tubercles, whereas D2-like receptors (of which the D2 isoforms 
are most prominent) can be found in the substantia nigra and ventral tegmental 
dopaminergic pathways, certain cortical regions, as well as the amygdala, olfactory 
tubercles, and hypothalamus. As a general observation, colocalization of D1-like and D2-
like receptors is the exception rather than the rule (Missale et al., 1998). D2 receptors also 
act as autoreceptors for dopaminergic neurons, reducing further neuronal dopamine 
release when activated and thereby providing a negative feedback response that acts to 
prevent unregulated release of dopamine (Elsworth and Roth, 1997). 
Based on what is understood of the dopaminergic tracts within the CNS, the 
symptomology of schizophrenia and the EPS associated with typical APD administration 
has been described in the following manner: 1) positive symptoms are the result of 
hyperdopaminergic activity within the mesolimbic dopaminergic system, 2) negative and 
cognitive symptoms are a consequence of reduced mesocortical dopaminergic activity, 
and 3) the typical APD-induced EPS arise from D2 receptor blockade within the basal 
ganglia (the brain region responsible for controlling fine motor movement and posture). 
Therefore, using the dopaminergic hypothesis as the foundation for APD research, it is 
 18 
hypothesized that compounds able to block mesolimbic dopaminergic activity, induce 
mesocortical activity, while essentially ignoring the dopaminergic receptors of the basal 
ganglia and tuberoinfundibular neuron [hypothetical therapies that have been dubbed 
“dopamine system stabilizers” by some (Stahl, 2001a)] will prove to be the most 
efficacious drugs while inducing little to no EPS or prolactin elevations. In fact, some 
newer generation drugs (commonly referred to as ‘atypical’ APDs) appear to have at least 
some of these characteristics. 
G protein-coupled receptors 
It has long been recognized that living cells employ a number of diverse surface 
protein structures, such as ion channels and receptors, in order to process and integrate 
information about their environment, respond to stimuli, and ultimately maintain cellular 
homeostasis. In general, the surface receptors are divided up into ion channel-linked, 
enzyme-linked and G protein-coupled receptors (GPCRs). GPCRs, representing the 
single-most targeted group of proteins by pharmaceuticals today, are comprised of three 
major receptor families totaling over 950 specific genes in humans, and are responsible 
for modulating diverse physiological and behavioral signaling pathways (Maudsley et al., 
2005; Palczewski, 2006).  
Although the seven transmembrane α-helices are secondary peptide structures 
homologous to all GPCRs, the relative difficulty of crystallizing these membranous 
proteins (Caffrey, 2003) has greatly hindered our understanding of tertiary and quaternary 
aspects of GPCR structure (Shi and Javitch, 2006). To date there have been only two 
proteins with relevant structures that have been crystallized: bacteriorhodopsin (Blaurock 
and Stoeckenius, 1971; Henderson, 1975) [a heptahelical transmembrane retinal proton 
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pump employed in early attempts at GPCR structural modeling (Pardo et al., 1992)] and 
bovine rhodopsin (Palczewski et al., 2000). Investigators, however, have been able to 
utilize the data provided by the latter of these crystal structures, in combination with 
receptor amino acid homology techniques, point mutation-ligand binding analyses, and 
resonance energy transfer techniques, to formulate models that provide clearer insights 
into the tertiary and quaternary structure of other GPCRs (Milligan and Bouvier, 2005) 
(especially those belonging to the rhodopsin-like, or class I, GPCRs). In fact, while much 
of this research has focused on the aminergic GPCRs, these studies have aided attempts at 
rationale drug design for many of the various receptor families (Brink et al., 2004). 
There are a diverse group of proteins that interact with GPCRs, regulating receptor 
signaling, surface expression and receptor trafficking, and the local structural milieu. 
While more and more of these GPCR regulatory components come to light, a majority of 
GPCR signaling research has revolved around the receptors’ most proximal signaling 
elements, the G proteins.  
GPCR signal transduction 
G proteins are a family of heterotrimeric guanine nucleotide-binding proteins 
responsible for moderating a majority of the known GPCR-associated signaling pathways. 
This family of highly conserved proteins is comprised of α, β and γ subunits (45, 35 and 
8-10 kDa, respectively)(Cabrera-Vera et al., 2003; Milligan and Kostenis, 2006). G 
protein signaling requires GTP replacement of GDP, and it is commonly thought that this 
induces the α and βγ subunits to separate and ultimately regulate intracellular second 
messengers. This signaling is interrupted by the α subunit’s intrinsic GTPase activity that 
hydrolyzes GTP to GDP and thus promotes the reassembly of the α and βγ subunits. 
 20 
It was discovered early on that certain bacterial exotoxins could disrupt receptor 
signaling by covalently modifying, and thereby inactivating, the α subunit of specific G 
proteins isoforms. For example, pertussis toxin was found to inactivate Gαi/o proteins that 
negatively couple to the cyclic AMP-producing membrane-bound enzyme adenylate 
cyclase. Such tools have been useful in identifying the G protein isoforms that associate 
with specific GPCRs. In fact, cloning techniques have provided a wealth of information 
on how many isoforms of G proteins exist: 35 genes encode 16 α, 5 β and 14 γ subunits 
(Milligan and Kostenis, 2006). It stands to reason that the combinatorial possibilities that 
comprise these heterotrimeric proteins are in part responsible for the complex nature of 
signaling sometimes observed through a single GPCR.  
From the perspective of the receptor, the third intracellular loop of class I GPCRs 
is most frequently responsible for the selectivity of the G protein isoform with which the 
receptor interacts (Kobilka et al., 1988; Liu et al., 1995). The Gα protein subunit is 
comprised of at least four regions that come into direct contact with the intracellular 
aspects of the GPCR and that have been implicated in receptor-coupling specificity 
(Conklin et al., 1993; Kostenis et al., 1997a; Kostenis et al., 1997b; Blahos et al., 1998). 
More recent research indicates that there are amino acid residues of the Gα subunit other 
than those in direct contact with the receptor that also play a role in the fidelity of 
receptor-G protein interactions, highlighting the importance of overall protein 
conformation in the specificity of such protein relations (Heydorn et al., 2004; Kostenis et 
al., 2005). As alluded to previously, a common view of G protein activation describes the 
separation of α and βγ subunits in order to regulate down stream effectors (Cabrera-Vera 
et al., 2003). This idea may not be so accurate, as more recent studies indicate a more 
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rigid system, where the heterotrimeric unit as a whole may undergo conformational 
changes that affect down stream pathways (Bunemann et al., 2003). Regardless of the 
specific molecular mechanism by which G protein subunits transduce their signal, the 
general concept of G protein signaling appears to hold true (Milligan and Kostenis, 2006).  
Pathways associated with GPCR activation 
Adenylate cyclase 
The most comprehensively studied GPCR-coupled second messenger system 
involves the regulation of AC. This family of proteins is comprised of two integral 
membrane ‘cassettes’, each of which traverses the membrane six times. The catalytic 
domains of these enzymes are located on the intracellular aspect of the membrane and 
convert ATP to cAMP, a second messenger responsible for protein kinase C regulation 
and, in some cases, calcium levels (Sunahara and Taussig, 2002).  
There have been at least nine AC subtypes cloned and characterized in mammals, 
with each isozyme having its own level of catalytic activity (Watts and Neve, 2005). 
Adding to the complexity of AC-dependent signaling is the fact that the activity of these 
isozymes can be differentially modulated by a number of various GPCR-independent 
factors, including expression levels of isozyme, protein kinases, calcium and magnesium 
cations, as well as the diterpene forskolin (Cumbay and Watts, 2004). Regarding GPCR-
regulation of these isozymes, Gα subunit activation is the most commonly reported 
mechanism for AC modulation, with stimulatory Gαs subunits usually associated with AC 
activation and inhibitory Gαi/o [although the latter G protein subunits are also thought to 
be involved in AC sensitization (Watts and Neve, 2005)]. It has been recognized more 
recently that at least some AC isoforms (e.g. AC2, AC4, and AC7) can be directly 
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stimulated by βγ heterodimer G protein subunits (Chakrabarti et al., 1998; Watts and 
Neve, 2005), adding another degree of complexity to this already intricate signaling 
paradigm.  
AC signal regulation has been implicated in many aspects of mammalian 
physiology. As it relates to neurobiology, there are a number of CNS functions, including 
neurotransmitter signal transduction, synaptic plasticity, and learning and memory that 
are thought to be intrinsically related to the cellular management of cAMP levels 
(Hanoune and Defer, 2001). Furthermore, heterologous sensitization of AC has been 
proposed to be a key element in models describing the neuroadaptive responses of 
tolerance and drug addiction (Sharma et al., 1975).  
Mitogen activating protein (MAP) kinase 
MAP kinase signaling cascades are ubiquitous and important cellular pathways 
employed by a number of neurotransmitters, growth factors and hormones to mediate 
cellular functions such as growth, proliferation and differentiation. This serine/threonine 
kinase family is comprised of three subfamilies: the extracellularly-responsive kinases 
(Erk), the c-Jun N-terminal kinases (JNKs), and the p38-MAP kinases (Sugden and Clerk, 
1997). Erk activity is important in regulating G0-G1 cell cycle transition as well as cell 
passage through mitosis and meiosis (Luttrell and Luttrell, 2003).  
Among the many diverse signaling pathways that are known to regulate Erk1/2 
activity, several GPCRs have been shown to couple to Erk1/2 cascade activation via 
heterotrimeric G proteins. There have been several distinct mechanisms attributed to 
GPCR regulation of Erk1/2, including the activation or transactivation of non-receptor or 
receptor tyrosine kinases, respectively (both of which result in a Ras-dependent activation 
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of Erk1/2), as well as through the activation of second messenger-dependent protein 
kinases (e.g. PKA) (Marinissen and Gutkind, 2001; Schmitt and Stork, 2002; Chan et al., 
2005). Thus it appears that the mechanism by which Erk1/2 activity is regulated by 
GPCRs is dependent on the GPCR isoform as well as the cell type being studied. 
One of the more recent GPCRs to be linked to Erk1/2 activation is the dopamine 
D2 receptor (Welsh et al., 1998; Choi et al., 1999). The mechanism of D2 receptor 
activation of Erk1/2, though not definitively elucidated, has been shown to be dependent 
on membrane-bound Gβγ proteins in a pertussis toxin-sensitive manner. It is thought that 
Gβγ phosphorylation of Shc, and the subsequent formation of the Shc/Grb2/Sos complex, 
recruits GTP-activated Ras for the rest of the Erk1/2 kinase pathway to be initiated 
(Sugden and Clerk, 1997; Lopez-Ilasaca, 1998). The role that these GPCR-mediated 
MAPK pathways play in the proliferation and differentiation of certain neurons is 
currently an area of active study. 
Arachidonic acid release 
Phospholipase A2 (PLA2)-mediated release of arachidonic acid (AA) from 
membranous glycerophospholipids is usually associated with the production of 
eicosanoids (i.e. prostaglandins, leukotrienes and thromboxanes) and therefore the 
regulation of inflammation (Needleman et al., 1986).A number of studies, however, have 
illustrated that this polyunsaturated fatty acid may also act as an important second 
messenger in both neuronal and non-neuronal cells, and may influence synaptic plasticity 
and long-term potentiation (Williams et al., 1989; Piomelli and Greengard, 1990). This 
observation suggests that the regulation of AA release may be involved in the 
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pathophysiology of such diseases as schizophrenia and Alzheimer’s (Horrobin, 1998; 
Lynch, 1998).  
A number of GPCRs, including D2 subtypes, have been shown to potentiate the 
stimulation of PLA2 and subsequent AA release through ATP binding of the P2-purinergic 
receptor (Felder et al., 1991), although the mechanism by which these GPCRs act 
synergistically has been subject for discussion. In fact, there has been conflicting data 
reported concerning whether or not D2 can directly activate PLA2 (Nilsson et al., 1998). 
Intracellular calcium signaling 
There is also extensive evidence that indicates the coupling of GPCRs with a 
number of other signaling mechanisms involved in the regulation of cytosolic calcium 
stores [Ca2+]i. A number of receptors have been shown to activate phospholipase C (PLC) 
through Gαq/11 subunits, including certain muscarinic and serotonin receptors (Berg et al., 
1998a; Ruiz, I et al., 2006). PLC activity results in IP3 and DAG production that leads to 
a corresponding increase in [Ca2+]i and protein kinase C (PKC) activity, respectively. 
Certain GPCRs, including GABAB, adenosine A1, and dopamine D2 receptors, have also 
been shown to regulate high voltage activity calcium channels (HVA-CC) located on the 
plasma membrane, thereby influencing such neuronal operations as vesicular release of 
neurotransmitters and maintenance of membrane potential (Miller, 1998). 
Regarding the dopaminergic receptors, however, there is conflicting evidence as to 
whether or not this family of GPCRs directly activates or inactivates PLC. In the case of 
the dopamine D1 receptor, although direct PLC activation via Gαq/11 subunits has been 
described (Undie and Friedman, 1990; Wang et al., 1995; Jin et al., 1998; Undie et al., 
2000; Jin et al., 2001), many of these reports relied on experiments in which suprahigh 
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concentrations of agonists were used to observe an effect. Since non-D1 receptor effects 
cannot be ruled out in such cases, and since there is further evidence from other 
laboratories that either fail to show D1-phosphoinositol pathway coupling (Kelly et al., 
1988; Leonard et al., 2006) or indicate a D1 inhibitory effect on this effector (Rubinstein 
and Hitzemann, 1990; Wallace and Claro, 1993), it would appear that the weight of 
evidence favors the latter two possibilities. This would indicate that there are probably 
other indirect factors, such as calcyon and/or non-dopaminergic GPCR activation, 
involved in Gαq/11 activation (Leonard et al., 2006).  
The case for D2 receptor modulation of PLC is even more ambiguous, as there 
have been reports of both positive coupling [in some cases via Gαq/11 (Hernandez-Lopez 
et al., 2000), in others through pertussis toxin sensitive G proteins (Vallar et al., 1990; 
Tang et al., 1994a; Gordon et al., 2001)] as well as direct negative coupling [via Gαi/o 
isoforms (Rasolonjanahary et al., 2002)] of this receptor to PLC activity. This regulation 
appears to be cell line specific, however, as such results cannot be duplicated in every cell 
line studied (Missale et al., 1998). Furthermore, there is evidence that D2 receptor 
activation bypasses PLC-regulation of [Ca2+]i altogether by promoting the direct 
interaction of Gαi subunits with the intracellular IP3 receptors responsible for modulating 
intracellular calcium stores (Neylon et al., 1998; Hu et al., 2005). Such observations 
further highlight the fact that subtle differences in protein expression and localization 
between cell lines can have profound effects on the ability of a specific receptor to 
modulate a particular function.  
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GIRK channel regulation 
G protein-coupled inward rectifier potassium channels (GIRKs) activity is another 
important factor in the regulation of neuronal action potentials and neurotransmitter 
secretion. The GIRK channel subfamily is comprised of five members, Kir3.1-Kir3.5 
(Kuzhikandathil et al., 1998). It was initially thought that channel structure required a 
heterotetrameric quaternary arrangement in order to be functional (Kofuji et al., 1995), 
although there is now plenty of in vitro evidence that indicate Kir3.2 homotetramers are 
also capable of producing substantial K+ currents (Liao et al., 1996; Kuzhikandathil et al., 
1998).  
GPCRs that regulate GIRK channels (e.g. somatostatin, muscarinic M2, serotonin 
5-HT1A and dopamine D2 receptors) do so in a pertussis toxin (PTX)-sensitive manner, 
and it is the βγ subunits of these G proteins that directly interact with specific domains of 
the GIRK channels and promote K+ conductance (Kofuji et al., 1995; Huang et al., 1997). 
It is this increase in K+ conductance that results in sufficient hyperpolarization of the 
local plasma membrane to decrease the probability of action potentials (Mark and 
Herlitze, 2000). Thus, by directly influencing local GIRK channels, GPCRs play an 
important role in regulating the excitability and neurotransmission of neurons. 
Cellular regulation of GPCR signaling 
While GPCR activation and signaling allows the cell to interact with and adapt to 
the extracellular environment, an integral aspect to cell homeostasis lies in the ability of 
the cell to regulate receptor signaling. Thus, management of receptor membrane 
expression and responsiveness is important to cellular vitality. Some of the mechanisms 
the cell employs to regulate receptor signaling include receptor desensitization and 
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endocytosis that is then followed by either receptor degradation or recycling and 
resensitization (Tan et al., 2004). The decline in responsiveness of a receptor to an 
agonist (i.e. desensitization) that prevents receptor overstimulation, is a process known to 
be directly mediated by a number of kinase families, including G protein-coupled receptor 
kinases (GRKs) and second messenger-dependent kinases like protein kinases A and C 
(Krupnick and Benovic, 1998; Limbird, 2004). These proteins phosphorylate specific 
serine and threonine residues on intracellular aspects of GPCRs, effectively uncoupling 
receptors from G protein activation and promoting receptor endocytosis (Ferguson, 2001).  
There are three mechanisms by which receptor internalization can occur: 1) 
arrestin- and dynamin-dependent, 2) arrestin-independent and dynamin-dependent, and 3) 
arrestin- and dynamin-independent endocytosis (Claing et al., 2002; Tan et al., 2004). In 
fact, the endocytotic trafficking of some homologous receptors (e.g., dopamine D1 versus 
D2 receptors coexpressed in the same heterologous HEK293 cell system) have been 
observed to be selectively regulated by distinct dynamin-dependent and -independent 
sorting mechanisms (Vickery and von Zastrow, 1999). There is further evidence 
indicating that the mechanism utilized for receptor internalization is probably determined 
by the specific amino acid residues phosphorylated by the above mentioned kinases 
(Rapacciuolo et al., 2003; Vargas and von Zastrow, 2004). Thus it would seem that the 
mechanism of receptor expression and trafficking can be predetermined depending on the 
receptor subtype and expression system being investigated. 
GPCR-G protein signaling is also regulated by a number of proteins that act on the 
G proteins themselves. These regulators of G protein signaling (RGS proteins) are a 
group of at least 30 GTPase-activating proteins (GAPs) that bind directly to activated Gα 
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subunits and accelerate the intrinsic Gα GTPase activity, thereby limiting the duration of 
Gα-GTP activity (Hepler, 2003). It appears that the specificity of this regulation has more 
to do with the specific GPCR and GPCR-G protein interaction rather than the specific G 
protein itself (Roy et al., 2003), highlighting another aspect of the complexity of GPCR 
signaling as well as suggesting that changes in receptor conformation may have far 
greater consequences than just selecting which G protein isoforms may be amenable to 
activation. Indeed Bernstein et al. recently reported evidence in support of this notion by 
illustrating that the third intracellular loop of the muscarinic M2 receptor directly interacts 
with RGS2 (Bernstein et al., 2004).  
These regulatory proteins are not bound to the plasma membrane, however, and 
therefore require translocation to the membrane in order to regulate G protein activity. 
There are a number of scaffolding proteins that have been implicated in regulating such 
translocation through the organization and assembly of machinery components, and it has 
been reported that some of the more complex RGS proteins have multiple functional 
domains that allow them to act in such a fashion (De Vries L. et al., 1998). For example, 
Jeanneteau et al. (2004) discovered that the dopamine D2 receptor-mediated recruitment 
of RGS19, a complex RGS protein, required the presence of another scaffolding protein, 
GIPC, and that this overall regulatory complex was essential to mediate two separate D2 
receptor signaling cascades. Such GPCR-interacting proteins (GIPs), as well as aspects of 
lipid rafts and caveolae, play an integral role in the sorting and compartmentalization of 
GPCR signaling, and demonstrate how cells expressing a wide variety of GPCRs and G 
proteins are able to arrange and coordinate complex signaling input (Bergson et al., 2003; 
Bockaert et al., 2004; Insel et al., 2005).  
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ARIPIPRAZOLE, FUNCTIONAL SELECTIVITY, AND THE GOALS OF THIS 
DISSERTATION  
Aripiprazole: a new class of atypical APD 
Aripiprazole (Abilify®) is the most recent addition to the atypical APD family, 
although many consider it to be a prototype of the next generation of APDs because of its 
proposed mechanism of action (D2 and 5-HT1A partial agonism) and improved side effect 
profile. It has been shown to be efficacious in treating positive and (to a lesser extent) 
negative schizophrenic symptoms, without significantly inducing the side effects 
generally associated with previous neuroleptics (i.e. short-term weight gain, EPS, QTc 
prolongation, and lower levels of plasma prolactin) (Goodnick and Jerry, 2002; Keck, Jr. 
and McElroy, 2003).  
The success of aripiprazole has generated much interest in the ‘dopamine system 
stabilization’ theoretical approach to neuroleptic development. Indeed, pharmaceutical 
companies are currently developing compounds with similar pharmacological activities in 
the hopes of at least duplicating, if not exceeding, the antipsychotic efficacy associated 
with aripiprazole [e.g. bifeprunox (Bolonna and Kerwin, 2005)]. Ultimately, however, 
better drugs will be developed when more is understood about the complex biomolecular 
consequences of ligand-receptor interactions. One aspect of the complexity of receptor 
signaling has been more recently realized under the auspices of “functional selectivity”, a 
key concept of this dissertation which will be described and reviewed at length in Chapter 
2 (Functional selectivity and classical concepts of quantitative pharmacology). 
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Research objectives of this dissertation 
The global objective of this research was to investigate D2 receptor functional 
selectivity as a potential mechanism of action for atypical APDs, as outlined in the 
following aims. 
Aim 1. Investigate the functionally-selective potential of a group of atypical APDs 
in a CHO-hD2L cell model 
Using the stable CHO-hD2L cell line, characterize the D2 receptor-mediated 
functional traits of a group of atypical APDs, including aripiprazole, clozapine, 
olanzapine and amisulpride, to determine whether or not they are functionally selective at 
the functional endpoints employed. 
Aim 2. Investigate the role of the 5.42, 5.43, and 5.46 serines in the D2 receptor on 
ligand binding and function  
Using stable CHO-hD2L S5.42A, S5.43A, and S5.46A stable cell line mutants, 
investigate the effects rendered by these mutations on the binding and function of the D2 
receptor functionally selective drug aripiprazole and two typical partial agonists [(-)3PPP 
and (-)terguride] to characterize the specific interactions of these ligands with the 
receptor. 
Aim 3. Characterize the N27-hD2L dopaminergic cell line  
After stably transfecting the FLAG-tagged D2L receptor into the N27 
dopaminergic cell line, further characterize this cell line to assess its value as a 
physiologically relevant model for investigating D2 receptor-mediated functional 
selectivity as mediated by such D2 receptor-mediated dopaminergic endpoints as 
dopamine uptake and release, as well as receptor expression regulation. 
  
CHAPTER 2. 
FUNCTIONAL SELECTIVITY AND CLASSICAL CONCEPTS OF  
QUANTITATIVE PHARMACOLOGY  
The following material is excerpted from  
Journal of Pharmacology and Experimental Therapeutics (Urban et al., 2006a) 
PREFACE 
The overall hypothesis underlying this dissertation is that a wealth of recent data 
has invalidated the half-century old “principle” of pharmacology, specifically the notion 
of “intrinsic efficacy.” Intrinsic efficacy held that the functional characteristics of a 
ligand acting at a single receptor were invariant, except as modified by quantitative 
factors such as receptor reserve. Thus, a ligand or drug could be assigned a name of 
agonist, partial agonist, antagonist/inverse agonist, and that this functional property 
would be observed in every system in which the target receptor was expressed. This 
chapter is a critical scholarly review of whether this hypothesis is correct, and includes 
references to some of my published research that are not included in this dissertation. I 
conclude that the notion of intrinsic efficacy is outmoded, setting the stage for the studies 
I performed related to “partial agonists” that have demonstrated or purported atypical 
antipsychotic activity.  
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ABSTRACT 
The concept of intrinsic efficacy has been enshrined in pharmacology for a half-
century, yet recent data reveal that many ligands can differentially activate signaling 
pathways mediated via a single G protein-coupled receptor (GPCR) in a manner that 
challenges the traditional definition of intrinsic efficacy. Some terms for this phenomenon 
include functional selectivity, agonist-directed trafficking, and biased agonism. At the 
extreme, functionally selective ligands may be both agonists and antagonists at different 
functions mediated by the same receptor. Data illustrating this phenomenon have been 
demonstrated in serotonin, opioid, dopamine, vasopressin, and adrenergic receptor 
systems (to name a few). A variety of mechanisms may influence this apparently 
ubiquitous phenomenon. It may be initiated by differences in ligand-induced intermediate 
conformational states, as shown for the β2-adrenergic receptor. Subsequent mechanisms 
that may play a role include diversity of G proteins, scaffolding and signaling partners, 
and receptor oligomers. Clearly, expanded research is needed to elucidate the proximal 
(e.g., how functionally selective ligands cause conformational changes that initiate 
differential signaling), intermediate (mechanisms that translate conformation changes into 
differential signaling), and distal mechanisms (differential effects on target tissue or 
organism). Besides the heuristically interesting nature of functional selectivity, there is a 
clear impact on drug discovery, as this mechanism raises the possibility of selecting or 
designing novel ligands that differentially activate only a subset of functions of a single 
receptor, thereby optimizing therapeutic action. It also may be timely to revise classic 
concepts in quantitative pharmacology and relevant pharmacological conventions to 
incorporate these new concepts. 
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RECEPTOR PHARMACOLOGY FOR A NEW MILLENIUM 
For the last half century, pharmacological theory has posited that ligands could be 
characterized by the nature of the functional effects elicited by their interaction with their 
target receptor. These effects are governed by two important properties: affinity, the 
property of attraction between a ligand and its receptor, and efficacy, the property that 
allows ligands, once bound, to produce a response (Kenakin, 1997). This concept has led 
to the classification of receptor ligands as full agonists, partial agonists, neutral 
antagonists, or inverse agonists. Perhaps the key idea that governs this classification is 
the notion of “intrinsic efficacy”, originally proposed by Furchgott as a measure of the 
stimulus per receptor molecule produced by a ligand (Furchgott, 1966). According to this 
notion, full agonists possess sufficiently high intrinsic efficacy such that they maximally 
stimulate all cellular responses linked to a given receptor. Partial agonists possess lower 
degrees of intrinsic efficacy (leading to submaximal responses), whereas inverse agonists 
reduce constitutive (ligand-independent, basal) receptor signaling. Neutral antagonists 
possess no intrinsic efficacy, but occupy the receptor to block the effects of full, partial, 
or inverse agonists. This idea has also led to the assumption, dearly held in 
pharmacology, that the ability of the ligand to impart (or reduce) stimulus once that 
ligand is bound to the receptor is an inherent property of the ligand-receptor complex. 
Intrinsic efficacy is thus differentiated from the more operational term “intrinsic activity” 
(Ariens, 1954), that simply refers to the maximal effect (Emax) of a ligand relative to a 
reference agonist in a given experimental system. 
In classical pharmacological terms, intrinsic efficacy has been viewed as a system-
independent parameter that is constant for each ligand at a given receptor, irrespective of 
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where that receptor is expressed. Any differences in the expression of agonism by a 
ligand between cell and tissue types were assumed simply to reflect differences in 
receptor density and/or the strength of stimulus-response coupling. In other words, the 
classification of compounds on the basis of intrinsic efficacy only allowed for variations 
in the quantity of the stimulus that was imparted to the cell, but not the quality. A full 
agonist would be expected to activate all of the signaling pathways linked to a receptor to 
the same degree as the endogenous ligand for that receptor. In contrast, a ligand that 
antagonizes one signaling pathway via a specific receptor should antagonize every 
pathway coupled to that receptor to the same extent. One consequence of this theory was 
the weight it added to Ehrlich’s idea of a therapeutic “magic bullet”. It led to a focus on 
discovery of new receptor ligands with high affinity and having specific functional 
characteristics at a single target. Although modern drug discovery recently has recognized 
that there is value in ligands that act by simultaneously targeting multiple receptors (Roth 
et al., 2004), there is still the widespread view that the characteristics of ligands at target 
receptors can be described by their “intrinsic efficacy”. In fact, the notion that intrinsic 
efficacy is system-independent forms a major underlying premise in drug discovery today 
– that the pharmacological characteristics of a drug tested in an experimental model 
system can be extrapolated to all systems. As discussed below, this premise may be 
frequently incorrect. 
More recently, however, there have been numerous examples reported in the 
literature in which certain ligands were shown to have quite diverse functional 
consequences mediated via a single receptor. As a general example, in some cases a 
ligand interacting with a specific receptor was seen to fully activate one signaling 
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pathway coupled to that receptor, while at another effector linked to that receptor the 
same ligand was observed acting as an antagonist. In order to be consistent with classical 
pharmacological concepts, these observations tended to be dismissed as an artifact of 
differences in “strength of signaling,” receptor reserve, undetected interactions with 
unknown receptors, effects of trace contaminants or drug metabolites, and/or similar 
mechanisms. Yet as more and more data have been amassed with a variety of different 
receptors, it is becoming clear that the classical concept of “intrinsic efficacy” as a 
system-independent constant, although once having conceptual utility, is probably not 
correct.  
These observations have led to the idea that ligands induce unique, ligand-specific 
GPCR conformations that can result in differential activation of signal transduction 
pathways associated with that particular receptor (Roth and Chuang, 1987; Kenakin, 
1995; Mailman et al., 1997; Mailman et al., 1998; Clarke and Bond, 1998; Ghanouni et 
al., 2001; Gonzalez-Maeso et al., 2003). It is well established that a single GPCR isoform 
can bind and regulate more than one isoform of G protein, and in some cases multiple G 
proteins of unrelated classes (Offermanns et al., 1994; James et al., 1994; Tsu et al., 1995; 
Laugwitz et al., 1996). This GPCR promiscuity indicates that unique conformational 
changes in receptor structure can dictate the isoform and pool of G proteins activated by a 
specific ligand, translating into diverse functional consequences (Milligan, 1997; 
Maudsley et al., 2005). This not only highlights the significance of ligand-specific 
changes in receptor conformation, but also underscores the importance of receptor 
location in determining whether a specific GPCR-ligand complex will differentially 
signal (Mailman and Gay, 2004). This differential activation of signaling pathways may 
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be expressed as differences in intrinsic activity and/or potency at one signaling pathway 
versus another, and which are not due to differences in affinity at the mediating receptor.  
A number of descriptive terms have been coined to allude to this concept 
(including “functional selectivity”, “agonist-directed trafficking of receptor stimulus”, 
“biased agonism”, “protean agonism”, “differential engagement”, and “stimulus 
trafficking”, to name just a few). There has yet to be an official decision made by the 
International Union of Basic and Clinical Pharmacology (IUPHAR) regarding the most 
appropriate terminology for this phenomenon; nonetheless “functional selectivity” is 
mechanism-neutral and least likely to be confused with other concepts of receptor 
pharmacology, and therefore will be used throughout the remainder of this dissertation. It 
should also be pointed out that although most of the research that supports this hypothesis 
is recent, and uses a variety of modern techniques, ideas related to “functional 
mismatches” had been theorized earlier, sometimes going back decades (Portoghese, 
1965; Jim et al., 1985; Roth and Chuang, 1987).  
FUNCTIONAL SELECTIVITY AT D2L AND D1 DOPAMINE RECEPTORS 
Recently, in our perspective on functional selectivity (Urban et al., 2006a), we 
provided examples of this phenomenon from many receptor systems (e.g., several 5HT2 
serotonin receptors, µ-opioid, β2-adrenergic, V2 vasopressin receptors, etc.). Of direct 
importance to my research, however, are such data with dopamine receptors. Dopamine 
receptors represent one subset of GPCRs that have been observed to differentially 
activate associated signaling cascades in response to certain compounds. In fact, much of 
the work on functional selectivity through dopamine receptors was an unexpected result 
of efforts directed at the rational discovery of novel D1 dopamine ligands (Charifson et 
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al., 1989; Mottola et al., 1996; Qandil et al., 2003). When dihydrexidine (DHX), the first 
high affinity full agonist for the D1 dopamine receptor was characterized (Lovenberg et 
al., 1989), it was found to have only ten-fold selectivity for D1 versus D2 receptors 
(Brewster et al., 1990; Mottola et al., 1992). DHX and its congener N-propylDHX were 
initially characterized as full agonists at the D2 receptor because they were equally 
efficacious to dopamine in inhibiting cAMP synthesis and efflux in striatal slices, 
inhibiting prolactin release in vivo, and stimulating GTPγS binding in rat substantia nigral 
tissue (Mottola et al., 1992; Kilts et al., 2002). Further characterization of the functional 
profile of these compounds, however, demonstrated that they are not typical full D2 
receptor agonists. Neither DHX nor N-propylDHX are able to inhibit the synthesis and 
release of dopamine in rat striatum, nor are they able to inhibit the firing of nigral 
dopaminergic neurons (Figure 2.1) (Mottola et al., 2002; Kilts et al., 2002). Effects in all 
of these functional assays would be expected for typical D2 receptor agonists. Thus, 
although DHX and N-propylDHX bind to the D2 receptors present in both neural tracks, 
they cause differential activation of specific signaling pathways, an overall concept that 
led to the coining of the term “functional selectivity” (Lawler et al., 1994; Mailman et al., 
1997; Mailman et al., 1998; Lawler et al., 1999). Interestingly, the functional selectivity 
of N-propylDHX in vitro may explain its unexpected behavioral effects in vivo (Smith et 
al., 1997). 
Similar trends are observed in vitro (rat lactotrophs as well as MN9D & CHO cells 
stably expressing the D2 receptor), verifying that the in situ observations are not artifacts 
produced by the activation of other GPCRs, and further confirming that functional 
selectivity as observed for specific dopaminergic compounds is not an epiphenomenon 
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associated with a particular signaling model (Mottola et al., 2002; Kilts et al., 2002; Gay 
et al., 2004). This functionally selective profile is not unique to DHX and N-propylDHX, 
as functional selectivity has been shown for other D2 receptor ligands [e.g. 
propylnorapomorphine (NPA) and dinapsoline (DNS)] in vitro (Gay et al., 2004 and 
unpublished)]. Not only have these latter compounds demonstrated varying intrinsic 
activities among the D2 receptor-mediated effectors studied, but some of them also 
exhibit significant variability in their relative potencies for the effectors they do activate 
(Figure 2.1).  
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Figure 2.1. Functional selectivity can be expressed as differences in intrinsic activity or potency 
although the two are interrelated. A. Quinpirole and propyldihydrexidine (PrDHX) are full 
agonists at the D2L receptor in MN9D cells, whose effects are completely blocked by the D2 
antagonist (butaclamol), B. Conversely, only quinpirole inhibits receptor-mediated DA release, 
and both PrDHX and butaclamol block quinpirole effects. C. As shown above in Figure 2, the 
relative potency of ligands can be markedly different even when the intrinsic activity is the same. 
Figure modified from Kilts et al. (2002) and Gay et al. (2004) 
Ligand-induced differential signaling has been more challenging to demonstrate in 
D1 dopamine receptors because there is a relative paucity of functional effectors known to 
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couple to this receptor. A recent report, however, has shown that apomorphine appears to 
regulate D1 signaling differentially, as determined by comparing its ability to fully 
activate D1 receptor-mediated cAMP accumulation and its inability to induce D1 receptor 
internalization (Ryman-Rasmussen et al., 2005). 
The therapeutic and clinical relevance of functionally selective compounds has 
been exemplified by the atypical antipsychotic drug aripiprazole. By the time it received 
FDA approval for the clinical treatment of schizophrenia, aripiprazole had been marketed 
as a partial agonist at both the 5-HT1A and D2 receptors as well as a 5-HT2A antagonist. 
This partial D2 agonism (Burris et al., 2002; Cosi et al., 2006) is postulated to lead to 
“dopamine system stabilization,” i.e. normalization of both dopamine hypo- and 
hyperactivity in pathologically-affected dopaminergic tracts (Stahl, 2001a; Stahl, 2001b; 
Tamminga and Carlsson, 2002; Lieberman, 2004).  
Further assessment of the literature, however, reveals that the intrinsic activity and 
potency of aripiprazole for the D2-mediated inhibition of cAMP accumulation is cell line-
dependent, as aripiprazole demonstrates weak partial agonist activity in the CHO-D2L cell 
line but strong partial agonist activity in HEK-D2L cells (Lawler et al., 1999; Burris et al., 
2002; Shapiro et al., 2003). Moreover, aripiprazole antagonizes both D2 receptor-
mediated GTPγS binding and GIRK channel activity (Shapiro et al., 2003), while acting 
as a full agonist in situ for D2-mediated inhibition of tyrosine hydroxylase (unpublished 
observation). Thus aripiprazole appears to elicit D2-mediated functional effects that 
encompass a whole range of classic pharmacological traits, and its functional properties 
probably depend on the signaling machinery associated with the D2 receptor (and hence, 
on the type of cell and location in the cell). Indeed, this conclusion is most consistent 
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with the fact that the drug is reported to antagonize post-synaptic D2 receptors, but 
partially activate presynaptic D2 autoreceptors (Kikuchi et al., 1995), Taken together, 
these data indicate that if “dopamine stabilization” is a result of aripiprazole treatment, it 
is primarily via a “correct” mix of direct effects on D2 receptors rather than “just the 
right” balance of pre- and post-synaptic actions in competition with dopamine (Urban et 
al., 2006b). 
MECHANISMS AND RESEARCH DIRECTIONS TO UNDERSTAND 
FUNCTIONAL SELECTIVITY 
Conformational changes at the β2AR: Possible mechanism of functional selectivity 
Direct evidence for multiple receptor states has been provided by investigations of 
agonist-induced conformational changes in purified β2AR protein. The labeling of 
specific sites on the receptor with fluorescent probes (Gether et al., 1997) allows for the 
detection of changes in the bound fluorophore, such as fluorescence lifetime, emission 
maximum and/or intensity, and thereby elucidates variations in receptor conformation 
(Kobilka and Gether, 2002). This approach has provided evidence that supports the notion 
that agonists and partial agonists produce distinct active state conformations, and suggests 
that agonist binding and activation occur through a series of discrete conformational 
intermediates (Ghanouni et al., 2001; Swaminath et al., 2004). 
To understand the multistep process of GPCR activation better, catecholamine 
agonist fragments (such as catechol and dopamine) have been utilized to study the 
structural and functional properties of these conformational intermediate states 
(Swaminath et al., 2005). Considering that receptor activation is thought to result from 
the ability of an agonist to disrupt certain intramolecular interactions responsible for 
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maintaining the basal state of the receptor, it was hypothesized that specific ligand 
moieties could be employed to identify these interactions.  
Swaminath et al. (2005) have reported that catechol, a weak partial agonist for 
GTPγS binding, was able to activate the rotamer toggle switch of transmembrane helix 6 
(TM6), but unable to produce a break in the ionic lock between helices TM3 and TM6. 
Dopamine, able to activate the TM6 rotamer toggle switch and break the TM3-TM6 ionic 
lock, also demonstrated strong partial activation of GTPγS binding but failed to induce β2 
adrenergic receptor internalization. The catecholamines norepinephrine and epinephrine 
produced additional conformational changes that promoted receptor internalization, 
suggesting that a ligand must induce a number of conformational changes for typical 
agonist activity to be satisfied. The non-catechol partial agonist salbutamol, however, is 
able to break the ionic lock but fails to activate the rotamer toggle switch. Molecular 
modeling indicates that the salbutamol aromatic ring does not interact with the same 
receptor residues as the catechol moiety of catecholamines, suggesting that salbutamol 
induces an active conformation distinct from those induced by catecholamines 
(Swaminath et al., 2005).  
These results suggest that the disruption of all of the interactions that maintain the 
basal conformational state is not required for a ligand to produce some level of receptor 
activation. It is likely that structurally distinct ligands are able to break different 
combinations of the basal state stabilizing interactions either directly by binding to amino 
acids that are involved in these intramolecular interactions, or indirectly by stabilizing 
new intramolecular interactions. These ligand-specific conformational changes may be 
responsible for differential activation of the signaling cascades of a receptor (Swaminath 
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et al., 2005). Furthermore, structurally distinct ligands are able to break different 
combinations of the basal state stabilizing interactions producing unique conformational 
states that ultimately may be responsible for differential activation of the signaling 
cascades of a receptor (Swaminath et al., 2005). 
Computational and theoretical approaches to understanding functional selectivity 
In addressing the apparent disruption of traditional thought in pharmacology 
generated by the functional selectivity phenomenon, there has been a focus on the reasons 
that make the observations leading to the definition of “functional selectivity” appear 
uncommon to classical pharmacology. It has been suggested that in order to incorporate 
such apparently discordant observations into the pharmacological characterization of drug 
action, it may be necessary to re-evaluate the current axioms underlying basic 
pharmacological definitions. This re-evaluation is provoked by experimental results from 
newly acquired abilities to: (1) identify and test naturally-occurring molecular variations 
of both receptors and ligands (e.g., peptide hormones); (2) engineer novel molecular 
structures (e.g., constitutively active constructs) that exhibit new types of 
pharmacological properties; (3) create uncommon adjacencies of receptors on the cell 
surface, allowing for new types of heterodimerizations; and (4) test a much larger variety 
(structurally and chemically) of artificially created ligands for the receptors.  
As a result of these developments, the phenomena that lead to the definition of 
“functional selectivity” must be examined to establish whether: A) the novel (or puzzling) 
phenotypes simply reveal underlying mechanisms that had not been identified in classical 
pharmacology; and B) these mechanisms depend on the same underlying structure-
function rules that explain classical pharmacology, but are richer in phenotypes. 
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In the context of the latter point, it has been suggested that the approaches must 
address structure-based mechanisms for modes of receptor activation, including a 
mechanistic understanding of the molecular processes involved in the discrimination 
between agonists and antagonists, full vs. partial agonists, neutral antagonists vs. inverse 
agonists, and the molecular details of constitutive activity to various degrees (Ebersole et 
al., 2003). Moreover, the protein-protein interaction responsible for homo- and hetero-
oligomerization (Filizola and Weinstein, 2005), as well as for the integration of the 
receptors in the signaling pathways in the cell (Weinstein, 2006), are likely to play 
important roles in determining the properties underlying the observed departures from 
what is considered to be “classical pharmacological activity.” 
Point B can be illustrated by examining results from combined experimental and 
computational approaches applied to investigating mechanisms essential to the 
hallucinogenic drug action of several classes of 5-HT2 receptor compounds. The goal of 
this endeavor is to uncover the subtle consequences of ligand-receptor interactions as they 
are mechanistically related to the subcellular elements ultimately responsible for 
hallucinogenic action (reviewed in Weinstein, 2006). It provides an excellent example of 
apparent pharmacological conundrums related to functional selectivity of the 5-HT2A 
receptor demonstrated by the elegant definition of the “transcriptome fingerprint” 
(Gonzalez-Maeso et al., 2003). 
In seeking the structural context of the ligand-determined receptor mechanisms, 
this interdisciplinary research has illuminated a number of conserved structural motifs in 
the configurations of rhodopsin-like GPCRs that are implicated in receptor signaling by 
acting as functional microdomains (Weinstein, 2006). Examples include (a) the NPxxY 
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motif of TM7 (Prioleau et al., 2002), and (b) the cluster of aromatic residues in TM6 that 
straddles a universally conserved proline and is thought to act as a “toggle switch,” 
thereby conveying the consequences of the ligand-binding event to the rearrangements 
associated with receptor activation (as reviewed in Visiers et al., 2002). 
Given this defined set of sites involved in ligand-dependent transitions in the 
conformation of the GPCRs, these studies have shown that structurally similar ligands 
can produce different, ligand-dependent modes of receptor activation by aligning 
themselves in different positions within the receptor-binding pocket. For example, it 
appears that bulky substitutions of the cationic moiety in the hallucinogenic compounds 
allow these ligands to adopt unique positions within the 5-HT2A receptor binding pocket 
relative to their non-hallucinogenic congeners (Ebersole et al., 2003). These observations 
highlight the idea that ligand-dependent conformations are able to produce functionally 
selective responses at the cellular level that ultimately can be translated to a unique 
physiological effect. This mechanistic translation depends on the interactions of the 
receptor molecule with its environment, such as in oligomer formation.  
The oligomerization mechanism is only one form of integration of the GPCR into 
the signaling networks of the cell, as different receptor conformations produced by ligand 
binding could select for the interaction of different proteins (e.g., PDZ domains, kinases) 
from the downstream signaling pathway (Figure 2.2). Consequently, it is important to 
integrate the examination of the putative mechanisms leading to the functional selectivity 
paradigm with the subcellular, cellular, and physiological levels of GPCR signaling. A 
powerful tool for this integrative approach is quantitative modeling of signaling 
pathways, as mathematical representations that are amenable to computational 
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simulations (Campagne et al., 2004). To produce useful models of these signaling 
systems, the components must be represented with the highest level of physical realism 
possible at our current understanding of cell physiology. 
 
Figure 2.2. The protein-protein interaction interface between a GPCR and its signaling 
environment is regulated by intramolecular interactions involving the NPxxY motif: The 
interaction between Y7.53 and the F7.60 that is in Hx8, controls the position of the helix and the 
C-terminal. This can regulate the interaction interface between the GPCRs and other proteins in 
the signaling cascade (e.g., PDZ domains), and may be affected differentially by ligands, 
providing one mechanism for functional selectivity.  
IMPACT ON RESEARCH AND TRAINING 
The impact of functional selectivity on quantitative pharmacology 
The initiation of the era of “analytical pharmacology,” i.e. the development and 
application of quantitative modeling to describe drug-receptor interactions and their 
consequences, can largely be attributed to the work of A.J. Clark. Along with Clark, the 
field has continued to develop and progress thanks in large part to the achievements of 
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Ariens, Gaddum, Schild, Stephenson, Furchgott, Black, Kenakin, and others. Indeed 
pharmacology, by its very nature, is a quantitative discipline, and as such biological and 
mathematical models are indispensable as tools for designing and interpreting 
experiments, and providing objective insights into potential mechanisms of action.  
An understanding of the simple model-building process provides a foundation for 
subjecting experimental data to mechanistic scrutiny. There are three possibilities that 
must be considered if the data are not in accord with the predictions of the model: (1) the 
incorporation of more complex mechanisms into the model is necessary; (2) the 
assumptions underlying the model fail to describe accurately the process used to generate 
the data; or (3) the process/quality of data generation needs to be scrutinized. 
According to this process, functional selectivity initially might be described by the 
simplest mechanism (i.e., a single state receptor model), as variations in stimulus-
response coupling efficiency are sufficient to model many experimentally-observed 
examples of tissue/cell-dependent differences in the expression of agonism for a given 
ligand. If one assumes for the sake of argument that possibilities (2) and (3) do not apply 
to the experimental approach and resulting data, then the simplistic premise of a single-
state receptor model becomes clearly inadequate as a mechanism that can explain 
phenomena such as reversals in agonist rank potencies, reversals in rank efficacies, and 
reversals of agonism to inverse agonism.  
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Figure 2.3. The three different types of models applied to biological systems are amenable to a 
pendulum analogy. Equilibrium models that encompass the ternary complex model (TCM), 
extended TCM (ETCM) and cubic TCM (CTCM) are akin to a pendulum that is static in nature. 
Steady-state models, such as the ternary complex activation model (TCAM), are more realistic in 
that they encompass the contribution of energy (e.g., wind for the pendulum) to maintain a 
behavior that appears static. The most biologically relevant models, however, are dynamic 
models, because they reflect the fact that the system is constantly changing in time. Thus, the more 
biologically relevant, the more complex the model becomes. Adapted from Woolf and Linderman 
(2000). 
One direction for reconciling these experimental observations is to build more 
complex drug-receptor models that not only accommodate our current understanding of 
protein biophysics, but also incorporate multiple receptor states (Christopoulos and 
Kenakin, 2002). The heuristic nature of these models may yield further insight into 
biological behavior, although the very nature of their complexity may sometimes make it 
difficult to test the model adequately. A potential pitfall of multi-state models is the 
temptation to avoid critical scrutiny of the underlying assumptions. Thus, the very model 
that was built to accommodate novel data might fail to describe accurately the conditions 
under which the data were generated. As an example, the most commonly used multi-state 
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models assume equilibrium between all reactants, an assumption that often may not be 
met. As shown in the cartoon in Figure 2.3, steady-state or kinetic models may provide 
more realistic mechanisms for understanding biological behavior under such 
circumstances (Christopoulos et al., 1999; Lew et al., 2000; Woolf and Linderman, 2000). 
Indeed, it may be that it is timely to bring non-linear dynamic approaches into the 
receptor pharmacology arena. 
Functional selectivity and its impact on drug discovery 
There are two general questions concerning functional selectivity as it relates to 
the pharmaceutical industry: (1) can functional selectivity be observed during the GPCR 
drug discovery process, especially within in vitro systems? and (2), if observed, can 
functional selectivity in vitro be applied toward measures of in vivo efficacy and/or safety 
liabilities?  
Of course the answer to the first question is “yes.” Functional selectivity is often 
observed with GPCRs expressed in recombinant systems that can have an immediate 
impact on lead identification. High throughput screening (HTS) campaigns, however, 
often employ a single functional endpoint with which to characterize the activities of test 
compounds, an approach that can potentially lead to overlooking or triaging important 
compounds that signal through alternative pathways via the same receptor. For example, 
it has been demonstrated with both 5-HT2C and D2 ligands that relatively small structural 
modifications can elicit functional selectivity (more than 100-fold) without affecting 
receptor affinity (Miller et al., 2000; Gay et al., 2004). It is important, therefore, to collect 
data on ligand affinity as well as on ligand activity through multiple functional endpoints. 
Within the realm of industry, however, the addition of multiple functional effectors to a 
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HTS operation is a substantial additional cost, and it is partially for this reason that 
industry has been slow to move in this direction. 
Even when functional selectivity can be demonstrated in vitro, it is not completely 
clear how it may affect in vivo efficacy and/or improved safety profiles. The 5-HT2C 
compounds that illustrated functionally selective profiles in vitro (i.e., high 5-HT2C 
receptor affinity, high GTPγS potency, but a 100-fold lower potency for the 5-HT2C-
mediated production of IP3) were found to produce a similar level of efficacy in both 
acute and chronic feeding models as those compounds considered typical potent 5-HT2C 
receptor agonists (Largent et al., 2002). Further in vivo examination of cFos activation in 
regions of the brain known to be involved in appetite regulation showed no difference 
among the compounds in the number or localization of activated neurons. Conversely, 
propyldihydrexidine (Figure 2.4), a compound with functionally selective in vitro 
properties (Kilts et al., 2002), causes quite unexpected behavioral effects (Smith et al., 
1997). These examples highlight the immaturity of this field, and the need for additional 
research.  
Ultimately, functional selectivity is a concept that must be considered when 
dealing with drug discovery. Both further discovery, and a better understanding of the 
multiple signaling pathways coupled to various GPCRs will allow for the design of more 
integrated HTS assays and thus lead to more informed interpretations of ligand-receptor 
structure-activity relationships. Appreciating this concept also may help to explain 
unexpected in vivo findings of functionally weak compounds that illustrate in vivo 
efficacies equivalent to typical agonists. 
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Figure 2.4. Structure and atypical effects of N-n-propyldihydrexidine (PrDHX). (from (Smith et 
al., 1997)) 
FUTURE DIRECTIONS 
A major point of discussion is how these observations of functionally selective 
ligands impact traditional pharmacological principles, from the bench and clinic to the 
classroom. For example, there is the line of thinking that the underlying mechanisms for 
this phenomenon should be more carefully illuminated before a significant push is made 
to establish functional selectivity as an accepted pharmacological mechanism. Proponents 
for this more conservative approach feel that current knowledge of local receptor milieus, 
the involvement of accessory and structural proteins in signaling, receptor dimerization, 
kinetics, and the like, is rather limited, and that this uncertainty opens the door for a 
variety of mechanisms that might provide alternate explanation(s) without requiring 
major revisions in current pharmacological theory.  
Although it is clear there are many gaps in our knowledge of receptor signaling, it 
is apparent that functional selectivity is a real phenomenon with a plethora of supporting 
examples. Indeed, the literature fails to demonstrate any data from appropriately 
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controlled studies that invalidate the functional selectivity hypothesis. Furthermore, some 
receptor mutations have been shown to cause standard ligands to become functionally 
selective, or to alter the signaling pattern of existing functionally selective ligands, 
thereby vividly illustrating that subtle changes to receptor structure (and thus the potential 
conformational landscape) are able to produce atypical functional consequences. It is 
important to note that although this review of functional selectivity has taken a GPCR-
centric view of the receptor world, similar phenomena (e.g., SERM - selective estrogen 
receptor modulation) have been recognized with other receptor superfamilies (e.g., see 
Gronemeyer et al., 2004 for recent review). Thus, the impact of this issue spans the 
breadth of pharmacology. 
In closing, there is a need for even greater understanding of local receptor 
environments and the factors that might play a role in the types of anomalous 
observations reviewed here. These range from accessory proteins (both catalytic and 
organizational), receptor dimerization (both homo- and heterodimers), alternative 
receptor splicing, mRNA editing, receptor polymorphisms (SNPs), trafficking of 
receptors, etc. There is also a need to understand how subtle changes in ligand structure 
can sometimes have profound effects on functional properties. Not only will such data 
provide a firm mechanistic base for functional selectivity (by whatever name it is called), 
but this knowledge also will help us to understand many apparent pharmacological 
anomalies, and potentially lead to novel drug discovery. Some years ago, it was written 
that functional selectivity “…could yield important therapeutic advances, although it 
introduces a new level of complexity that will require significantly greater understanding 
of receptor dynamics and the interaction with transduction mechanisms” (Mailman et al., 
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1997; Mailman et al., 1998). The discussions resulting from the paradoxical data found in 
the literature suggests that the time is ripe to explore these issues further. 
 
  
CHAPTER 3. 
ARIPIPRAZOLE HAS FUNCTIONALLY SELECTIVE ACTIONS AT DOPAMINE 
D2 RECEPTOR-MEDIATED SIGNALING PATHWAYS 
Published in Neuropsychopharmacology (Urban et al., 2006b) 
PREFACE 
Aripiprazole is the newest approved atypical antipsychotic drug that is generally 
accepted as having the best clinical side effect profile of any drug in its class, but a 
controversial mechanism of action. Although the thought leaders in psychiatry have 
called this drug a partial agonist, an alternate hypothesis our laboratory has developed is 
that it is a functionally selective D2 agonist. This chapter explores this issue adding 
additional functional measures to those in the literature, and provides significant data in 
support of the latter hypothesis explaining the antipsychotic atypicality of aripiprazole.  
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ABSTRACT 
Aripiprazole is a unique atypical antipsychotic drug with an excellent side effect 
profile presumed, in part, to be due to lack of typical D2 dopamine receptor antagonist 
properties. Whether aripiprazole is a typical D2 partial agonist, or a functionally selective 
D2 ligand, remains controversial (e.g., D2-mediated inhibition of adenylate cyclase is 
system dependent; aripiprazole antagonizes D2 receptor-mediated G protein-coupled 
inwardly rectifying potassium channels and GTPγS coupling). The current study 
examined the D2L receptor binding properties of aripiprazole, as well as the effects of the 
drug on three downstream D2 receptor-mediated functional effectors: mitogen-activated 
protein kinase (MAPK) phosphorylation, potentiation of arachidonic acid (AA) release, 
and D2 receptor internalization. Unlike quinpirole (a full D2 agonist) or (-)3PPP (a D2 
partial agonist), the apparent D2 affinity of aripiprazole was not decreased significantly 
by GTP. Moreover, full or partial agonists are expected to have Hill slopes < 1.0, yet that 
of aripiprazole was significantly > 1.0. Whereas aripiprazole partially activated both the 
MAPK and AA pathways, its potency versus MAPK phosphorylation was much lower 
relative to potencies in assays of either AA release or inhibition of cAMP accumulation. 
In addition, unlike typical agonists, neither aripiprazole nor (-)3PPP produced significant 
internalization of the D2L receptor. These data provide clear evidence that aripiprazole 
affects D2L-mediated signaling pathways in a differential fashion. The results are 
consistent with the hypothesis that aripiprazole is a functionally selective D2 ligand rather 
than a simple partial agonist. Such data may be useful in understanding the novel clinical 
actions of this drug.  
 55 
INTRODUCTION 
Traditional pharmacology posits that a single compound acting through a single 
receptor will cause a single type of functional response (either full, partial or inverse 
agonism, or antagonism) for all effector pathways associated with that receptor and its 
milieu. Accordingly, compounds have been categorized by their “intrinsic efficacy”, often 
defined by the ability of a ligand to modulate receptor-mediated adenylate cyclase 
activity. There is increasing evidence, however, that many ligands do not conform to such 
a rigid definition of function. In fact, recent observations have led to a growing 
acceptance of the idea that one ligand, while acting on a specific receptor subtype, can 
have multiple intrinsic activities depending upon the effectors being examined and the 
model being employed (Mailman and Gay, 2004; Simmons, 2005).  
For example, we have shown previously that a number of dopamine D2 ligands 
exhibit functionally selective profiles (Mottola et al., 2002; Kilts et al., 2002; Gay et al., 
2004). Further evidence for the ability of ligands to activate GPCR-mediated effectors 
differentially has been illustrated in serotonin 5-HT2A and 5-HT2C (Berg et al., 1998b; 
Kurrasch-Orbaugh et al., 2003), α2A-adrenergic (Brink et al., 2000; Kukkonen et al., 
2001), β2-adrenergic (Ghanouni et al., 2001), cannabinoid CB1 (Glass and Northup, 
1999), µ-opioid (Allouche et al., 1999) and the oxytocin (Reversi et al., 2005) receptor 
expression systems, among others, effectively illustrating functional selectivity as a 
universal mechanism of GPCR effector regulation. It is also important to point out that 
functional selectivity is not an epiphenomenon of a specific receptor expression system, 
as all of the above observations were made in a number of different physiological models. 
This mechanism may be relevant to topical issues in neuropsychopharmacology. 
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Dysfunctional dopaminergic neurotransmission is considered a primary 
mechanism of schizophrenic symptomology (Kapur and Remington, 2001), indeed, the 
early pharmacotherapy for schizophrenia was based on serendipitous discovery of drugs 
that turned out to be dopamine receptor antagonists (Carlsson, 1964). Until recently, all of 
the antipsychotic drugs, whether “typical” or “atypical”, or whether of high or low 
affinity, have been functional D2 antagonists (Miyamoto et al., 2000; Davies et al., 2004; 
Maudsley et al., 2005). A clear exception to this, however, is the recently approved 
antipsychotic drug (APD) aripiprazole (Abilify®). The unique pharmacology of this 
compound first was demonstrated in models that showed aripiprazole activated effectors 
associated with presynaptic D2 autoreceptors, whereas it antagonized D2 postsynaptic 
receptor-mediated effects (Kikuchi et al., 1995). Aripiprazole partially activated D2 
receptor-mediated inhibition of cAMP accumulation, although this action was system-
specific (Lawler et al., 1999; Shapiro et al., 2003). It was suggested that aripiprazole 
appeared to activate D2 receptor-mediated effectors differentially, and could be termed a 
D2 functionally selective drug (Lawler et al., 1999; Shapiro et al., 2003). Conversely, 
Burris et al. (2002) proposed that the unique properties of aripiprazole result solely from 
its partial agonist properties.  
The potential of partial D2 agonists as a novel treatment of schizophrenia was 
based in large part on data showing that apomorphine, a high affinity D2 dopamine 
receptor agonist, could preferentially activate D2 autoreceptors at low doses (Tamminga 
et al., 1978; Roth, 1979). It was hypothesized that a D2 partial agonist might attenuate the 
activity of hyperactive mesolimbic neurons, and possibly increase neurotransmission in 
neurons where there was a deficit of activity (i.e. mesocortical neurons related to working 
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memory). Presumably such compounds also would induce minimal extrapyramidal side 
effects (and tardive dyskinesia) that are associated with the receptor blockade caused by 
typical APDs. The potent D2-like receptor selective agonist N-propylnorapomorphine 
(Tamminga et al., 1986) and (-)3PPP, a D2 receptor partial agonist, thus seemed to have 
antipsychotic potential, although patients quickly lost beneficial effects of these agonists 
rather than having increased efficacy with time as with antipsychotic drugs (Clark et al., 
1982; Tamminga et al., 1992; Lahti et al., 1998b). For these reasons, there was a great 
deal of interest in aripiprazole based on the suggestion that it was the long-anticipated D2 
partial agonist (Lawler et al., 1999; Burris et al., 2002; Shapiro et al., 2003). In the 
process, the idea of functional selectivity (Lawler et al., 1999), despite additional support 
for this mechanism (Shapiro et al., 2003), has been dismissed by many authoritative 
sources (Stahl, 2001b; Tamminga, 2002; Lieberman, 2004).  
Previous work has examined functional effects of aripiprazole at D2-regulated 
adenylate cyclase and receptor-regulated potassium channels (Lawler et al., 1999; Burris 
et al., 2002; Shapiro et al., 2003). The current study extended this by examining the 
binding characteristics of aripiprazole at the low and normal affinity states of the 
dopamine D2 receptor, as well as the effects of the drug on D2L receptor-mediated 
phosphorylation of MAP kinase (extracellular signal-regulated kinases 1 and 2), 
potentiation of AA release (Missale et al., 1998), and ligand-induced D2 receptor 
internalization.  
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METHODS 
Materials 
The following were generously donated to this study: aripiprazole (OPC-14597) 
from Otsuka America Pharmaceuticals (Rockville MD); olanzapine from Eli Lilly Inc. 
(Indianapolis IN), melperone (from Cilag AG-Switzerland), and amisulpride from Dr. 
Shitij Kapur (University of Toronto, Canada). Quinpirole, (-)3PPP [(-)-3-(3-
hydroxyphenyl)-N-(1-propyl)piperidine], haloperidol, and clozapine were purchased from 
Sigma/RBI (Natick, MA), whereas dopamine, mepacrine, staurosporine, melittin, 
adenosine triphosphate, guanosine triphosphate, EDTA, dithiothreitol, sucrose, pepstatin 
A, leupeptin, PMSF and other standard laboratory compounds were purchased from 
Sigma Chemical Co. (St. Louis, MO). Sources of other reagents were as follows: 2’-
amino-3’-methoxyflavone (PD98059) was purchased from BIOMOL Research 
Laboratories, Inc. (Plymouth Meeting, PA); [3H]N-methylspiperone from PerkinElmer 
Life Sciences, Inc. (Boston, MA); [5,6,8,9,11,12,13,14-3H]arachidonic acid from 
Amersham Biosciences Inc. (Piscataway, NJ); HEPES from Research Organics Inc. 
(Cleveland, OH); Ham’s F-12 and DMEM media, penicillin, streptomycin and geneticin 
(G418) from Invitrogen Co. (Carlsbad, CA); primary antibody to phospho-Erk1/2 MAP 
kinase and secondary anti-rabbit HRP-conjugated antibody from Cell Signaling 
Technology Inc. (Beverly, MA). M1 anti-FLAG antibody was purchased from Sigma and 
Alexa594-conjugated goat anti-mouse was from Jackson ImmunoResearch (Malvern, 
PA). 
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Cells and membranes 
The CHO-hD2L cells are a stable line originally obtained from Dr. Tony 
Sandrasagra (Aventis, Bridgewater, NJ). CHO-hD2L cells were maintained in Ham’s F-12 
medium supplemented with 10% FBS, 100 U/mL penicillin, 100 µg/mL streptomycin and 
500 µg/mL G418 at 37°C and 5.0% CO2. CHO-hD2L cells were grown to confluence in 
75-cm2 flasks. Five mL of cold phosphate buffered saline was used per flask to rinse the 
cells, after which 5 mL of lysis buffer (2 mM HEPES, 2 mM EDTA, 1 mM dithiothreitol, 
1 µg/mL pepstatin A, 0.5 µg/mL leupeptin and 10 µg/mL PMSF, pH 7.4 with HCl) was 
added to each flask. Following 10-20 min of incubation at 4°C, the cells were scraped and 
collected. The cell suspension was homogenized with three strokes in a Wheaton glass 
homogenizer and centrifuged at 30,000g for 20 min. The resulting supernatant was 
discarded, the pellet resuspended in storage buffer (50 mM HEPES, 0.32 M sucrose, 1 
µg/mL pepstatin A, 0.5 µg/mL leupeptin and 10 µg/mL PMSF, pH 7.4 with NaOH) at 
approximately 1 mg protein/mL, homogenized again and aliquoted into 1-mL 
microcentrifuge tubes. The cell membranes then were frozen, and stored at -80°C until 
further use. 
Saturation and Competition Binding 
Saturation studies were performed to verify the expression level of hD2L receptor 
in the CHO cells, as well as to determine the levels of FLAG-tagged D2L receptor 
expressing in the HEK cells. Membranes were incubated with varying concentrations of 
[3H]N-methylspiperone in binding buffer (50 mM HEPES, 4 mM MgCl2, pH=7.4 with 
KOH). Non-specific binding was determined using 10 µM domperidone. Competition 
binding studies were carried out using 0.3 nM [3H]N-methylspiperone with and without 
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600 µM GTP to determine differences in affinity of each D2 receptor ligand for the high 
and low affinity hD2L receptor states in the CHO cell line. Total binding was determined 
by the amount of radioligand binding in the absence of competing drug, while non-
specific binding was defined by the amount of radioligand bound in the presence of 10 
µM haloperidol. Six to seven log orders of concentrations of each D2 receptor ligand were 
used. For both binding paradigms, addition of the tissue to each assay tube initiated the 
binding. Each drug condition was run in triplicate per experiment in a final volume of 500 
µL. Following a 15 min incubation at 37°C, tubes were filtered through a FilterMate 196 
Cell Harvester (PerkinElmer Life and Analytical Sciences, Boston, MA) and the plates 
were washed four times with ice-cold buffer. The filters were dried in an oven at 55°C for 
30 min., and 35 µL of Packard MicroScint 20 scintillation cocktail was added to each 
well (PerkinElmer). A Packard TopCount NXT (PerkinElmer) was used to determine the 
radioactivity of each sample. Saturation binding data were expressed in fmol of 
receptor/mg of protein. Competition binding data were expressed as a percentage of 
specific binding. 
Cell-based ELISA for the measurement of MAPK activation 
Measurements of phosphorylated extracellular signal-regulated kinase 1 and 2 
(Erk1/2) were made using a published protocol (Versteeg et al., 2000). CHO cells (both 
wild type and those transfected with the human D2L receptor) were seeded in 96-well 
plates in F-12 Ham’s media (10% FBS) at 50,000 cells/cm2 and allowed to grow at 37°C 
and 5% CO2 for 48 hr. Cells were serum-starved for six hr prior to stimulation, after 
which appropriate drugs were added to each well at a volume of 100 µL for 10 min. The 
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reaction was terminated and cells fixed by aspirating each well and adding 100 µL of 4% 
formaldehyde PBS solution for 20 min. Cells were washed three times with 100 µL wash 
buffer (0.1% Triton X-100/PBS solution), followed by a 20 min incubation with 0.6% 
H2O2 Triton/PBS solution to quench endogenous peroxidases. After washing the cells 
three times again with wash buffer, and after a 1 hr incubation with 10% BSA in 
Triton/PBS solution (to block non-specific antibody binding), cells were incubated 
overnight (about 12 hr) with a 1:250 dilution of PhosphoPlus® p44/42 1° antibody in the 
Triton/PBS solution (100 µL) containing 5% BSA at 4°C. Cells were washed three times 
with wash buffer for five minutes and incubated with 100 µL HRP-conjugated goat anti-
rabbit 2° antibody (1:100 dilution) with 5% BSA at room temperature for 1 hr. Again, 
cells were washed three times with wash buffer for five minutes, and then twice with 
PBS. Cells were then incubated with 50 µL of an o-phenylenediamine (OPD) solution 
(0.4 mg/mL OPD, 17.8 mg/mL Na2HPO4·7H2O, 7.3 mg/mL citric acid and 0.015% H2O2) 
for 15 min at room temperature in the dark. The reaction was terminated by the addition 
of 25 µL of 1 M H2SO4, and the well-solution analyzed spectrophotometrically (using the 
Vmax Kinetic Microplate Reader from Molecular Devices) at absorbance wavelengths 
A490 - A650.  
Arachidonic Acid Release Assay 
Measurements of PLA2 arachidonic acid release were made by modifying a 
protocol described by Berg et al. (1996). CHO-K1 cells (both wild type and those 
transfected with the human D2L receptor) were seeded in 24-well plates in F-12 Ham’s 
media (10% FBS) at 50,000 cells/well and allowed to grow at 37°C and 5% CO2 for 24 
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hr. 500 µL of serum-free Ham’s complete media containing 0.5 µCi/mL 
[5,6,8,9,11,12,14,15-3H] arachidonic acid was added to wells, after which cells were 
preincubated for 5 hr. Cells were then washed three times for 5 min with Hank’s balanced 
salt solution (HBSS) containing 0.5% fatty acid free BSA and appropriate enzyme 
inhibitors and antagonists (500 µL/well/wash). Following the washes, the cells were 
incubated for 15 min with appropriate agonists with or without ATP dissolved in the 
HBSS/BSA (1 mL/well). Three 200 µL sample aliquots were taken from each well and 
the radioactivity of the samples was counted using liquid scintillation spectrometer 
techniques.  
Epifluorescence microscopy 
HEK293 cells had been stably transfected with FLAG epitope-tagged D2L 
receptors, and their functional integrity previously confirmed (Vickery and von Zastrow, 
1999). As described previously (Vargas and von Zastrow, 2004), these cells were plated 
on glass coverslips and the surface receptors specifically labeled using 3 µg/ml anti-
FLAG M1 monoclonal antibody. Cells were exposed to the indicated ligands at 37°C for 
30 min, fixed using 4% formaldehyde dissolved in PBS, and then labeled receptors were 
detected by secondary incubation with Cy3-conjugated goat anti-mouse antibody (1:1,000 
dilution). Specimens were visualized by confocal fluorescence microscopy using a Zeiss 
LSM510 microscope fitted with a Zeiss 63XNA1.4 objective operated in single photon 
mode with standard filter sets and standard (1Airy disc) pinhole. Metamorph software 
(Molecular Devices) was employed to count internalized vesicles in 20 random cells per 
condition per coverslip, with 3-6 coverslips representing each condition. 
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Data analysis 
Except where noted, data are expressed as means ± SEM. Data from receptor 
saturation isotherms was analyzed using non-linear regression with a one-site hyperbolic 
model, and the data converted to KD and Bmax. The receptor competition data was 
analyzed by non-linear regression using a sigmoidal model with variable slope, yielding 
IC50 and Hill slopes values. The IC50s were corrected for radioligand concentration and 
converted to K0.5 values using the Cheng-Prusoff formula for a bimolecular competition 
model (Cheng and Prusoff, 1973). Changes in affinity in the competition assays were 
tested for significance by performing a one-way analysis of variance (ANOVA), followed 
by a Tukey-Kramer multiple comparisons post hoc analysis. Functional dose-response 
curves also were analyzed by nonlinear regression using Prism 4.0’s sigmoidal equation 
with variable slope in order to determine estimates of intrinsic activity and apparent 
potency. Differences in potency values between the MAPK and AA release effectors for 
each agonist was analyzed with an unpaired two-sided t-test, whereas differences among 
the drug groups were assessed by ANOVA. Significant ANOVA results were followed by 
the appropriate (Bonferonni’s or Dunnett’s) post hoc analysis, again performed using 
Prism 4.0. 
RESULTS 
Experiment 1: [3H]N-methylspiperone binding 
The saturation data for [3H]N-methylspiperone binding to this receptor fit a one-
site binding model in both cell lines, and yielded the following parameters. 1) CHO-hD2L: 
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KD = 0.39 ± 0.11 nM, Bmax = 6.57 ± 0.63 pmol/mg protein; and 2) HEK293-FLAG-D2L: 
KD = 0.34 ± 0.07 nM, Bmax = 1.5 ± 0.26 pmol/mg protein (N = 3 for both lines).  
Competition of four D2 ligands versus [3H]N-methylspiperone binding was carried 
out using CHO-hD2L cell membranes both in the absence and presence of 600 µM GTP. 
The resulting competition curves were best fitted to a variable slope binding model, from 
which their apparent affinities (K0.5) and Hill slope values (nH) were derived (Table 3.1). 
Analysis of variance was utilized to evaluate shifts in affinity in the presence of GTP. 
Both quinpirole and (-)3PPP demonstrated significant loss of affinity in the presence of 
GTP, as would be expected of a GPCR agonist, and is illustrated by a rightward shift of 
their competition curves (Figures 3.1A- 1B). They also display Hill slope values typical 
of agonists (nH < 1) in the absence of GTP. Conversely, aripiprazole failed to demonstrate 
a significant change in affinity (Table 3.1 & Figure 3.1C).  
Table 3.1. Binding affinities and Hill slope values of ligands for hD2L receptors in CHO 
cells in the absence and presence of 600 µM GTP.  
 Drug alone + 600 µM GTP 
Compound K0.5 nH K0.5 nH 
Quinpirole 820 ± 70 -0.79 ± 0.12 2180 ± 160 *** -0.89 ± 0.09 
(-)-3PPP 1300 ± 170 -0.74 ± 0.13 2360 ± 200 *** -0.96 ± 0.13 
Aripiprazole 40.3 ± 4.3 -1.4 ± 0.2 52.7 ± 5.7 -1.2 ± 0.2 
Haloperidol 2.68 ± 1.02 -1.1 ± 0.2 2.38 ± 0.79 -0.90 ± 0.12 
Binding data represent the means ± SEM (in nM) from five to seven independent experiments 
performed in triplicate. Significant shifts are appropriately marked according to the results of 
ANOVA and Tukey-Kramer multiple comparison’s post hoc analyses (***p < 0.001). 
It was observed, however, that there was a small, but consistent, shift in every 
experiment. A more stringent analysis (paired one-tailed t test) was employed, and it 
determined that the slight shifts were indeed significant. It appears, therefore, that the 
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binding of aripiprazole is slightly affected by the G protein coupled state of the D2L 
receptor, and is unique among the D2 receptor agonists studied. Moreover, the Hill slope 
for aripiprazole (nH > 1) does not correspond with what would be expected of either an 
agonist or antagonist following the law of mass action. There appears to be a suggestion 
of positive cooperativity that affects the binding of aripiprazole to the D2L receptor. As 
expected, the apparent affinity of the typical APD and known D2 receptor antagonist, 
haloperidol, was not affected by GTP (Figure 3.1D), and its Hill slope value in the 
absence of GTP corresponds well with what would be expected of an antagonist (nH ~ 1).  
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Figure 3.1. Binding of test ligands to hD2L receptors in the presence or absence of 600 µM GTP. 
Membranes were prepared from CHO cells stably expressing hD2L receptors. Receptors were 
labeled with ~ 0.3 nM [3H]N-methylspiperone. Non-specific binding was defined by 10 µM 
haloperidol. For each compound, five to seven independent experiments were performed. The 
curves shown are from representative experiments. Summary of quantitative analysis is shown in 
Table 1. 
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Experiment 2: Aripiprazole activation of D2 receptor-mediated MAP Kinase 
phosphorylation 
To confirm that the D2 receptor-mediated activation of the MAPK pathway was 
indeed regulated by MEK, the maximal MAPK phosphorylation by quinpirole was shown 
to be fully inhibited by 50 µM PD98059, an inhibitor of MEK (data not shown). 
Quinpirole exhibited slightly higher intrinsic activity than the endogenous agonist 
dopamine, while (-)3PPP and aripiprazole displayed about 60% and 50% of the activity of 
quinpirole, respectively (Figure 3.2).  
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Figure 3.2. Activation of MAPK phosphorylation. The ability of D2L ligands with known agonist 
activity to phosphorylate MAPK was assessed in CHO-hD2L cells, and observations were 
quantified using an enzyme-linked immunosorbent assay. Cells were incubated with increasing 
concentrations of D2L ligand for 10 min at room temperature (20C). Both quinpirole and 
dopamine displayed intrinsic activities that corresponded to full agonists, while aripiprazole and 
3PPP were partial agonists. The rank order of potency was quinpirole = dopamine > 3PPP > 
aripiprazole. Data are expressed as a percentage of the maximal stimulation of quinpirole over 
basal phosphorylation. All values represent the mean ± SEM of four to five experiments conducted 
in quadruplicate. 
The rank order of potency among the four compounds was dopamine = quinpirole 
> (-)3PPP > aripiprazole. Haloperidol fully inhibited maximally stimulating 
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concentrations of all four agonists, further indicating that the pathway is D2 receptor-
mediated. It was also confirmed that aripiprazole failed to promote the phosphorylation of 
MAPK in the untransfected CHO-K1 cell line (Figure 3.3). The other atypical APDs 
(clozapine, olanzapine, amisulpride and melperone) showed no significant intrinsic 
activity for MAPK phosphorylation, and largely inhibited a maximally-stimulating 
concentration (100 nM) of quinpirole (Figure 3.3). The inability of clozapine, olanzapine 
and melperone to inhibit the MAPK effector pathway fully can be attributed to inadequate 
fractional occupancy at concentrations used rather than low intrinsic partial agonism. 
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Figure 3.3. Atypical APD effect on D2L-mediated phosphorylation of MAPK. Abbreviations: 
Haloperidol (Hal), Amisulpiride (Ami), Clozapine (Clz) Melperone (Mel), Olanzapine (Ola), 
Aripiprazole (Ari), the following design was used. Open bars: each compound alone (10 µM). 
Antagonism study (black bars) were versus a challenge concentration of quinpirole (100 nM 
except in the case of aripiprazole where 10 µM was used (see results). None of the compounds 
except aripiprazole caused a significant response alone. All of the atypical APDs except 
aripiprazole were able to block quinpirole stimulation to a similar degree as haloperidol. Inset: 
the degree of MAPK stimulation elicited by aripiprazole (Ari) (closed bars) relative to basal levels 
of MAPK activity (open bars) in the untransfected parental CHO-K1 cell line. Data are expressed 
as a percentage of the maximal stimulation of quinpirole over basal phosphorylation. Each value 
represents the mean ± SEM of three independent experiments conducted in triplicate. 
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Experiment 3: Aripiprazole promotes the D2 receptor-mediated potentiation of 
arachidonic acid release 
There has been much debate on the pathway mechanism of GPCR-mediated 
arachidonic acid release, and it appears that the mechanism may vary somewhat among 
different receptors and may be dependent on multiple signaling pathways (Xu et al., 
2002). We used staurosporine (a pan-kinase inhibitor), PD98059 (a MEK inhibitor), and 
Ro318220 (a protein kinase C inhibitor), in the presence of 10 µM quinpirole. 
Staurosporine and PD98059 both inhibited AA release (73% and 54%, respectively), but 
did not cause an additive change when cells were treated with both (53% inhibition). 
Analysis by ANOVA with Bonferroni’s post hoc test demonstrated that there was no 
significant difference among these three inhibitor treatment scenarios (Figure 3.4). 
Treatment with Ro318220 failed to affect the intrinsic activity of quinpirole, indicating 
that the activity of PKC does not appear to influence D2L-meditated potentiation of AA 
release in this CHO cell line. Our observations indicate that, at least in the CHO cell line, 
the potentiation of AA release as regulated by hD2L receptor activation is dependent on 
multiple pathways. Mepacrine (100 µM) fully inhibited the quinpirole potentiation of AA 
release, whereas melittin was found to stimulate the release of AA (data not shown), 
suggesting the role of PLA2 in the hD2L receptor-mediated potentiation of the AA release 
signaling pathway.  
Similar to the MAPK effector studies, all four of the D2 ligands were able to 
potentiate the release of AA to varying degrees. Both quinpirole and dopamine fully 
stimulated AA release, while aripiprazole and (-)3PPP demonstrated partial activity of the 
effector pathway (Figure 3.5). The rank order of potency among the four compounds was 
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aripiprazole > dopamine = quinpirole > (-)3PPP. Of interest, however, were the potencies 
that characterized the activities of the compounds for the pathway (Table 3.2).  
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Figure 3.4. PD98059 and staurosporine inhibition of [3H]AA release. Cells were treated with 
PD98059 (50 µM) and staurosporine (100 nM) either alone or together in the presence of a 
maximally-stimulating concentration of quinpirole (10 µM). Both inhibitors were able to block 
significantly quinpirole-stimulated [3H]AA release, but there was no significant difference used 
alone or together (ANOVA, Bonferroni post hoc). In addition, neither alone nor in combination 
did these compounds cause total inhibition of [3H]AA release. Ro318220 (100 nM) also was used 
in the presence of quinpirole, but this PKC-specific inhibitor failed to block quinpirole activity. 
Data are expressed as a percentage of the maximal stimulation of quinpirole over ATP basal 
[3H]AA release. Each value represents the mean ± SEM of three independent experiments 
conducted in triplicate. 
Whereas the three typical agonists had potencies for AA release fairly congruent 
with those observed for the MAPK pathway, aripiprazole illustrated a 20-fold higher 
potency for the D2 mediated potentiation of AA release than MAPK phosphorylation. 
Further analysis of the potency differences between MAPK and AA release experiments 
for each drug using ANOVA (followed by a Dunnett’s post hoc multiple comparisons 
test) illustrated that only aripiprazole exhibited a significant potency shift relative to that 
of quinpirole (p < 0.01). Incidentally, the EC50 of aripiprazole for AA release is similar 
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to the potency of aripiprazole reported for D2 receptor-mediated inhibition of adenylate 
cyclase (Lawler et al., 1999; Burris et al., 2002; Shapiro et al., 2003).  
Table 3.2. Functional potencies of agonists for hD2L receptors in CHO cells.  
Compound Quinpirole Dopamine (-)-3PPP Aripiprazole 
MAPK 
phosphorylation 
13.4 ± 3.3 8.8 ± 0.9 92.8 ± 12.5 170 ± 35 ** 
[3H]arachidonic 
acid release 
17.3 ± 1.5 31.9 ± 11.8 71.1 ± 12.9 1.53 ± 0.39 
Functional data represent the means ± SEM (in nM) of three to five independent experiments. 
Significant potency shifts between the functional endpoints among the compounds was determined 
by ANOVA followed by a Dunnett’s multiple comparisons post hoc analysis with each compound’s 
mean shift difference compared to that of quinpirole (**p < 0.01, with all other comparisons 
having p > 0.05). See Material and Methods for further details. 
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Figure 3.5. Potentiation of [3H]AA release. The ability of D2L ligands with known agonist activity 
to potentiate the release of [3H]AA was assessed in CHO-hD2L cells that were incubated with 0.5 
µCi/mL [3H]AA-supplemented media for 5 hrs. Cells were then exposed to varying concentrations 
of ligand at 37°C for 15 min. dopamine stimulated AA release with similar intrinsic activity to 
quinpirole, while both 3PPP and aripiprazole were partial agonists. The rank order of potency 
was aripiprazole > quinpirole = dopamine > 3PPP. Data are expressed as a percentage of the 
maximal stimulation of quinpirole over ATP basal [3H]AA release. All values represent the mean 
± SEM of three independent experiments conducted in triplicate. 
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As with the MAPK studies, haloperidol was able to fully inhibit the ability of all 
four compounds to potentiate AA release, verifying D2L receptor activation as the means 
by which these ligands were able to exact their influence on the pathway. It was also 
observed that aripiprazole was unable to promote the release of AA in the parental CHO-
K1 cell line, confirming that the activity of aripiprazole at this effector is specific to the 
transfected D2L receptor. Finally, none of the other atypical APDs examined illustrated 
agonist activity for the AA release pathway (Figure 3.6). 
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Figure 3.6. Atypical APD effect on D2L receptor-potentiation of [3H]AA release. Abbreviations: 
haloperidol (Hal), amisulpiride (Ami), clozapine (Clz) melperone (Mel), olanzapine (Ola), 
aripiprazole (Ari). Open bars: intrinsic activity of each compound alone (10 µM). Antagonism  
(black bars) used same concentration of each potential antagonist vs.  quinpirole (100 nM except 
in the case of aripiprazole, where 10 µM was used). No compound except aripiprazole caused a 
significant response alone. All atypical APDs except aripiprazole were able to block quinpirole 
stimulation to a similar degree as haloperidol. Inset: the degree of MAPK stimulation elicited by 
aripiprazole (closed bars) relative to basal levels of MAPK activity (open bars) in the 
untransfected parental CHO-K1 cell line. Data are expressed as a percentage of the maximal 
stimulation of quinpirole over ATP basal [3H]AA release. Each value represents the mean ± SEM 
of two to three independent experiments conducted in triplicate. 
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Figure 3.7. Ligand effects on receptor internalization. FLAG-tagged D2L receptors expressed 
stably in HEK293 cells were specifically labeled at 37°C with M1 mAb as described in Materials 
and Methods. Fluorescence microscopy was used to visualize the localization of antibody-labeled 
receptor in cells incubated for 30 min in: (A) No drugs; (B) 10 µM dopamine; (C), 10 µM 
aripiprazole; or (D) 10 µM 3PPP. Representative micrographs of each condition are shown. 
Aripiprazole fails to stimulate internalization of the FLAG-tagged hD2L receptor 
It was originally thought a compound that displayed an agonist functional profile 
would induce some degree of receptor endocytosis, and that competitive antagonists, by 
their very nature, would be unable to provoke such a response (Ferguson, 2001). More 
recent evidence indicates, however, that certain antagonists can internalize certain 
receptors (Berry et al., 1996; Roettger et al., 1997), and that the internalization process 
can be agonist-specific depending on the cellular milieu specific to that receptor 
expression system (Ryman-Rasmussen et al., 2005). These observations complement the 
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fundamentals of functional selectivity which state that the intrinsic activity of a ligand is 
dependent upon the pathway being examined and the model around which the 
investigation revolves. Thus the study of the ability of a ligand to stimulate receptor 
internalization has been utilized to understand this aspect of the functional profile of 
many GPCR ligands. Utilizing HEK293-fD2L cells (Bmax = 1.50 ± 0.26 pmol receptor/mg 
protein) and epifluorescent microscopy techniques, we were able to observe a pronounced 
dopamine-induced increase in the internalization of the FLAG-tagged D2L receptors 
relative to basal levels (Figure 3.7A & 3.7B). Neither aripiprazole, nor the D2 partial 
agonist (-)3PPP, however, were able to elicit a detectable endocytotic response relative to 
basal levels (Figure 3.7C & 3.7D). Quantification of these results is shown in Figure 3.8.  
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Figure 3.8. Quantification of ligand-mediated differences in dopamine receptor internalization 
in stably transfected D2L cells. Ligand-dependent dopamine receptor internalization was assayed 
as described in the Methods. A significant number of endocytic vesicles containing endocytosed 
M1 antibody were observed in untreated cells (NT), consistent with the constitutive internalization 
that has been observed for this receptor. There was, however, a large increase in antibody uptake 
induced by dopamine (10 µM for 30 min). In contrast, neither aripiprazole (Arip) or S(-)-3-(3-
hydroxyphenyl)-N-propylpiperidine hydrochloride [(-)3PPP] mediated significant endocytosis of 
monoclonal antibody. The bars represent the mean number of antibody-positive vesicles (± S.E.) 
detected by MetaMorph (Molecular Devices) analysis of a region of interest that outlined the 
entire intracellular area in 20 cells.  
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DISCUSSION 
Pharmacotherapy for the treatment of schizophrenia has utilized several strategies 
over the past five decades, although the pharmacological mechanism common to all 
successful drugs is the antagonism of dopamine D2 receptors (Kapur and Mamo, 2003). 
The unique pharmacology of aripiprazole, a drug having both partial agonist and 
antagonist activity at D2 receptor functions depending on the endpoint under study, 
suggests that functionally selective ligands may provide a new arena for the development 
of novel therapeutics for psychoses and other disorders (Miyamoto et al., 2000; Davies et 
al., 2004; Maudsley et al., 2005). The current study was designed to shed further light on 
the question of whether the D2 activity of aripiprazole is simple partial agonism or a case 
of ligand-induced differential signaling. To further investigate this issue, the D2 receptor-
mediated signaling profile of aripiprazole was compared to several other atypical APDs 
and to both a full and partial agonist, by investigating effectors that, to date, had been 
used infrequently to characterize APD pharmacology.  
First, the apparent affinity of the D2 receptor ligands was determined in CHO cells 
stably expressing the hD2L receptor. The rank order of apparent affinities was similar to 
what has been reported previously (haloperidol > aripiprazole > quinpirole > (-)3PPP). 
Agonists for GPCR receptors are expected to produce competition isotherms that shift to 
the right in the presence of guanine nucleotides (Lefkowitz et al., 1978), a phenomenon 
clearly illustrated by the current quinpirole and (-)3PPP binding data. Although GTP 
caused a consistent shift in the aripiprazole competition curves, this effect was very 
small, and was statistically significant only when utilizing a one-sided paired t-test. 
Conversely, quinpirole and (-)3PPP, but not haloperidol, caused a larger shift in affinity 
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and Hill slope (see Table 3.1). These data with aripiprazole may reconcile with the 
previously published GTPγS binding data in which aripiprazole was found to be a pure 
antagonist of D2 receptor-mediated GTPγS release in CHO-hD2L membranes (Shapiro et 
al., 2003).  
Also of interest were Hill slopes (nH) for aripiprazole that were greater than 1.0. A 
Hill slope less than one is often considered a reflection of the ability of a ligand to bind to 
G protein precoupled receptors with a higher affinity than uncoupled receptors. Thus, 
antagonists tend to have Hill slope values close to one since they fail to differentiate 
between the precoupled and uncoupled receptor populations, thereby obeying the general 
law of mass action for single site competition. As expected, both the typical full and 
partial agonists quinpirole and (-)3PPP had different affinities for these populations of 
hD2L receptors based on the changes in competition curves seen in response to GTP. The 
competition isotherm of haloperidol fits the binding profile of a typical antagonist (i.e., it 
both lacks a GTP shift and has an nH value close to one). The steep slope for aripiprazole, 
as well as a small but significant GTP effect, suggests additional mechanisms are 
involved. One hypothesis for such observations is that certain ligands may promote 
positive cooperativity of dimerized or oligomerized receptor (Lavoie and Hebert, 2003), 
or by allosteric interaction with a secondary domain of the receptor or another protein 
present in the microdomain (e.g. a scaffolding or accessory/chaperone protein). It is 
plausible that the receptor-receptor or receptor-protein interaction that imparts this 
positive cooperativity only occurs upon the induction of specific receptor conformations. 
Whatever the case, the unique receptor binding characteristic of aripiprazole is not 
exclusive to the CHO-hD2L stable cell model, as similar observation was made in brain 
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tissue (Lawler et al., 1999). Further study is necessary to understand the underlying 
mechanism. 
It is known that D2 receptor agonists can stimulate the MAPK pathway in stable 
C6 and CHO transfected cells (Luo et al., 1998; Choi et al., 1999). By modifying an 
ELISA high-throughput assay (Versteeg et al., 2000), we were able to determine intrinsic 
activities and potencies for the D2 ligands we studied. The intrinsic activity of 
aripiprazole correlates well with its reported activity for the D2L-mediated inhibition of 
cAMP accumulation (Lawler et al., 1999; Burris et al., 2002; Shapiro et al., 2003). The 
major point of interest, however, lies in the low potency of aripiprazole for the MAPK 
effector pathway. With the exception of aripiprazole, prior cAMP inhibition EC50 data 
for all compounds correspond fairly well with the MAPK potencies reported in this study 
(Wilson et al., 2001; Burris et al., 2002; Gay et al., 2004).  
The biosynthesis and regulation of prostaglandin-like compounds by 
catecholamines has been of interest for several years (Levine and Moskowitz, 1979). The 
ability of the D2 receptor to mediate the release and metabolism of arachidonic acid from 
the intercellular membrane is known (Piomelli et al., 1991; Felder et al., 1991), and 
although the exact mechanism is not well understood, there has been much discussion as 
to how it might be regulated by other signaling effectors, most notably adenylate cyclase, 
MAPK and PKC (see Chakraborti, 2003 for review). There appears to be significant 
evidence that the GPCR-mediated release of arachidonic acid, in fact, may be regulated 
by more than just one pathway, and both the MAPK and PKC effectors appear to play 
significant roles in arachidonic acid release (Xu et al., 2002). For this study it was vital to 
demonstrate that the release of arachidonic acid was not solely dependent on a D2 
 77 
receptor-mediated effector already under study (i.e., MAPK phosphorylation). Neither 
staurosporine, nor PD98059, was able to inhibit the D2 receptor-mediated release of 
arachidonic acid fully. This demonstrates a significant degree of independence of 
arachidonic acid release from modulation by MAPK signaling pathways. In addition, 
PKC inhibition had no effect on the D2 receptor regulation of this pathway. This 
independence of D2L-mediated arachidonic acid release from PKC indicates that this cell 
line differs from some others (Xu et al., 2002). 
The intrinsic activity (Emax) of aripiprazole for arachidonic acid release proved to 
be similar to its ability to stimulate the phosphorylation of MAPK (Figures 3.3 and 3.6), 
although its potency for the former endpoint clearly paralleled its reported potency for the 
D2 receptor-mediated inhibition of cAMP accumulation (Lawler et al., 1999; Burris et al., 
2002; Shapiro et al., 2003). This method of comparison assessment is valid because the 
intrinsic activity of aripiprazole was similar at both MAPK and AA release, and therefore 
the direct comparison of ED50’s is equivalent to the direct comparison of ED50/Emax. 
Unlike aripiprazole, the D2 agonists quinpirole, dopamine and (-)3PPP all displayed 
potencies for the release of arachidonic acid similar to that for the phosphorylation of 
MAPK. In fact, the difference in the potencies of aripiprazole between the two effectors 
is over twenty-fold (Figure 3.9). This disparity is especially striking in context with the 
observation that other functionally selective D2L ligands (e.g., DHX, DNS, RNPA) also 
have demonstrated significant potency differences among D2 receptor effectors (Gay et 
al., 2004).  
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Figure 3.9. Relative potency of D2L ligands for the potentiation of AA release and 
phosphorylation of MAPK. Ligands with similar potency for both AA release and MAPK 
phosphorylation have a log (fold change) of close to zero [quinpirole (QUIN) and 3PPP], 
whereas compounds having decreased potency for MAPK phosphorylation relative to AA release 
display a negative change [aripiprazole (ARI)], and ligands with an increased potency for MAPK 
phosphorylation compared to AA release display a slight positive change [dopamine (DA)]. Data 
illustrated for each ligand are expressed as the log of EC50 (nM) for MAPK phosphorylation 
divided by their respective log of EC50 value for AA release. 
The intrinsic activity of aripiprazole for the D2L receptor-mediated 
phosphorylation of MAPK may not be of significant physiological relevance since the 
cell system used had a high level of receptor expression (Bmax ~ 6 pmol/mg protein). It is 
well-documented that, in systems with high receptor reserve, compounds with low 
intrinsic activity can mimic compounds with higher intrinsic activities for that effector 
system (e.g., Watts et al., 1995). This notion, coupled with preliminary experiments that 
utilized the non-specific, irreversible protein binding compound EEDQ to reduce receptor 
levels (data not shown), suggests that D2-modulation of MAPK may not be an effector 
pathway affected by aripiprazole in physiologically-relevant systems. It underscores the 
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importance of using, when available, cell lines that mirror as much as feasible those cells 
expressing the receptor under study in situ. 
The model commonly used to illustrate GPCR internalization describes an agonist-
receptor interaction that promotes receptor phosphorylation via a GRK or other kinase, 
with subsequent arrestin binding and receptor sequestration via clathrin-coated pits (von 
Zastrow, 2003). Not all GPCRs follow the same mechanism of internalization, and the 
intracellular loops of a receptor, as well as the local cellular milieu, play an important 
role in the mechanism of endocytosis (Ferguson, 2001). D2 receptors have been shown to 
internalize in a manner dependent upon GRKs, clathrin, and dynamin (Kim et al., 2001) 
although dynamin-independent internalization can be observed in cells expressing GRKs 
at lower levels (Vickery and von Zastrow, 1999). Studies in an HEK293-fD2L system 
showed that the D2L receptor displays both basal (constitutive) and dopamine-induced 
internalization, and that haloperidol can block dopamine-induced, but not constitutive, 
internalization (Vickery and von Zastrow, 1999). Our study indicates that neither 
aripiprazole, nor the typical partial agonist (-)3PPP, induce a significant degree of 
internalization relative to basal levels, indicating that either D2 ligands with low intrinsic 
activity fail to produce D2 receptor internalization, or that these two compounds are 
unique in their promotion of receptor conformations that cannot be phosphorylated by the 
appropriate kinases. Although (-)3PPP can desensitize the D2 receptor (Lahti et al., 
1998b), it is clear that this does not necessarily predict internalization (Lewis et al., 1998; 
Ryman-Rasmussen et al., 2005). Further experiments are needed to determine whether D2 
receptor internalization is a product unique to ligands that are full agonists, or if 
aripiprazole and (-)3PPP are unique in their inability to internalize the D2 receptor.  
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Some of the most efficacious atypical APDs (clozapine, amisulpride, olanzapine), 
as well as a compound considered to have good atypical APD potential (melperone), were 
also studied. Vanhauwe et al., (2000) had reported that these compounds should be 
considered as D2 receptor antagonists based on their inhibition of adenylate cyclase, 
although melperone was not studied by them. We hypothesized that a study of their 
regulation of D2L function might reveal functional characteristics that explained some of 
their behavioral atypicality. The current study demonstrates that none of these four 
atypicals have any D2L intrinsic activity for either MAPK phosphorylation or AA release, 
and all four blocked the activity of quinpirole for both endpoints. Thus, these data suggest 
that neither the efficacy nor low EPS of these compounds involves functional selectivity. 
In conclusion, the promise of even more effective D2 partial agonists has been 
widely proposed based on the success of aripiprazole (Burris et al., 2002; Lieberman, 
2004; Bolonna and Kerwin, 2005). Conversely, we have suggested that functional 
selectivity at D2 receptors, probably combined with actions at non-dopamine receptors 
(Lawler et al., 1999; Shapiro et al., 2003), is the more likely mechanism responsible for 
the atypicality of this drug. It seems clear to us that the available evidence (including the 
current work) supports only the latter hypothesis. No other D2 partial agonist has shown 
similar therapeutic promise to aripiprazole. More importantly, even those who have 
advocated for simple partial agonism (Burris et al., 2002) now have shown cell-dependent 
differences in the intrinsic activity of aripiprazole (Tadori et al., 2005). The most 
parsimonious way to reconcile the available data is accept the hypothesis that the pattern 
of D2 functional selectivity, and/or combined with actions at other receptors systems (e.g., 
5-HT1A, 5-HT2C, etc.), mediate the novel actions of aripiprazole, rather than simple partial 
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agonism. More detailed understanding of these mechanisms may help find a drug with an 
improved clinical profile.  
 
  
CHAPTER 4. 
INVOLVEMENT OF D2L DOPAMINE RECEPTOR TM 5 SERINES IN BINDING 
AND FUNCTION OF PARTIAL AGONISTS AND FUNCTIONALLY SELECTIVE 
LIGANDS  
To be submitted to: 
Molecular Pharmacology 
PREFACE 
In the previous Chapters, I have provided evidence for the phenomenon of 
functional selectivity, and the role of this mechanism in the actions of the atypical 
antipsychotic drug aripiprazole. Recent data have shown that TM 5 serine residues of the 
D2L receptor, thought to be involved in the binding of almost all D2L ligands with any 
agonist activity, also regulate the functional profile of a drug. Specifically, it was 
demonstrated that some mutations (e.g., S5.43A) can cause a drug like quinpirole that has 
full intrinsic activity at the WT receptor, to become functionally selective. The current 
work sought to test the hypothesis that these serine residues also could affect the 
functional profile of aripiprazole and two other “partial agonists”, namely (-)terguride and 
(-)3PPP.  
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ABSTRACT 
Serines (S5.42 and S5.46) of the dopamine D2L receptor hydrogen bond to ligand 
catechol hydroxyls, whereas a third (S5.43) may either directly or indirectly influence 
binding. D2 agonists lacking a catechol moiety are thought to use only a portion of these 
interactions. In this study, we investigated the role of these three serines in the binding 
and function of three D2 partial or functionally selective agonists [(-)3PPP, (-)terguride, 
and aripiprazole]. The S5.42A mutation only affected the binding of (-)3PPP, while also 
ablating the function associated with (-)3PPP. In general, the binding and functions 
studied in the presence of the S5.43A mutation appeared to be preserved for the three 
compounds. Both (-)3PPP and (-)terguride lost affinity for the S5.46A receptor, although 
for all of the compounds there was a concomitant increase in intrinsic activity for 
adenylate cyclase but not other functions studied. These results indicate that the S5.46 has 
a role in binding affinity for these two prototypical partial agonists, but it is also involved 
in moderating a partial versus full cyclase response. S5.42 appears to be necessary for 
only (-)3PPP function, while the S5.43A mutant had the least significant impact on the 
pharmacology of any of the partial agonists studied. These findings supplement the 
results of previous studies of the significance of these three serine residues, and are 
valuable to our understanding of how low intrinsic activity D2 receptor ligands interact 
with and signal via the D2L receptor. 
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INTRODUCTION 
All of the currently approved antipsychotic drugs have at least some affinity for 
dopamine D2-like receptors (Kapur and Remington, 2001). Until recently, all of these 
drugs shared the property of being functional antagonists of the D2 receptors, leading to 
the hypothesis that D2 antagonism was essential for therapeutic efficacy against positive 
symptoms (e.g., blocking hyperactivity of the mesolimbic dopamine system)(Carlsson, 
1977). The typical antipsychotics also were thought to cause extrapyramidal side effects 
(EPS) via blockade of normal dopamine neurotransmission in the basal ganglia (Carlsson, 
1977). The atypical antipsychotics were equally efficacious to the typicals, but caused 
markedly fewer neurological side effects. The mechanism(s) of this atypicality has been 
unclear, but often is ascribed to simultaneous interactions of several dopamine and 
serotonin receptors (Meltzer et al., 1989), although other neurotransmitter systems 
(cholinergic, adrenergic, etc.) have sometimes been implicated (Tandon, 1999; Svensson, 
2003). 
At the same time, a variety of hypotheses have been proposed about novel ways to 
achieve antipsychotic action. One of the most interesting is the partial agonist hypothesis. 
This idea was based on the greater functional sensitivity of presynaptic D2 receptors 
versus their postsynaptic counterparts (a result due in part to increased presynaptic 
receptor reserve)(Skirboll et al., 1979; Roth, 1979). One mechanism underlying the 
commonly accepted “dopamine hypothesis of schizophrenia” was that increased synaptic 
dopamine was responsible for some of the disease symptoms. Thus, there has been a 
search for partial agonists that would cause a high degree of activation of the more 
sensitive presynaptic D2 dopamine receptors, thereby causing markedly decreased 
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neuronal activity and decreased release of dopamine. Conversely, it was hypothesized 
that these drugs would not cause marked activation of postsynaptic receptors unless there 
were deficiencies of dopamine, thus either being innocuous or actually helping other 
symptoms (Coward et al., 1989; Tamminga, 2002). Although these were appealing 
hypotheses, clinical trials with several agents were largely disappointing (Lahti et al., 
1998a; Lahti et al., 1998b).  
This research arena gained increased attention when Otsuka Pharmaceuticals first 
reported that aripiprazole had antipsychotic activity with an excellent clinical profile 
(Toru et al., 1994; Murasaki, 1995). Aripiprazole caused very atypical actions in animal 
models used for schizophrenia drug discovery (Kikuchi et al., 1995), the mechanisms for 
which have been controversial. Many of the thought leaders in the field (Tamminga and 
Carlsson, 2002; Lieberman, 2004) believe that aripiprazole causes “dopamine system 
stabilization” (Stahl, 2001a) via its partial agonist effects at D2 receptors (Burris et al., 
2002). Conversely, although noting that aripiprazole also had effects at serotonin 
receptors (Lawler et al., 1999; Shapiro et al., 2003), our laboratory and others have 
proposed that the novel effects of aripiprazole are due to its functionally selective actions 
at D2L receptors (Lawler et al., 1999; Shapiro et al., 2003; Tadori et al., 2005; Urban et 
al., 2006b).  
Thus, aripiprazole can act as a D2 antagonist in some systems (Inoue et al., 1997; 
Shapiro et al., 2003), show unusual binding kinetics to the D2 receptor (Urban et al., 
2006b), and also demonstrate marked variability in potency among D2 receptor-mediated 
effectors within a single heterologous expression system (Urban et al., 2006b). Together 
these observations led to the hypothesis that aripiprazole is actually a functionally 
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selective D2 ligand (see Urban et al., 2006a for review of this concept). Whatever the 
mechanism, the success of aripiprazole has led to new research to discover and develop 
new D2 “partial agonists” as potential APDs. Indeed, another such compound, bifeprunox 
(Solvay Pharmaceuticals), has its approval pending before the FDA, and others are on the 
horizon (Yokoi et al., 2002; Bolonna and Kerwin, 2005).  
What has been lacking, however, is an understanding of which structural elements 
of such ligands interact with the D2 receptor pharmacophore, and how this causes either 
partial agonism or functionally selective activation. Three serine residues in TM5 (S5.42, 
S5.43, and S5.46) are known to be important for ligand binding and signaling for Class A 
GPCRs, including the dopamine D2 receptors (Cox et al., 1992; Javitch et al., 1995a; 
Woodward et al., 1996; Wiens et al., 1998). It has been proposed that these serines form 
hydrogen bonds with catechol hydroxyl groups, thereby stabilizing the ligand-receptor 
interaction (Cox et al., 1992; Javitch et al., 1995a; Woodward et al., 1996; Wiens et al., 
1998). Unfortunately, the only partial agonists that have been studied at these mutations 
are meta- and para-tyramine, two relatively low affinity ligands (Cox et al., 1992). The 
current study is the first to explore how two prototypical partial agonists, (-)3PPP and 
terguride, and aripiprazole interact with these three critical serines. In addition, this study 
utilizes multiple functional endpoints [inhibition of adenylate cyclase (AC); 
phosphorylation of MAP kinase (MAPK), and release of arachidonic acid (AA)] to 
ascertain the role of these three serines in the partial agonism/functional selectivity of 
these ligands. 
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MATERIALS AND METHODS  
Materials 
Aripiprazole (OPC-14597; 7-{4-[4-(2,3-dichlorophenyl)-piperazin-1-yl]-butoxy}-
3,4-dihydro-1H-quinolin-2-one) was a gift of Otsuka America Pharmaceuticals (Rockville 
MD). Quinpirole, (-)3PPP [(-)-3-(3-hydroxyphenyl)-N-(1-propyl)piperidine], 
S(-)terguride (transdihydrolisuride; 1,1-diethyl-3-((6aR,9S,10aR)-7-methyl-4,6,6a,7,8,-
9,10,10a-octahydroindolo[4,3-fg]quinolin-9-yl)urea), and haloperidol were purchased 
from Sigma/RBI (Natick, MA), whereas dopamine, adenosine triphosphate, EDTA, 
dithiothreitol, sucrose, pepstatin A, leupeptin, PMSF and other standard laboratory 
compounds were purchased from Sigma Chemical Co. (St. Louis, MO). Sources of other 
reagents were as follows: [3H]N-methylspiperone from PerkinElmer Life Sciences, Inc. 
(Boston, MA); [5,6,8,9,11,12,13,14-3H]arachidonic acid from Amersham Biosciences Inc. 
(Piscataway, NJ); [125I] for cAMP assays was purchased from NEN/Perkin Elmer 
(Boston, MA); HEPES from Research Organics Inc. (Cleveland, OH); Ham’s F-12 media, 
penicillin, and streptomycin from Invitrogen Co. (Carlsbad, CA); Hygromycin B was 
purchased from Roche Applied Science (Indianapolis, IN); primary antibody to phospho-
Erk1/2 MAP kinase and secondary anti-rabbit HRP-conjugated antibody from Cell 
Signaling Technology Inc. (Beverly, MA). cAMP primary antibody was obtained from 
Dr. Gary Brooker (George Washington University, Washington DC) and secondary 
antibody, rabbit anti-goat IgG, was purchased from Advanced Magnetics (Cambridge, 
MA). 
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Molecular biology and cell culture 
CHO-hD2L wild type and mutant cell lines were maintained in Ham’s F-12 
medium supplemented with 10% FBS, 100 U/mL penicillin, 100 µg/mL streptomycin and 
100 µg/mL Hygromycin at 37°C and 5.0% CO2. Mutant cell lines were constructed using 
the pcDNA5/FRT plasmid (courtesy of Jonathan Javitch). Following subcloning of the 
hD2L receptor into the plasmid, point mutations were introduced using PCR techniques. 
The presence of each mutation was verified by DNA sequencing. Stable transfections of 
point mutants into CHO K1 cells were conducted using modifications of a previously 
published protocol (Ward and Milligan, 1999). The identification of the mutated amino 
acid residue will be made using universal notation as proposed by Ballesteros et al. 
(1995). The residues (in both universal notation and absolute position) that we studied 
were S5.42A (S193A), S5.46A (S197A), and S5.43A (S194A). 
Preparation of membranes 
CHO-hD2L cell mutants were grown to confluence in 75-cm2 flasks. Five mL of 
cold phosphate buffered saline was used per flask to rinse the cells, after which 5 mL of 
lysis buffer (2 mM HEPES, 2 mM EDTA, 1 mM dithiothreitol, 1 µg/mL pepstatin A, 0.5 
µg/mL leupeptin, and 10 µg/mL PMSF, pH 7.4 with HCl) was added to each flask. 
Following 10-20 min of incubation at 4°C, the cells were scraped and collected. The cell 
suspension was homogenized with three strokes in a Wheaton glass homogenizer and 
centrifuged at 30,000g for 20 min. The resulting supernatant was discarded, the pellet 
resuspended in storage buffer (50 mM HEPES, 0.32 M sucrose, 1 µg/mL pepstatin A, 0.5 
µg/mL leupeptin and 10 µg/mL PMSF, pH 7.4 with NaOH) at approximately 1 mg 
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protein/mL, homogenized again and aliquoted into 1-mL microcentrifuge tubes. The cell 
membranes then were frozen, and stored at -80°C until further use. 
Radioreceptor studies with the hD2L receptor 
Saturation studies for each mutant were as described previously (Fowler et al., 
2006a). Competition binding studies were carried out using 0.3 nM 
[3H]N-methylspiperone to determine the affinity of each ligand for each of the hD2L 
receptor mutants. Non-specific binding was defined by the amount of radioligand bound 
in the presence of 10 µM haloperidol, and seven to eight concentrations of each test 
ligand were used in competition assays. Addition of tissue to each assay tube initiated the 
binding. Each drug condition was run in triplicate per experiment in a final volume of 500 
µL. Following a 15 min incubation at 37°C, tubes were filtered through a FilterMate 196 
Cell Harvester (PerkinElmer Life and Analytical Sciences, Boston, MA) and the plates 
were washed four times with ice-cold buffer. The filters were dried in an oven at 55°C for 
30 min., and 35 µL of Packard MicroScint 20 scintillation cocktail was added to each 
well (PerkinElmer). A Packard TopCount NXT (PerkinElmer) was used to determine the 
radioactivity of each sample. Competition binding data were expressed as a percentage of 
specific binding. 
hD2L-mediated inhibition of adenylate cyclase (AC) 
CHO-K1 cells transfected with each of the three human hD2L receptor serine 
mutants were seeded in 24-well plates at a density of 25,000 per well in F-12 Ham’s 
media (10% FBS) and allowed to grow at 37°C and 5% CO2 for 48 hr. Cells were 
preincubated with media containing 500µM IBMX, 0.1% ascorbic acid and 50mM 
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HEPES buffer for 10 min, after which the media was aspirated off and replaced with 
assay media containing FSK and/or drug (final volume = 500 µl). Cells were incubated 
for 15 min at 37°C after which they were rinsed with warm assay media. The reaction was 
stopped with the addition of 500µl of ice cold 0.1M HCl and incubated at 4°C for 10 min. 
cAMP was measured via RIA method modified from (Harper and Brooker, 1975).  
hD2L-mediated MAP kinase phosphorylation (MAPK) 
Measurements of phosphorylated MAPK were made using a published protocol 
(Versteeg et al., 2000). Each transfected mutant CHO cell line was seeded in 96-well 
plates in F-12 Ham’s media (10% FBS) at 20,000 cells/well and allowed to grow at 37°C 
and 5% CO2 for 48 hr. Cells were serum-starved for six hr prior to stimulation, after 
which appropriate drugs were added to each well at a volume of 100 µL for 10 min. The 
reaction was terminated and cells fixed by aspirating each well and adding 100 µL of 4% 
formaldehyde PBS solution for 20 min. Cells were washed three times with 100 µL wash 
buffer (0.1% Triton X-100/PBS solution), followed by a 20 min incubation with 0.6% 
H2O2 Triton/PBS solution to quench endogenous peroxidases. After washing the cells 
three times again with wash buffer, and after a 1 hr incubation with 10% BSA in 
Triton/PBS solution (to block non-specific antibody binding), cells were incubated 
overnight (about 12 hr) with a 1:250 dilution of PhosphoPlus® p44/42 1° antibody in the 
Triton/PBS solution (100 µL) containing 5% BSA at 4°C. Cells were washed three times 
with wash buffer for five minutes and incubated with 100 µL HRP-conjugated goat anti-
rabbit 2° antibody (1:100 dilution) with 5% BSA at room temperature for 1 hr. Again, 
cells were washed three times with wash buffer for five minutes, and then twice with 
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PBS. Cells were then incubated with 50 µL of an o-phenylenediamine (OPD) solution 
(0.4 mg/mL OPD, 17.8 mg/mL Na2HPO4·7H2O, 7.3 mg/mL citric acid and 0.015% H2O2) 
for 15 min at room temperature in the dark. The reaction was terminated by the addition 
of 25 µL of 1 M H2SO4, and the well-solution analyzed spectrophotometrically (using the 
Vmax Kinetic Microplate Reader from Molecular Devices) at absorbance wavelengths 
A490 - A650.  
hD2L-mediated arachidonic acid release (AA) 
Measurements of PLA2 arachidonic acid release were made by modifying a 
protocol described by Berg et al. (Berg et al., 1996). Each transfected mutant CHO cell 
line was seeded in 24-well plates in F-12 Ham’s media (10% FBS) at 25,000 cells/well 
and allowed to grow at 37°C and 5% CO2 for 24 hr. 500 µL of serum-free Ham’s 
complete media containing 0.5 µCi/mL [5,6,8,9,11,12,14,15-3H] arachidonic acid was 
added to wells, after which cells were preincubated for 5 hr. Cells were then washed three 
times for 5 min with Hank’s balanced salt solution (HBSS) containing 0.5% fatty acid 
free BSA and appropriate enzyme inhibitors and antagonists (500 µL/well/wash). 
Following the washes, the cells were incubated for 15 min with appropriate agonists with 
or without ATP dissolved in the HBSS/BSA (1 mL/well). Three 200 µL sample aliquots 
were taken from each well and the radioactivity of the samples was counted using liquid 
scintillation spectrometer techniques.  
Molecular modeling 
The experimental studies outlined in this chapter take advantage of an ongoing 
collaboration with the computational laboratory of Dr. Marta Filizola at the Weill 
Medical College of Cornell University in New York. To provide a reasonable structural 
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description of the interaction of (-)3PPP, terguride, and aripiprazole with the hD2L 
receptor, our collaborators conducted systematic docking studies using an energy-
minimized three-dimensional (3D) molecular model of hD2L. This model was built using 
the crystal structure of the transmembrane region of bovine rhodopsin (Palczewski et al., 
2000) as a template. The restraints for the hD2L receptor transmembrane regions from the 
known rhodopsin crystal structure were derived using the latest version of the software 
MODELLER (Sali et al., 1995). The sequence alignment between hD2L and rhodopsin 
receptors was taken from the GPCRDB (http://www.gpcr.org). The hD2L model was then 
energy minimized using version 27 of CHARMM (Brooks et al., 1983), and was used as a 
ligand-free model for docking of (-)3PPP, terguride, and aripiprazole.  
Initial structures of the three selected ligands were constructed using the 
BUILDER module of InsightII or the crystallographic atomic coordinates when available. 
Consistent with the parameterization of QUANTA 3.2/CHARMm all atom force field 
(Momany and Rone, 1992), atomic partial charges for these ligands were generated by 
fitting the molecular electrostatic potential computed with a 6-31G* basis set using 
GAUSSIAN03. The ligands were then docked manually inside the putative binding site of 
the ligand-free model of hD2L receptor that has been suggested in the literature for 
aminergic GPCRs (see Shi and Javitch, 2002 for review). Specifically, docking modes 
were dictated by establishing a hydrogen bond between the protonated amine group 
common to aminergic ligands and the D3.32 residue of hD2L. Whenever possible, polar 
groups of the ligand were directed towards the serine residues of TM5 to increase ligand 
binding stability. Each ligand-receptor complex was then energy minimized in two steps 
using the QUANTA 3.2/CHARMm Force Field with a 2r distance-dependent dielectric 
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constant. To eliminate possible steric repulsions between atoms of the side chains, the 
models were first subjected to 200 cycles of steepest descent keeping all the receptor 
backbone atoms restrained by harmonic potentials. In a subsequent step, unconstrained 
energy minimization was carried out using 200 cycles of steepest descent followed by 
conjugate gradient minimization. Residues within 5 Å of each ligand were then identified 
as the interacting residues in each binding site. 
Data analysis 
Except where noted, data are expressed as means ± SEM. The receptor 
competition data was analyzed by non-linear regression (Prism 4.0, GraphPad, Inc., San 
Diego CA) using a sigmoidal model with variable slope, yielding IC50 and Hill slopes 
values. The IC50s were corrected for radioligand concentration and converted to K0.5 
values using the Cheng-Prusoff formula for a bimolecular competition model (Cheng and 
Prusoff, 1973). Changes in affinity in the competition assays were tested for significance 
by performing a one-way analysis of variance (ANOVA), followed by a Dunnett’s 
multiple comparisons post hoc analysis. Functional dose-response curves also were 
analyzed by non-linear regression using the sigmoidal variable slope model to determine 
estimates of intrinsic activity (Emax) and apparent potency (EC50). Differences in Emax 
and EC50 values among the drug groups for the three functions (AC, MAPK, and AA) 
were assessed by ANOVA. Significant ANOVA results were followed by the appropriate 
(Bonferonni’s or Dunnett’s) post hoc analysis, again performed using Prism 4.0. 
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RESULTS 
Binding characteristics 
The Bmax values for saturation experiments with [3H]N-methylspiperone were as 
follows (in pmol/mg protein): hD2L wildtype – 4.8; S5.42A – 4.0; S5.43A – 20.7; and 
S5.46A – 2.3 (Fowler et al., 2006a). Competition studies for each compound versus 
[3H]N-methylspiperone were then conducted. The data for aripiprazole and (-)3PPP at the 
hD2L wildtype receptor are in agreement with recent data we have reported (Urban et al., 
2006b). Terguride and aripiprazole both had markedly higher affinity than (-)3PPP, and 
as we reported earlier (Lawler et al., 1999; Urban et al., 2006b), aripiprazole also has a 
steep slope (i.e., nH > 1.0), unusual for any D2L ligand, especially ones with some agonist 
properties (Figure 4.1; Table 4.1). 
  
Figure 4.1. Competition curves for aripiprazole, terguride, and (-)3PPP at the WT and serine 
mutant receptors.  
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Table 4.1. Effects of serine mutations on ligand binding characteristics 
Mutation  Aripiprazole Terguride (-)3PPP 
CHO-wt K0.5 (nM) 22 ± 7.5 1.6 ± 0.38 1,200 ± 210 
 nH -1.1 ± 0.02 -0.84 ± 0.03 -0.65± 0.12 
CHO-S5.42A K0.5 (nM) 39 ± 25 5.6 ± 2.8 19,000 ± 4,400* 
 nH -1.2 ± 0.15 -0.95 ± 0.1 -1.4 ± 0.27 
CHO-S5.43A K0.5 (nM) 23 ± 1.4 2.7 ± 0.21 4,100 ± 1000 
 nH -0.98 ± 0.15 -0.81± 0.06 -0.71± 0.11 
CHO-S5.46A K0.5 (nM) 48 ± 14 12 ± 5.7 11,000 ± 1,700 
 nH -0.96 ± 0.1 -1.0 ± 0.14 -0.91 ± 0.09 
* one-sided ANOVA (Dunnett post hoc) indicates only wt vs. S5.42A is significant for 3PPP (*P < 
0.05); (WT: n=2-3; S5.42A: n=4-5; S5.43A: n=3-4; S5.46A: n=3) 
A similar pattern of effects was caused by the S5.42A and S5.46A mutant 
receptors. The affinity of aripiprazole was essentially unaffected, and there were only 
trends for modest losses of affinity for terguride and (-)3PPP (Table 4.1), although the 
same rank order was seen in each replicate experiment (e.g., Figure 4.1). These mutations 
also caused the curves for both (-)3PPP and (-)terguride to have normal steepness (i.e., nH 
~ 1.0), possibly leading one to predict changes in functional intrinsic activity. 
Interestingly, the S5.43A mutation had only subtle effects on binding, with the notable 
finding being that the competition curve for aripiprazole was no longer steep, whereas 
those of terguride and (-)3PPP were no longer shallow (Table 4.1). 
Molecular modeling 
The three energy-minimized ligand-hD2L receptor complexes obtained by 
molecular modeling provide a structural context to the binding affinity data reported 
above. Analysis of the 3D molecular models of (-)3PPP, (-)terguride, and aripiprazole 
docked inside the hD2L receptor (see Figure 4.2, below) suggests the differential 
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involvement in ligand-binding of S5.42, S5.43, and S5.46, as an explanation for their 
different functional profiles (see following sections). Specifically, the proposed (-)3PPP-
hD2L complex shows the involvement of the meta-OH of the ligand in hydrogen-bonding 
with both S5.42 and S5.46, justifying the substantial loss in affinity to both alanine 
mutants (see Table 4.1, above).  
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Figure 4.2. Structures and hypothesized docking of aripiprazole, terguride, and (-)3PPP.  
The propyl group of (-)3PPP contributed to the stabilization of the binding mode 
by establishing direct interaction with receptor residues F6.51, T7.39, Y7.43. Consistent 
with the binding affinity data, the aripiprazole-hD2L molecular model shows no 
significant interactions between the TM5 serine residues of hD2L and the ligand. The 
phenyl group with chlorine in the ortho- and meta- positions points towards these serines, 
but is not expected to form strong interactions with the receptor. The fused rings on the 
 97 
other end of the molecule are found within 3.5 Å from receptor residues Y7.35, Y7.43, 
F6.51, and H6.55 that contribute to the ligand binding stability. Lastly, only one hydrogen 
bonding interaction between the NH group on the fused aromatic rings of terguride and 
S5.46 was kept after energy minimization of the corresponding ligand-receptor complex. 
With the other end, the molecule extends towards TM3 and TM7, and directly interacts 
with receptor residues F3.28, V3.33, F6.51, T7.39, and Y7.43.  
The effects of serine mutations on hD2L receptor-mediated adenylate cyclase 
inhibition 
Consistent with earlier reports (Lawler et al., 1999; Wilson et al., 2001; Burris et 
al., 2002; Shapiro et al., 2003; Tadori et al., 2005), all three compounds were partial 
agonists (relative to quinpirole) with the WT receptor, with relatively similar intrinsic 
activities [aripiprazole - 44%; terguride - 56%; and (-)3PPP - 62% (Figure 4.3)] and 
potencies consistent with these earlier reports (Table 4.2). 
All three serine mutations had marked effects with all three receptors, generally 
increasing intrinsic activity. Thus, all three ligands became full agonists at this function 
for both the S5.43A and S5.46A receptors. The one exception was with the S5.42A 
mutant at which the intrinsic activity of aripiprazole and terguride increased, whereas that 
of (-)3PPP decreased (Figure 4.3C; Table 4.2). Interestingly, despite the small to 
moderate losses of affinity caused by these mutations (see table 4.1), the potencies of all 
three compounds either were unaffected or actually increased at this function (Table 4.2).  
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Table 4.2. Effects of serine mutations on ligand-induced inhibition of adenylate cyclase  
Mutation  Aripiprazole Terguride (-)3PPP 
CHO-wt Emax 44% ± 9.9 56% ± 5.5 64%± 13 
 EC50 (nM) 33 ± 24 1.8 ± 1.3 108 ± 74 
CHO-S5.42A Emax 100% ± 11** 107% ± 3.1** 25% ± 5.0* 
 EC50 (nM) 27 ± 12 0.68 ± 0.16 104 ± 89 
CHO-S5.43A Emax 109% ± 1.1** 117% ± 0.1** 104% ± 4.2* 
 EC50 (nM) 19 ± 2.8 0.72 ± 0.48 96 ± 22 
CHO-S5.46A Emax 112% ± 2.0** 117% ± 1.8** 100% ± 4.6* 
 EC50 (nM) 2.6 ± 0.34 0.62 ± 0.22 61 ± 21 
Emax values are expressed relative to maximal effects of quinpirole (see Fowler et al., 2006a for 
details); significant differences in compound Emax values among mutations was determined by one-
sided ANOVA (Dunnett post hoc, with hD2-wt values as control group); *P<0.05, **P<0.01 (WT: 
n=3; S5.42A: n=3; S5.43A: n=3; S5.46A: n=3) 
 
 
Figure 4.3. Effects of serine mutations on ligand-induced inhibition of adenylate cyclase.  The 
ordinate values were obtained by taking the absolute effects on inhibiting cAMP synthesis for each 
concentration of ligand at each receptor, and making this effect relative to the maximal decrease 
of quinpirole seen with each of the receptors. Thus, a value of 50% equates to an inhibitory effect 
equal to half that of a maximal concentration of quinpirole.  
To confirm that these actions were mediated by the hD2L receptor, we determined 
the effects of a D2 antagonist (haloperidol) on the actions of aripiprazole, terguride, and 
(-)3PPP. As can be seen in Figure 4.4, haloperidol (10 µM) completely blocked the 
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inhibition of adenylate cyclase caused by these three ligands. In addition, none of these 
compounds had effects in CHO cells not containing the transfected hD2L receptor. 
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Figure 4.4. Haloperidol blocks the inhibitory effects of aripiprazole (Arip - 1 µM), terguride 
(Terg - 100 nM), and (-)3PPP (10 µM) confirming hD2L mediation of function. The closed bars 
represent the degree of adenylate cyclase inhibition for each ligand alone versus quinpirole (Quin 
– 10 µM), and the open bars represent this inhibition in the presence of haloperidol (Halo - 10 
µM). Data represent the mean ± SEM of three independent experiments conducted in triplicate. 
The effects of serine mutations on hD2L receptor-mediated MAP kinase 
phosphorylation 
As can be seen in Figure 4.5 and Table 4.3, aripiprazole and (-)3PPP were partial 
agonists at the hD2L WT receptor for stimulation of MAP kinase phosphorylation (Urban 
et al., 2006b). Terguride had somewhat higher intrinsic activity than either aripiprazole or 
3PPP at the WT receptor. The pattern of effects caused by the mutations was quite 
different at MAPK than it was at AC. Thus, the intrinsic activities of aripiprazole and 
terguride were either not significantly affected or were lower, respectively, with all three 
serine mutant receptors. Conversely, the potency of these two ligands was not markedly 
affected. The intrinsic activity of (-)3PPP with both the S5.43A and S5.46A receptor was 
somewhat lower (similar to what was seen with aripiprazole and terguride), yet unlike 
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those ligands its potency was markedly lower with both of these mutants. Much as was 
seen with AC, the S5.42A mutant caused almost a total loss of intrinsic activity for 
(-)3PPP. (Figure 4.5C; Table 4.3).  
 
Figure 4.5.  Effects of serine mutations on ligand-induced stimulation of MAPK (data 
normalized to maximal quinpirole hD2L WT effect). Aripiprazole and 3PPP values for the hD2L WT 
receptor were previously reported (Urban et al., 2006b). 
Table 4.3. Effects of serine mutations on ligand-induced MAP kinase phosphorylation 
Mutation  Aripiprazole Terguride (-)3PPP 
CHO-wt Emax 50 ± 10% 78 ± 9.9% 62± 5.7% 
 EC50 (nM) 170 ± 35 2.9 ± 1.4 93 ± 13 
CHO-S5.42A Emax 37 ± 3.5% 35 ± 3.7%* 5.0± 1.2%** 
 EC50 (nM) 300 ± 140 3.0 ± 2.3 n/a 
CHO-S5.43A Emax 46 ± 11% 47 ± 10%* 41 ± 11% 
 EC50 (nM) 150 ± 17 4.9 ± 0.93 860 ± 92** 
CHO-S5.46A Emax 39 ± 3.9% 47 ± 4.6%* 35 ± 3.0%* 
 EC50 (nM) 64 ± 30 3.8 ± 0.87 550 ± 130* 
*one-sided ANOVA (Dunnett post hoc with hD2-wt values as control group);  
*P<0.05, **P<0.01 (WT: n=3-4; S5.42A: n=3; S5.43A: n=5; S5.46A: n=5) 
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As previously demonstrated with quinpirole (Urban et al., 2006b), these effects 
were shown to be hD2L-mediated. Haloperidol again was able to block all observable 
ligand-induced intrinsic activity for MAP kinase phosphorylation (Figure 4.6). 
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Figure 4.6. Haloperidol blocks the actions of all three ligands (10 µM, 100 nM and 10 µM, 
respectively) at the hD2L WT receptor. This confirms hD2L receptor regulation of function for each 
ligand. The closed bars represent the degree of MAPK activity for each ligand alone versus 
quinpirole (Quin – 10 µM), and the open bars represent this inhibition in the presence of 
haloperidol (Halo - 10 µM). Data represent the mean ± SEM of three independent experiments 
conducted in triplicate. 
The effects of serine mutations on hD2L receptor-mediated arachidonic acid release 
We previously demonstrated (Urban et al., 2006b) that both aripiprazole and 
(-)3PPP partially activate the hD2-mediated potentiation of arachidonic acid release in a 
CHO-hD2L cell line. As shown in Figure 4.7B and Table 4.4, terguride also is a partial 
agonist for AA having 77% intrinsic activity relative to quinpirole and a potency similar 
to its potency for AC and MAP kinase phosphorylation (vide supra). Aripiprazole had a 
similar functional profile with all three serine mutants, having almost identical partial 
agonist activity, albeit with slightly lower potency. On the other hand, terguride had a 
similar functional profile with all three serine mutants, having almost identical partial 
agonist activity, albeit with slightly higher potency. Again, the actions of (-)3PPP at the 
three serine mutants were differentially affected. There was a complete loss of intrinsic 
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activity with the S5.42A mutant, whereas intrinsic activity at S5.43A and S5.46A was 
unaffected. Conversely, there was a modest loss of potency at these two receptors. (Figure 
4.7A-C)(Table 4.4).  
 
Figure 4.7. Effects of serine mutations on ligand-induced potentiation of arachidonic acid 
release. Data are normalized to maximal quinpirole hD2L WT effect. Aripiprazole and 3PPP 
values for the hD2L WT receptor were previously reported (Urban et al., 2006b). 
 
Table 4.4. Effects of serine mutations on ligand-induced AA release 
Mutation  Aripiprazole Terguride (-)3PPP 
CHO-wt Emax 59 ± 7.7% 77 ± 11% 76 ± 5.6% 
 EC50 (nM) 1.5 ± 0.4 2.6 ± 1.5 71 ± 13 
CHO-S5.42A Emax 40 ± 14% 63 ± 6.7% 2.6% ± 3.7%** 
 EC50 (nM) 9.1 ± 5.2 3.6 ± 0.1 n/a 
CHO-S5.43A Emax 75 ± 7.8% 78 ± 5.4% 79 ± 7.6% 
 EC50 (nM) 12 ± 6.5 0.64 ± 0.27 1200 ± 850 
CHO-S5.46A Emax 58 ± 14% 69 ± 4.9% 79 ± 20% 
 EC50 (nM) 13 ± 12 0.61 ± 0.21 270 ± 83 
*one-sided ANOVA (Dunnett post hoc with hD2-wt values as control group); **P<0.01 (WT: n=2-
3; S5.42A: n=2-3; S5.43A: n=3; S5.46A: n=3)  
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As shown for the other two functions, haloperidol completely blocked the effects 
of all three ligands at the potentiation of arachidonic acid release, as has been shown 
previously for quinpirole (Urban et al., 2006b)(Figure 4.8). 
 
Figure 4.8 Haloperidol blocks the actions of aripiprazole, terguride, and (-)3PPP. The actions of 
all three ligand (1 µM, 100 nM and 10 µM, respectively) were blocked at the hD2L WT receptor by 
haloperidol, confirming hD2L receptor regulation of function for each ligand. The closed bars 
represent the degree of adenylate cyclase inhibition for each ligand alone versus quinpirole (Quin 
– 10 µM), and the open bars represent this inhibition in the presence of haloperidol (Halo - 10 
µM). Data represent the mean ± SEM of three independent experiments conducted in triplicate. 
DISCUSSION 
One of the dominant current themes in the neuropsychopharmacology of 
schizophrenia is the potential utility of drugs that are partial agonists at the D2 dopamine 
receptors (Miyamoto et al., 2005; Bolonna and Kerwin, 2005; Cosi et al., 2006). Of the 
currently approved drugs, only aripiprazole has significant partial D2 agonist activity 
(Burris et al., 2002; Tadori et al., 2005; Urban et al., 2006b), but its clinical success has 
caused a renewed interest in such a mechanism after relatively disappointing earlier 
results with compounds like (-)3PPP (Tamminga et al., 1992). The current dogma posits 
that partial agonists attenuate dopamine neurotransmission where there are supranormal 
amount of dopamine, and increase dopamine neurotransmission where synaptic dopamine 
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is too low. Together, these effects have been termed “dopamine stabilization.” An 
alternate approach to explain the dopaminergic mechanism of aripiprazole has called 
upon the concept of functional selectivity.  
Functional selectivity describes the ability of some ligands to activate only a 
subset of effectors mediated by a single receptor subtype. Observations supporting this 
hypothesis have been reported using a number of different cell lines in studies examining 
a diverse group of GPCRs, and also have been demonstrated in in situ and in vivo models 
(see Urban et al., 2006b for review). Aside from typical D2 partial agonism, aripiprazole 
has been observed to block D2 receptor function [e.g., GTPγS binding and GIRK channel 
activation (Shapiro et al., 2003)], and fully activate D2 receptor function [e.g., inhibition 
of tyrosine hydroxylase activity (unpublished results)]. The functional profile of any 
ligand is going to be dependent upon the signaling machinery at its disposal, and thus 
upon cell type, physiological location, and receptor localization within the cell. In light of 
some of the curious in vivo data associated with aripiprazole activity [i.e., partial agonist 
activity at the presynaptic D2 receptors with concomitant antagonist activity at the post-
synaptic D2 receptors (Kikuchi et al., 1995)], these basic principles of cell physiology 
further accommodate the notion of aripiprazole being functionally selective. Thus, a drug 
can differentially activate and block receptor function in a neuron along one neural tract 
while only activating or antagonizing the receptor-mediated effects in a neuron with a 
different protein expression profile. Together, these concepts demonstrate how it is 
plausible for functionally selective compounds (like aripiprazole) to produce clinical 
effects regardless of the levels of endogenous neurotransmitter present.  
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One mechanism for functional selectivity has been hypothesized to be unique 
ligand-induced conformational changes (Mailman and Gay, 2004; Simmons, 2005; Urban 
et al., 2006a). Recently this concept has provided the impetus for research into 
elucidating the specific ligand-receptor interactions of a number of functionally selective 
compounds to determine which interactions might be amenable to producing functionally 
selective receptor conformations (Fowler et al., 2006a; Fowler et al., 2006c). There has 
been little research, however, into the molecular interactions between partial and 
functionally selective agonists and the D2L or D2S receptor pharmacophore. This study 
examined the binding and functional consequences of the serine-to-alanine mutations 
S5.42A, S5.43A, and S5.46A on the actions of the functionally selective drug aripiprazole 
and two typical D2 receptor partial agonists. It is our view that all D2 “partial agonists” 
are not equal, and that many are functionally selective. Thus, elucidating how specific 
ligand-receptor interactions affect function can offer insight into the mechanisms of 
action of these drugs, and possibly the discovery of novel ligands with different patterns 
of action. 
If it were true that these partial agonists are equivalent, it could be hypothesized 
that they should interact similarly with receptor mutants that do not dramatically affect 
ligand binding, resulting in similar functional consequences. This study provides data to 
the contrary, however, supporting the idea that each ligand is responsible for receptor 
conformational changes unique to that ligand, and by extension the notion that not all 
receptor-mediated effectors will be activated to the same extent. In the current study, for 
example, (-)3PPP is found to lose a significant degree of intrinsic activity for all three D2 
functions studied for the S5.42A mutant. Thus, the loss of the hydroxyl group in this part 
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of the receptor binding pocket prevents (-)3PPP from inducing the receptor 
conformation(s) required for maintaining partial activity for any function. Aripiprazole 
and terguride, on the other hand, demonstrate very different functional profiles in the 
absence of this mutant, both becoming full agonists for D2-mediated adenylate cyclase 
inhibition while maintaining low intrinsic activity for D2-mediated MAP kinase 
phosphorylation and AA release (terguride has an even more unique S5.42A functional 
profile, going from a high to low intrinsic activity partial agonist for MAP kinase 
phosphorylation). These observations indicate that the D2 receptor conformation(s) 
associated with aripiprazole binding is unique relative to the other prototypical partial 
agonists in that MAP kinase and AA functions are not S5.42-dependent. Furthermore, 
these data provide support for the slight variances in receptor conformations even among 
typical partial agonists, as (-)3PPP and terguride display quite different S5.42A mutant 
functional profiles. 
The S5.46A mutant illustrates another unique aspect of the D2 pharmacophoric 
interactions of these compounds. With this mutant, the intrinsic activity of (-)3PPP for 
adenylate cyclase inhibition actually increased (i.e., it became a full agonist) (as also seen 
with the other two ligands). The MAP kinase and AA signaling pathways are also 
affected differently for (-)3PPP at the S5.46A mutant, with lower intrinsic activity for the 
former and lower potency for the latter (although unlike the S5.42A mutant, significant 
intrinsic activity has been maintained for these effectors). This, combined with a 
significant decrease in apparent affinity for the receptor, demonstrates the lack of a 
consistent correlation between affinity and activity, another fact that invalidates some 
traditional notions of ligand-receptor pharmacology.  
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It is also evident that partial agonism of the D2 receptor incompletely describes the 
overall D2 receptor pharmacology of aripiprazole, as it has also demonstrated antagonist 
properties as well as receptor binding properties atypical of an agonist (Lawler et al., 
1999; Shapiro et al., 2003; Urban et al., 2006b). The apparent affinity of aripiprazole, 
(-)3PPP, and terguride for the D2 wild type receptor and the three serine mutants was 
determined, and the rank order of affinity for the wild type receptor was terguride > 
aripiprazole > (-)3PPP, similar to previous reports (for a list of published affinities, refer 
to http://pdsp.cwru.edu/pdsp.php). Both terguride and (-)3PPP had Hill slopes (nH) of less 
than one, an indication that these compounds bind with higher affinity to receptors 
precoupled to heterotrimeric G proteins than uncoupled receptors. As we had reported 
previously, aripiprazole had a Hill slope greater than one, indicating a binding profile not 
typical of a receptor agonist (Lawler et al., 1999; Urban et al., 2006b).  
The binding of aripiprazole was not affected markedly by any of these three serine 
mutations (Table 4.1). Based on these results and our modeling analysis of the 
aripiprazole-binding pocket interactions, aripiprazole is not predicted to interact directly 
with any of the hydroxyl groups of the serines (Figure 4.2). To test this hypothesis 
further, it will be necessary to perform similar experiments in cell lines expressing 
multiple serine mutations. Previous studies have utilized such multiple serine mutation 
models and reported that they generally had little effect on D2 antagonist binding, 
although the agonists assessed were indeed affected (Coley et al., 2000). Terguride 
showed only a loss of apparent affinity in the absence of the S5.46 serine, and the Hill 
slope value associated with terguride binding at the S5.46A mutant further suggests that 
this serine is involved in terguride binding. Analysis of the molecular modeling results for 
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terguride indicate that the NH group integral to the aromatic ring structure of this ligand 
forms a hydrogen bond with this serine (Figure 4.2). Using comparative molecular field 
analysis (CoMFA), Wilcox et al (1998; 2000) predicted that ergolines such as pergolide 
and lisuride (an analogue of terguride) would partially stabilize a D2 receptor binding 
pocket interaction via a hydrogen bond between S5.43 and the nitrogen of the five-
membered ring inherent to the structure of this group of ligands. The current data would 
suggest that unlike pergolide and lisuride, the S5.46 rather than the S5.43 is partly 
responsible for stabilizing terguride binding. Again, the actual influence of these serine 
mutations on terguride binding will be better assessed in multiple mutant cell lines. The 
binding of (-)3PPP is clearly affected by the loss of hydroxyl groups at the S5.42A and 
S5.46A, but not the S5.43A, serine positions (Table 4.1), thus providing a much clearer 
picture of the D2L binding pocket requirements for (-)3PPP interaction. Molecular 
modeling analysis of the (-)3PPP-D2 receptor interaction predicts the involvement of 
hydrogen bonds between the meta-OH group of (-)3PPP and both of these serines. We 
also were able to verify previous data (Woodward et al., 1996) showing that none of these 
single serine mutations affected the affinity of haloperidol for the receptor (data not 
shown).  
Finally, we believe that this study is the first to provide evidence that single point 
mutations within the putative binding pocket of the D2 receptor can confer full agonist 
characteristics on prototypical partial agonists. This observed increase in intrinsic activity 
was an effect unique to the inhibition of adenylate cyclase, a receptor-mediated effector 
well known to be dependent upon inhibitory Gα subunit isoforms [for review see (Watts 
and Neve, 2005)]. Both aripiprazole and terguride were converted from partial to full 
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agonists for adenylate cyclase inhibition at all three serine mutations relative to the 
activity elicited by a maximally-stimulating concentration of the full agonist quinpirole 
(Table 4.2). A similar effect also was seen with (-)3PPP but only at the S5.43A and 
S5.46A mutations; the S5.42A mutation actually decreased the intrinsic activity of 
(-)3PPP for adenylate cyclase inhibition (Table 4.2). Moreover the potencies of all three 
compounds generally remained equal between wild type and mutant receptors. These 
functional data suggest that the absence of the 5.42, 5.43 or 5.46 hydroxyl groups may 
allow aripiprazole, terguride, and (with the exception of S5.42A) (-)3PPP to promote a 
receptor conformation amenable to the highly efficient activation of Gαi and/or Gαo 
proteins (thereby fully activating D2-mediated inhibition of adenylate cyclase). 
In contrast, the serine mutation studies on MAP kinase phosphorylation and 
arachidonic acid release, effectors known to be mediated by the βγ heterodimer subunits 
of G proteins [reviewed in (Neve et al., 2004)], either demonstrate no overall change (e.g. 
aripiprazole), function-dependent loss (e.g. terguride at MAP kinase), or a mutant-
dependent loss [e.g. S5.42A and (-)3PPP] in intrinsic activity (Tables 4.3 & 4.4). In 
addition to these discrete intrinsic activity profiles, the only mutant-dependent changes in 
ligand potency were observed in these two signaling pathways. Therefore, the ligand-
induced conformations responsible for the novel effects on adenylate cyclase appear to 
have a concomitantly variable effect on the βγ-mediated endpoints studied with these 
compounds, either decreasing the ligand activity or having no effect at all relative to the 
wild type activity of the ligand.  
In conclusion, these results further demonstrate that subtle conformational changes 
induced by receptor ligands and/or different modes of ligand binding can have substantial 
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functional consequences. This study complements recent work that used similar 
mutational analysis of these three serines to study the interactions of typical and 
functionally selective agonists with rigid backbones (Fowler et al., 2006a; Fowler et al., 
2006c). We demonstrate here that the consequences of these mutations, as stably 
expressed in the CHO-K1 cell line, on the D2 receptor binding and function of 
aripiprazole and two typical D2 receptor partial agonists are ligand-dependent, and not 
necessarily equivalent. Therefore, the observation that these mutations can have 
inconsistent effects on the functional profile of these compounds (varying from full to 
partial to antagonistic) demonstrates that, all things being equal, these three “partial” 
agonists are far from equivalent in their D2 pharmacophore interactions, and these 
differences may help account for the dramatic differences in therapeutic efficacy. We 
believe the current work also underscores the importance of future research into other 
residues (e.g., F3.28, V3.33, F6.51, H6.55, Y7.35, T7.39, Y7.43) that are predicted to 
possibly affect the actions of these partial/functionally selective agonists.  
 
 
  
CHAPTER 5. 
CHARACTERIZATION OF THE DOPAMINERGIC N27-D2L CELL LINE AND 
ASSESSMENT OF ITS UTILITY AS A MODEL FOR INVESTIGATING D2L 
RECEPTOR-MEDIATED DOPAMINERGIC FUNCTION  
For publication in:  
Neuroscience 
PREFACE 
A major weakness in most in vitro systems for the study of receptor function is 
that the physiological relationship to the in situ systems is often unclear at best. The 
importance of the D2L receptor as a drug target for Parkinson’s disease and schizophrenia, 
to name two major central nervous system disorders, would make a physiologically 
relevant in vitro system of great importance as a research tool, and potentially as a drug 
screening system. Many laboratories have attempted to develop such systems, by either 
screening various tumor lines of central origin, or by creating lines via cell fusion or 
genetic manipulation. One of the obvious targets of such research would be a cell that had 
the phenotype of dopamine neurons. For the research directions described in my 
dissertation, such a line would be of exceptional utility because of demonstrations of D2 
functional selectivity in such cells in situ. One line, MN9D cells, actually appeared to 
have appropriate characteristics, but for reasons that are unclear, the desirable phenotype 
of that line was lost in all of the several laboratories that were studying it. The current 
chapter describes my attempts to develop another promising line for this purpose.  
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ABSTRACT 
There is no available immortal cellular model of the function of dopamine neurons 
that functionally reflects the brain neuron. This has been an impediment to many lines of 
research, including understanding of the functional mechanisms of action of intrinsic 
dopamine D2 receptors. In this study we assess the characteristics of the N27 cell line to 
determine its utility as such a model system. First, we verified previous reports that the 
N27 line contained functional dopamine biosynthetic machinery, and endogenously 
expresses the dopamine transporter. We used radioreceptor assays to show that N27 cells 
do not express any of the dopamine receptors at measurable levels. A FLAG-tagged hD2L 
receptor was stably transfected into the cell line, and was found to couple to adenylate 
cyclase inhibition (a Gαi/o-mediated functional response). Real time PCR revealed the 
endogenous expression of a number of G protein isoforms, as well as low levels of 
tyrosine hydroxylase and dopamine transporter. After transfection, the cells, however, 
failed to show D2L-mediated effects on dopamine uptake or release assessed using either 
biochemical or electrochemical methods. In addition, agonist-induced D2L receptor 
internalization also did not occur. Thus, although this cell line can synthesize dopamine, 
D2L receptors are not able to couple to functions they normally regulate in dopamine 
neurons. These data suggest that N27 cells may not be a good model for dopamine 
neurons, and that their use as a cellular model for neurodegeneration of dopamine neurons 
should be done cautiously.  
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INTRODUCTION 
Many CNS diseases, including schizophrenia and Parkinson’s disease, have been 
associated with dysfunctional dopaminergic function. In general, pharmacotherapies that 
target dopamine receptors are the most common approach for treating patients with such 
psychiatric and neurological disorders. For example, it is well established that all 
currently approved antipsychotic drugs have some degree of dopamine D2 receptor 
affinity, generally acting as antagonists at these receptors (e.g., see use in MN9Dcells by 
Kapur and Remington, 2001). All of the dopamine agonists currently approved for the 
treatment of Parkinson’s disease also target the D2 receptor, although there are some 
suggesting that D1 selective agonists may be more effective (Mailman et al., 2001). Thus, 
a cell line with characteristics resembling a dopamine neuron would be useful both 
heuristically and as part of a novel drug screening program.  
A plethora of different cell models, ranging from generic immortalized cell lines 
(e.g. CHO-K1, HEK-293, and C6 dopamine receptor transfectants) to those purportedly 
dopaminergic in nature (e.g. PC12, MN9D, and SN4741 cell lines), have been employed 
to study the mechanisms by which such compounds act through these receptors. The non-
dopaminergic heterologous cell models have provided useful information regarding 
general receptor mechanisms, but are limited in that they cannot offer system-specific 
representations of the consequences of dopamine receptor activity. Primary neuronal 
cultures have also been used, but isolation of these cells is a tedious process that often 
results in only a small fraction of the surviving neurons being dopaminergic (Branton and 
Clarke, 1999; Torres et al., 2001), and such preparations are not for repeated long-term 
use. Those clonal lines that have been offered as in vitro dopaminergic models have had 
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major limitations. The most commonly used “dopaminergic” cell model is the PC12 cell 
line that has been employed for a wide range of dopamine-related studies (Martin and 
Grishanin, 2003). This cell line originated from a rat adrenal pheochromocytoma, and has 
a mix of adrenergic, cholinergic, serotonergic, as well as dopaminergic phenotypes 
(McGee, Jr., 1980; Zhu et al., 1997; Homma et al., 2006). It also has been observed that 
PC12 cells express an isoform of tyrosine hydroxylase distinct from that found in the 
brain, another confounding factor if this line is used to draw inferences about brain 
dopaminergic function (Schussler et al., 1995; Laniece et al., 1996).  
Another potentially useful line was the MN9D, an immortalized dopamine-
containing neuronal hybrid cell line derived from mouse mesencephalon (Choi et al., 
1991). Although many interesting studies made use of this line (e.g., Tang et al., 1994a; 
Kilts et al., 2002), its phenotype changed markedly with time. Problems included the fact 
that D2 receptor transfectants were no longer functional within 6-8 years after their 
establishment (unpublished observations; personal communications from Dr. K. 
O’Malley). More recently the SN4741 cell line, derived from embryonic mouse substantia 
nigra, was offered as a dopaminergic cell line (Son et al., 1999). Of the dozen or so 
subsequent reports using this line, most employ the cells for study of neuroprotective 
mechanisms without verifying their actual D2-mediated dopaminergic properties. Only 
one looked at D2 receptor function (Nair et al., 2003), and this was with regard to D2-
mediated phosphoinositide-3 kinase as a neuroprotective response. 
The current studies focused on a potentially promising dopaminergic cell model: 
the rat 1RB3AN27 (N27) cell line. This is an immortalized cell line derived from rat 
mesencephalic (Prasad et al., 1994). It has been reported to express tyrosine hydroxylase 
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(TH), synthesize dopamine, and express the dopamine transporter (DAT) (Prasad et al., 
1998). These reports also showed that differentiation of these cells results in higher 
expression levels of TH and DAT, along with an increase in dopamine synthesis. It was 
unclear, however, whether these cells endogenously express any of the dopamine 
receptors (Adams et al., 1996). This study involved stably expressing a FLAG-tagged 
human D2L receptor in to the N27 cell line, and then using this cell line (N27-hD2L) to 
assess its utility as a model for studying D2 receptor-mediated function of dopamine 
neurons. 
MATERIALS AND METHODS  
Materials 
Quinpirole, (-)3PPP [(-)-3-(3-hydroxyphenyl)-N-(1-propyl)piperidine] and 
haloperidol were purchased from Sigma/RBI (Natick, MA), whereas dopamine, EDTA, 
dithiothreitol, sucrose, pepstatin A, leupeptin, PMSF, fetal bovine serum (FBS), and other 
standard laboratory compounds were purchased from Sigma Chemical Co. (St. Louis, 
MO). Sources of other reagents were as follows: [3H]N-methylspiperone from 
PerkinElmer Life Sciences, Inc. (Boston, MA); [125I] for cAMP assays from NEN/Perkin 
Elmer (Boston, MA); [7,8-3H]dopamine from Amersham Biosciences Inc. (Piscataway, 
NJ); RNeasy Midi kit from QIAGEN (Hilden, Germany); TaqMan Gene Expression 
Assays, TaqMan Universal PCR Master Mix, TaqMan rodent GAPDH control reagents, 
optical caps, and 96-well optical reaction plates from Applied Biosciences (Foster City, 
CA); HEPES from Research Organics Inc. (Cleveland, OH); RPMI-1640 media, 
lipofectamine, OPTIMEM, penicillin, streptomycin, geneticin (G418), and Cloned AMV 
 116 
First-Strand cDNA Synthesis Kit from Invitrogen Co. (Carlsbad, CA). cAMP primary 
antibody was obtained from Dr. Gary Brooker (George Washington University, 
Washington DC) and secondary antibody, rabbit anti-goat IgG, was purchased from 
Advanced Magnetics (Cambridge, MA).  
Cells and membranes 
The immortalized dopaminergic cell line 1RB3AN27 (N27; a generous gift from 
Dr. Damani Parran, National Institute of Environmental Health Sciences, Research 
Triangle Park, NC) was cultured as described in Adams et al (1996). For stable 
transfection, 35 mm culture dishes of N27 WT cells at >70% confluence were transfected 
with 2 µg of FLAG-tagged human dopamine D2L receptor cDNA in pCIN4 expression 
vector (a gift from Dr. Jonathan A. Javitch) using 9 µL of lipofectamine and 2 mL of 
OPTIMEM. Five hours after transfection, the OPTIMEM solution was replaced with fresh 
RPMI-1640 media (containing 10% FBS). Cells were split into a 100 mm culture dish 24 
hrs later. 24 hrs after this, nonselective media was replaced with selective media (RPMI-
1640 with 10% FBS and 100 µg/mL geneticin) and periodically changed (every 48 hrs) 
over the next three weeks. Cells that survived were verified as stably expressing the D2L 
receptor by saturation isotherm (described below).  
For harvesting cell membranes, N27 wild type and N27-D2L cell lines were grown 
to confluence in 100-mm dishes. Five mL of cold phosphate buffered saline was used per 
dish to rinse the cells, after which 5 mL of lysis buffer (2 mM HEPES, 2 mM EDTA, 1 
mM dithiothreitol, 1 µg/mL pepstatin A, 0.5 µg/mL leupeptin and 10 µg/mL PMSF, pH 
7.4 with HCl) was added to each dish. Following 10-20 min of incubation at 4°C, the 
cells were scraped and collected. The cell suspension was homogenized with three strokes 
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in a Wheaton glass homogenizer and centrifuged at 30,000g for 20 min. The resulting 
supernatant was discarded, the pellet resuspended in storage buffer (50 mM HEPES, 0.32 
M sucrose, 1 µg/mL pepstatin A, 0.5 µg/mL leupeptin and 10 µg/mL PMSF, pH 7.4 with 
NaOH) at approximately 1 mg protein/mL, homogenized again and aliquoted into 1 mL 
microcentrifuge tubes. The cell membranes then were frozen, and stored at -80°C until 
further use. 
Dopamine receptor and transporter saturation binding 
Saturation studies were performed to determine potential expression of 
endogenous D1-like and D2-like receptors and the dopamine transporter in the N27 wild 
type cells, as well as to verify the presence and expression level of the stably transfected 
hD2L receptor in the N27 cells. Membranes were incubated with varying concentrations of 
[3H]SCH23390 (for D1R), [3H]N-methylspiperone (for D2R), or [3H]mazindol (for DAT) 
in binding buffer [50 mM HEPES, 4 mM MgCl2, pH=7.4 with NaOH (D1R) or KOH 
(D2R); 50 mM HEPES, 120 mM NaCl, and 5 mM KCl, pH = 7.4 with NaOH (DAT)]. 
Non-specific binding was determined using 10 µM SCH23390 (D1R), haloperidol (D2R) 
or GBR12909 and desipramine (DAT). Addition of the tissue to each assay tube initiated 
the binding. Each drug condition was run in triplicate per experiment in a final volume of 
500 µL. For D1R and D2R binds, reactions were incubated for 15 min at 37°C. For DAT 
binding, reactions were incubated for 4 hours at 4°C. Following the incubations, tubes 
were filtered through a FilterMate 196 Cell Harvester (PerkinElmer Life and Analytical 
Sciences, Boston, MA) and the plates were washed four times with ice-cold buffer. For 
DAT binding, filters were presoaked in polyethyleneimine for 24 hours before use. The 
filters were dried in an oven at 55°C for 30 min, and 35 µL of Packard MicroScint 20 
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scintillation cocktail was added to each well (PerkinElmer). A Packard TopCount NXT 
(PerkinElmer) was used to determine the radioactivity of each sample. Saturation binding 
data were expressed in fmol of receptor/mg of protein.  
Adenylate cyclase 
N27 wild type and N27-D2L transfected cells were seeded on poly-D-lysine-coated 
24-well plates at a density of 25,000 per well in RPMI-1640 media (10% FBS, without or 
with 100 µg/mL G418, respectively) and allowed to grow at 37°C and 5% CO2 for 48 hr. 
Cells were preincubated with media containing 500µM IBMX, 0.1% ascorbic acid and 
50mM HEPES buffer for 10 min, after which the media was aspirated off and replaced 
with assay media containing FSK and/or drug (final volume = 500 µL). Cells were 
incubated for 15 min at 37°C after which they were rinsed with warm assay media. The 
reaction was stopped with the addition of 500 µL of ice cold 0.1M HCl and incubated at 
4°C for 10 min. cAMP was measured via RIA method modified from (Harper and 
Brooker, 1975).  
HPLC quantification of dopamine content 
N27 wild type cells were grown to confluence in 75 mm2 flasks. Cells were then 
trypsinized (number of flasks varied from one to six for a sample) and spun down in 50 
mL conical tubes at 25ºC and 1000 rpm (centrifuge name). Supernatant was aspirated, 
replaced with 0.85 mL of wash buffer (0.05 M Na2HPO4 and 0.03 M citric acid, pH = 7.4 
with NaOH). This process was repeated twice, after which the final aspirated samples 
were placed in ice. Quantitative determination of N27 cellular dopamine content was 
made using amperomeric detection of the column effluent with an EG & G Princeton 
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Applied Research Model 400 electrochemical detector (Princeton, NJ); the electric 
potential was +0.75 V vs. Ag/AgCl reference electrode. Chromatographic separations 
were performed using a C-18 Phenomenex (Rancho Palos Verdes, CA) stainless steel 
column (100 x 4.6 mm i.d.) packed with 3 µM bonded C-18 microparticulate silica. The 
mobile phase was 0.05 M Na2HPO4 with 0.03 M citric acid, 0.1 M disodium 
ethylenediaminetetraacetate, 2 mM sodium octyl sulfate, and 20% methanol, with a final 
pH of 3.4 and a flow rate of 0.80 mL/min. The column temperature was maintained at 
39ºC. Standard curves for the quantification of dopamine were prepared by analyzing a 
series of solutions containing a fixed amount of a internal standard (isoproterenol) and 
varying 100 µL of internal standard (1 ng/µL isoproterenol) in mobile phase (see above) 
was added to each sample. Each sample was then sonicated for 1-2 sec using a Cell 
Disrupter 200 (Branson Sonifier), and centrifuged at 5ºC and 14000 rpm for 18 min. 
Tissue pellet was reserved for protein determinations with the BSA protein assay reagent 
(Pierce, Rockford, IL) adapted for use with a microplate reader (Molecular Devices, 
Menlo Park, CA).  
Dopamine Release 
[3H]dopamine uptake and release 
This protocol is a modified version of a procedure described earlier (Kilts et al., 
2002). Briefly, N27 wild type cells and D2L transfectants were seeded on poly-D-lysine-
coated 24-well plates at a density of 50,000 per well in RPMI-1640 media (10% FBS, 
without or with 100 ug/ml G418, respectively) and allowed to grow at 37°C and 5% CO2 
for 48 hr. Cells then were washed 3 times with KRS (2.5 mM CaCl2, 1 mM NaH2PO4, 1.3 
mM MgSO4, 10 mM glucose, 26.2 mM NaHCO3, 2.5 mM KCl, 119 NaCl, and 50mM 
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HEPES) and then incubated in incubation buffer (1 mM ascorbic acid, 2 mM β-alanine, 
and 100 µM pargyline) at 37º C for 5 min. The cells were then aspirated, and incubated 
with 25 nM [3H]dopamine in incubation buffer at 37º C for 1, 2, 5, and 10 min. After the 
radioactive media was aspirated, the cells were washed 3 times with KRS, and then 
incubated with 1 mL KRS or high K+ buffer (the same as KRS but with 0 NaCl and 97 
mM KCl) with or without drugs. Samples were collected, centrifuged for 5 min at 1000 g, 
and the radioactivity quantified by liquid scintillation spectroscopy. Stimulated 
[3H]dopamine release was defined as the difference in the amounts of [3H]dopamine 
released between KRS-treated and high K+ buffer-treated cells. 
Amperometric analysis of dopamine release 
The second approach for detecting dopamine release utilized a modified version of 
an electrophysiology protocol previously described by Hochstetler et al. (2000). N27 wild 
type and N27-D2L cell lines were seeded in 35 mm culture dishes and incubated in the 
appropriate growth medium for 48 hours. Growth media was replaced by extracellular 
buffer solution (137 mM NaCl, 5 mM KCl, 5 mM CaCl2, 1 mM MgCl2, 5 mM HEPES, 
and 20 mM glucose, pH adjusted to 7.4 with NaOH). Dishes were then mounted on the 
stage of on inverted microscope (Diaphot 300, Nikon, Inc.) and cells located using a 20X 
objective lens. Preparation of the system involved arranging a glass-encased electrode 
(precalibrated with slow-scan cyclic voltammetry in a 50 µM dopamine solution) adjacent 
to the desired cell. Dopamine release was initiated by introducing a bolus of high [K+] 
buffer (10 – 120 mM KCl in extracellular buffer solution) to the local cellular 
environment via pressure injection by micropipet. Amperometric data were obtained 
using a CV201A head stage connected to an Axopatch 2000A amplifier (Axon 
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Instruments). The Axopatch 200A controlled the applied potential (in this case +0.650 
mV for catecholamine oxidation versus an Ag/AgCl reference electrode) after appropriate 
modifications as described by Hoschtetler et al. (2000).  
FLAG-D2L receptor internalization 
N27 cells were stably transfected with FLAG epitope-tagged D2L receptors as 
described above. The FLAG epitope has been shown previously not to markedly affect 
the function of this receptor (Vickery and von Zastrow, 1999). The cells were plated on 
glass coverslips that had been pre-treated with poly-D-lysine, and the surface receptors 
specifically labeled using 3 µg/mL anti-FLAG M1 monoclonal antibody using previously 
described procedures (Vargas and von Zastrow, 2004). Cells were treated with the ligands 
at 37°C for 30 min, and then fixed using 4% formaldehyde dissolved in PBS. The 
receptor label was detected by secondary incubation with Cy3-conjugated goat anti-
mouse antibody (1:1,000 dilution). Specimens were visualized by confocal fluorescence 
microscopy using a Zeiss LSM510 microscope fitted with a Zeiss 63XNA1.4 objective 
operated in single photon mode with standard filter sets and standard (1Airy disc) pinhole. 
Real-Time PCR 
Expression levels of six individual genes were evaluated with TaqMan 
primer/probe sets commercially available as “Assay on Demand” (Table 5.2). RNA was 
harvested followed manufacturer’s instructions from confluent 100 mm culture dishes of 
three different passages of differentiated and undifferentiated N27 cells using the 
QIAGEN RNeasy Midi kit. RNA samples were then reverse-transcribed using the 
Invitrogen Cloned AMV First-Strand cDNA Synthesis Kit, and resultant cDNA was 
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amplified according to manufacturer’s instructions; PCR performed with a MJ Research 
Peltier Thermal Cycler 220 (Waltham, MA). Negative controls using RNA preps without 
reverse transcriptase were “amplified” to verify the absence of DNA from harvested 
RNA. For each of the six genes, all mixtures contained 2.5 µL primer/probe mix, 2.0 µL 
cDNA, 20.5 µL H2O, and 25 µL TaqMan Master Mix, for a final volume of 50 µL. For the 
Rodent GAPDH control gene, each well contained 0.5 µL of both forward and reverse 
primers, plus 0.5 µL probe, 23.5 µL H2O, and 25 µL TaqMan Master Mix. Each 96-well 
reaction plate was set up to analyze the relative expression of three different genes and 
the control in triplicate between the differentiated and undifferentiated N27 cDNA. 
Quantitative PCR was performed on each 96-well plate using an Applied Biosciences 
7500 Real-Time PCR System (Foster City, CA) using the following default cycling 
conditions: 50ºC for 2 min (optimal conditions for AmpErase UNG activity), 95ºC for 10 
min (activation of AmpliTaq Gold enzyme), followed by 40 denature (95ºC for 15 sec) 
and anneal/extend (60ºC for 1 min) cycles. Baseline and threshold Ct calculations were 
set automatically by SDS Software 1.3.1, which transformed fluorescence data into a 
format that compares the spectral differences of a passive reference dye versus the 
reporter dye (VIC for control and FAM for other genes) for each primer/probe set 
(quencher dyes: TAMRA for control and MGB for other genes). Relative Quantification 
(RQ) values were also determined with SDS Software 1.3.1, and represent the change in 
gene expression of the differentiated samples versus the untreated control calibrator 
sample (undifferentiated N27 samples).  
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Data analysis 
Except where noted, data are expressed as means ± SEM. Data from receptor and 
transporter saturation isotherms were analyzed using non-linear regression with a one-site 
hyperbolic model (Prism 4.0, GraphPad, San Diego CA), and the data converted to KD 
and Bmax. To estimate intrinsic activity and apparent potency, functional dose-response 
curves were analyzed by nonlinear regression using the sigmoidal model with variable 
slope (Prism 4.0). As noted above, Real-Time PCR data was analyzed using SDS 
Software 1.3.1, and reported as means ± SEM. 
RESULTS 
D2L receptor expression and adenylate cyclase inhibition 
It has been reported that N27 cells do not express functional D1-like receptors 
since exposure to dopamine did not produce a substantial increase in cellular cAMP 
levels (Adams et al., 1996). These results, however, were not verified pharmacologically 
using antagonists specific to the dopamine receptor subtypes. We decided to explore this 
question about the endogenous expression of functional D1-like and D2-like dopamine 
receptors by using saturation assays with selective D1-like ([3H]SCH23390) and D2-like 
([3H]N-methylspiperone) radioligands. No specific binding was detected with either 
radioligand, indicating that N27 cells either do not express these receptors, or express 
them below the limits of detection of tritium-based radioreceptor assays (<5 fmol/mg 
protein). 
Once it was determined that measurable levels of dopaminergic receptor 
expression did not occur in N27 cells, human D2L receptors were stably transfected into 
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the cell line so that D2 receptor regulation of dopaminergic function could be assessed. 
The results of saturation assays with [3H]N-methylspiperone are shown in Figure 5.1. The 
transfected D2L receptor was expressed at a density of 3.6 ± 0.9 pmol/mg protein, with a 
KD for [3H]N-methylspiperone of 0.33 ± 0.024 nM. Differentiation of the cells with 
dibutryl-cAMP had only modest effects on D2L expression (Bmax = 4.6 ± 0.62 pmol/mg 
protein; KD = 0.26 ± 0.08 nM; data not shown). These observations were made over the 
course of thirty cell passages. 
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Figure 5.1. Saturation assay for FLAG D2 receptors stably expressed in undifferentiated N27 
cells. Receptors were labeled with increasing concentrations of [3H]N-methylspiperone and 
nonspecific binding was defined by 10 µM haloperidol. Curve represents one of three independent 
experiments and was generated using nonlinear one-site binding by saturation formula (see 
Materials and methods for more details). 
The N27 wild type and N27-hD2L transfectants were then assessed for receptor-G 
protein coupling by investigating cellular cAMP levels in the presence and absence of 
appropriate agonists and antagonists. Figure 5.2 shows that neither dopamine, nor 
isoproterenol (10 µM), significantly increase basal cAMP levels. Forskolin (FSK), a 
direct activator of most isoforms of adenylate cyclase, was able to produce a substantial 
increase in cellular cAMP levels (Figure 5.2). Neither dopamine, nor quinpirole (full 
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agonist), nor aripiprazole (functionally selective D2 ligand with known partial agonist 
properties at adenylate cyclase) decreased forskolin-induced cAMP, consistent with the 
absence of functional D2 receptors.  
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Figure 5.2. Effects of test ligands on basal and forskolin stimulated adenylate cyclase activity in 
WT N27 cells. Data represent means ± SEM of two to three independent experiments. DA = 
dopamine, ISO = isoproterenol; Phe = phenylephrine; Qui = quinpirole; Ari = aripiprazole. 
The N27-D2L transfectants, however, demonstrated clear coupling to the inhibition 
of adenylate cyclase. FSK-induced stimulation of adenylate cyclase activity was 
substantially inhibited by quinpirole, as well as compounds with known D2 agonist 
activity including aripiprazole, dihydrexidine, dinapsoline and dinoxyline (Figure 5.3). 
Aripiprazole was a partial agonist consistent with its usual behavior at this function 
(Lawler et al., 1999; Burris et al., 2002; Shapiro et al., 2003). The remaining compounds 
were all full agonists, and the intrinsic activities and potencies of these agonists for 
cyclase inhibition (Table 5.1) are similar to those reported in CHO-D2 cell line 
transfectants (Gay et al., 2004). 
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The inhibitory action of a maximally stimulating concentration of quinpirole (100 
nM) was blocked by a number of D2 receptor antagonists, including those representing 
typical D2 antagonists (i.e., domperidone) as well as several atypical antipsychotic drugs 
such as amisulpride, clozapine and olanzapine (Figure 5.4). As expected, aripiprazole 
only partially antagonized the activity of quinpirole, consistent with its known partial 
agonist actions at this function (Figure 5.4).  
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Figure 5.3. Dose-response curves showing inhibition of adenylate cyclase in N27-D2L cells. 
Quin = quinpirole; DNX = dinoxyline; DHX = dihydrexidine; DNS = dinapsoline; Arip = 
aripiprazole.   
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Table 5.1. Intrinsic activity and potency of D2 receptor ligands for inhibition of FSK-
stimulated adenylate cyclase in the N27-hD2L cell line 
 Quinpirole Aripiprazole Dihydrexidine Dinapsoline Dinoxyline 
Emax 99 ± 0.3% 58 ± 5.0% 88 ± 3.9% 93 ± 5.5% 97 ± 4.0% 
EC50 
(nM) 
14 ± 2.5 4.3 ± 1.3 160 ± 40 240 ± 46 10.1 ± 2.4 
Functional data represent the means ± SEM of three independent experiments. Intrinsic activities 
(Emax) are represented as percent maximal stimulation of quinpirole inhibition and potency data 
(EC50) are described by nM concentrations. All data were generated using variable slope 
nonlinear regression analysis (see Materials and methods for more details). 
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Figure 5.4. Attenuation of the D2L-mediated effects of quinpirole on adenylate cyclase by 
dopamine full and partial antagonists.   
Dopamine uptake and release 
The capability of these cells to release dopamine first was investigated using a 
radiotracer method as described by Kilts et al. (2002) that depends on functional 
dopamine transporters (DAT) for the uptake of radiolabeled dopamine 
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([7,8-3H]dopamine) before receptor regulation of induced-release is assessed. Saturation 
binding assay verified that DATs were indeed expressed (Bmax = 0.71 ± 0.23 pmol/mg; KD 
= 96 ± 30 nM) at a level similar to rat striatum (Bmax = 1.4 ± 0.13 pmol/mg; KD = 35 ± 8.9 
nM). Despite this, the cells failed to show uptake of [3H]dopamine over a range of time 
courses and [3H]dopamine concentrations. These results corroborate previous reports 
(Torres et al., 2001) that also failed to detect measurable uptake of dopamine by WT N27 
cells.  
We then approached this problem by using endogenous dopamine. The N27 cells 
have been reported to express tyrosine hydroxylase and synthesize dopamine (Prasad et 
al., 1994). Cellular dopamine was quantified by HPLC-EC, and was found to be 
approximately 0.25 nmol DA/mg protein, a level consonant with the concentration found 
in many of the non-basal ganglia dopamine terminal fields. This concentration is actually 
in between the dopamine levels reported in two other cell lines. PC12 cell have been 
reported to produce very high levels of dopamine [10 – 16 nmol DA/mg in 
undifferentiated cells and 4 nmol DA/ mg protein in differentiated cells (Greene and 
Tischler, 1976; Charalampopoulos et al., 2005)], while SN4741 cells were found to 
produce much lower dopamine levels [0.004-0.016 nmol DA/mg protein (Son et al., 
1999)]. We then utilized a sensitive amperometric electrophysiological technique capable 
of detecting zeptomolar levels of dopamine (Hochstetler et al., 2000). In this method, a 
bolus of high [K+] buffer is introduced to the local environment of a single cell, and 
dopamine release is detected by an electrochemical probe placed just above that single 
cell in culture. Experiments were performed on both undifferentiated and differentiated 
N27 cells over a range of K+ concentrations (10-100 mM). Both somal and apparent 
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neuritic aspects of the differentiated cells were assayed. Dopamine release was not 
detectable even by this sensitive method, suggesting that the vesicular exocytosis of 
dopamine does not occur after depolarization as it does in typical neurons. 
Analysis of ligand effects on D2L receptor internalization 
The regulation of surface receptor expression is essential to signal mediation and, 
by extension, overall cell homeostasis. It has been well illustrated that human embryonic 
kidney (HEK-293) cells transfected with D2L receptors tagged with an N-amino terminus 
FLAG epitope are viable models for studying receptor turnover and regulation upon 
ligand activation (Vickery and von Zastrow, 1999; Urban et al., 2006b). This was then 
studied in N27 cell line since the aforementioned adenylate cyclase experiments 
demonstrated that these transfected receptors were functional for at least one signaling 
pathway. Epifluorescence microscopy experiments illustrated that there was a high rate of 
constitutive receptor turnover, such that there was no observable difference in surface 
receptor expression between basal and dopamine-treated N27-D2L cells (Figure 5.5). 
Therefore it does not appear that the N27-D2L cell line is a feasible model with which to 
investigate the regulation of D2 receptor expression. 
Analysis of relevant gene expression  
Real time PCR was performed on undifferentiated and differentiated N27 cellular 
RNA in order to ascertain the relative expression of a number of genes that should be 
expressed in a dopaminergic cell line, and ones essential to GPCR-mediated signaling. 
Table 5.2 illustrates that although the relative levels of TH and DAT appear to be more 
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highly expressed in the differentiated versus undifferentiated cells (illustrated by greater 
RQ values), the overall expression (Ct values) of both genes is fairly low.  
 
 
Figure 5.5. Assessment of N27-D2L receptor internalization. FLAG-tagged D2L receptors 
expressed stably in N27 cells were specifically labeled at 37°C with M1 mAb as described in 
Materials and methods. Fluorescence microscopy was used to visualize the location of antibody-
labeled receptors in cells incubated for 30 min in: (A) no drugs; or (B) 10 µM dopamine. 
Representative micrographs of each condition are shown. 
The relative abundance of inhibitory G protein isoforms was also investigated. The 
rank order of overall relative expression of G proteins in undifferentiated cells was: 
Gαi2=Gαi3>Gαo>>Gαi1. Only Gαo was found to be expressed differentially between the 
differentiated and undifferentiated cells, exhibiting higher relative levels in the 
differentiated cell state (Table 5.2). Interestingly, Gαo gene expression was also found to 
be increased in nerve growth factor (NGF)-treated (i.e. differentiated) PC12 cells (Li et 
al., 1995; Greene and Angelastro, 2005), possibly indicating a neuronal reliance on this 
inhibitory G protein as neurons differentiate and mature.  
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Table 5.2. Comparison of N27 gene expression related to dopaminergic phenotype and 
GPCR activity 
Gene 
(protein) 
Genebank ID 
(ABI Assay ID) 
 N27  
Undifferentiated 
N27 
differentiated 
RQ 1.28 ± 0.27 10.2 ± 5.0 Th 
(tyrosine hydroxylase) 
NM_012740 
(Rn00562500_m1) 
Ct 33.7 ± 0.27 32.2 ± 0.52 
RQ 10.2 ± 12.7 39.6 ± 28.3 DAT 
(dopamine transporter) 
NM_012694 
(Rn00562224_m1) 
Ct 36.9 ± 1.3 34.8 ± 1.3 
RQ 1.79 ± 0.67 2.28 ± 0.16 Gnai1 
(guanine nucleotide 
binding protein, alpha i1) 
NM_013145 
(Rn00565716_m1) 
Ct 36.3 ± 0.91 35.9 ± 1.0 
RQ 1.40 ± 0.35 1.96 ± 0.19 Gnai2 
(guanine nucleotide 
binding protein, alpha i2) 
NM_031035 
(Rn00578973_g1) 
Ct 21.7 ± 0.73 21.2 ± 0.58 
RQ 1.13 ± 0.10 1.48 ± 0.39 Gnai3 
(guanine nucleotide 
binding protein, alpha i3) 
NM_013106 
(Rn00565387_m1) 
Ct 23.2 ± 0.15 24.0 ± 0.55 
RQ 2.31 ± 1.04 22.0 ± 1.09 Gnao 
(guanine nucleotide 
binding protein, alpha o) 
NM_017327 
(Rn00569089_m1) 
Ct 31.1 ± 0.67 29.0 ± 0.49 
Gene expression is reported by relative quantification (RQ) to demonstrate differences between 
cell types (differentiated versus undifferentiated for each gene), and cycle threshold (Ct) values to 
demonstrate general gene transcription activity (lower values indicate higher expression). Rodent 
GAPDH was used as control and demonstrated Ct values of ~ 16 in each experiment. Data 
reported as mean ± SEM and represent three different cell passages analyzed in triplicate for each 
gene (see Materials and methods). 
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DISCUSSION 
The establishment of specific clonal cells with desired phenotypes is recognized to 
be of general utility as a research tool. Model systems that mimic in situ events can be 
especially important in understanding drug mechanisms, and in novel drug discovery. 
Currently, there are relatively few models of dopamine neuronal functional, and the 
limitations associated with these models prompted the current study. Like the SN4741 
line, N27 cells were derived from the neuronal tracts of rodent embryos (mouse substantia 
nigra and rat mesencephalon, respectively), and this study evaluated the potential of N27 
cells as a model for studying D2 receptor regulation of dopaminergic function.  
After verifying certain dopaminergic characteristics of this line (e.g., the synthesis 
of dopamine and presence of dopamine transporters), we assessed dopamine receptor 
expression using radioreceptor methods. These data indicated that the wildtype N27 cells 
expressed neither D1-like nor D2-like receptors, the former result consistent with an 
earlier report (Adams et al., 1996). We then created a stable hD2L receptor-expressing 
N27 cell line, and verified receptor activity by studying the capability of D2 receptor 
agonists to inhibit the FSK-stimulated adenylate cyclase response. These studies revealed 
that D2 receptor agonists promoted the coupling of the transfected receptors to 
endogenous inhibitory G proteins to block FSK-induced adenylate cyclase activity. The 
intrinsic activity and potency of these compounds in this assay were similar to effects 
reported in other cell lines (Lawler et al., 1999; Burris et al., 2002; Gay et al., 2004). On 
the other hand, there were several unexpected results. Adams et al. (1996) reported both 
β- and α-adrenergic regulation of adenylate cyclase in N27 cells, whereas we found no 
effects from agonists for either receptor. The cause for this discrepancy is unclear, as the 
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only major technical difference was the use of a relatively selective type IV PDE inhibitor 
(RO20-1724) by Adams et al. (Adams et al., 1996), and our use of the nonselective PDE 
inhibitor IBMX.  
The potential of this cell line, however, resides in its potential as a model for 
studying D2 receptor-mediated regulation of dopaminergic function. The quantification of 
the release and turnover of dopamine and the other monoamines (Carlsson and Lindqvist, 
1963; Hertel et al., 1996; Westerink et al., 1998; Broderick and Piercey, 1998) would be 
important functions that are affected by centrally active drugs, often playing a role in 
therapeutic effects. A previous CNS-derived dopaminergic cell model (MN9D-D2L cell 
line) was found to be a useful model for studying receptor-mediated inhibition of 
dopamine release (O'Hara et al., 1996), and was employed to study the unique D2 receptor 
functional profile of DHX and N-propyl-DHX (Kilts et al., 2002). Issues of cell line 
stability, however, eventually limited the usefulness of this particular cell model for 
investigating this receptor functional endpoint (unpublished observations; personal 
communications from Dr. K. O’Malley). Thus, since N27 cells were reported to have TH 
activity and synthesize dopamine, we hypothesized that they would be an ideal model 
with which to study the effects of D2 ligands on dopamine release, especially in the 
context of known and potential functionally selective compounds.  
Unfortunately, the results from this present study indicate that the N27 cell line 
fails to release any detectable amounts of dopamine upon depolarization. The initial 
methodology for studying dopamine release utilized a radiometric method in which 
[3H]dopamine was preloaded into cells (Kilts et al., 2002). No uptake of [3H]dopamine 
from the media was found, making radiometric assessment of release impossible. In 
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retrospect, these findings were consistent with two previous studies in which investigators 
studying the mechanisms of dopamine transport and uptake in N27 cells, and reported a 
lack of endogenous functional DAT (Torres et al., 2001; Miranda et al., 2004). Thus, 
although endogenous expression of the DAT has been verified in N27 cells (previously by 
immunological techniques and in the current study by saturation isotherms), the protein is 
clearly not functional. It is interesting to speculate on whether this may be due to the local 
milieu (e.g., the absence of a specific sodium pump).  
Although the cells could not be preloaded with [3H]dopamine, we hypothesized 
that we could use a sensitive amperomeric technique that has the capability of measuring 
zeptomolar amounts of dopamine release (Hochstetler et al., 2000). This technique too 
failed to detect any dopamine release by the N27 cell line, regardless of the cell state 
(undifferentiated versus differentiated), the concentration of depolarizing K+ (10–100 
mM), or the specific physiological component (i.e., somatic versus neurite components). 
Although it is not clear why this cell line fails to take up or release dopamine, these 
results indicate that the N27 cell line is not an appropriate cell model for investigating D2 
receptor modulation of dopaminergic function. 
Cellular regulation of surface receptor expression and receptor turnover in 
response to agonist stimulation is another aspect of cell physiology that has been shown 
to be important to cell signaling and homeostasis. Indeed, typical antipsychotic drugs 
promote D2 receptor up-regulation (Silvestri et al., 2000), but some drugs with partial D2 
agonist activity [aripiprazole and (-)3PPP] fail to induce D2 receptor internalization as 
might be expected (Urban et al., 2006b). We hypothesized that investigating D2 receptor 
internalization within the confines of a dopaminergic model would help elucidate the 
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mechanisms underlying prior observations regarding atypical APD dopaminergic activity 
(Urban et al., 2006b). Our current study, however, suggests that the N27-D2L cell line is 
not an appropriate model with which to study these mechanisms. Epifluorescence 
microscopy, employing an anti-FLAG primary antibody and an appropriate secondary 
(Cy3 fluorophore-labeled) antibody, was used to study ligand-dependent D2 receptor 
internalization. The results indicate a high degree of basal receptor turnover in this 
particular model, however, and it was not possible to discern potential dopamine-induced 
receptor internalization versus constitutive turnover. Previous studies also have reported 
elevated levels of constitutive D2 receptor internalization in other cell models, a property 
not shared by analogous D1 receptor models (Vickery and von Zastrow, 1999; Vargas and 
von Zastrow, 2004; Ryman-Rasmussen et al., 2005), although it had not fully 
compromised the ability to measure agonist-dependent D2 receptor endocytosis (Vickery 
and von Zastrow, 1999; Urban et al., 2006b). 
Lastly, we employed Real-Time PCR to assess the RNA expression of genes 
associated with the reported dopaminergic traits of the N27 cell line, as well as those 
proteins involved in receptor activity transduction. Specifically, we assessed the impact 
of cell differentiation on these genes. We found that the TH and DAT genes, although 
more highly expressed in the differentiated cells, were overall expressed at fairly low 
levels (Table 5.2). This was surprising if viewed in the context of the overall dopamine 
levels and levels of DAT expression we and others have found (Prasad et al., 1994; 
Adams et al., 1996; Prasad et al., 1998). Together with the failure to detect many 
functions expected of dopamine neurons, the value of this line as a model of dopamine 
neurons is unclear. The N27 cells had many similarities with other lines regarding the 
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expression of certain inhibitory G proteins. For example, Gαi2 and Gαi3 are the most 
highly expressed of the inhibitory G protein isoform genes, with Gαo moderately 
expressed and Gαi1 barely detectable. These observations are similar to those made in the 
CHO cell line (Law et al., 1993b; Gettys et al., 1994). Since it has been established that 
receptor coupling to distinct G protein isoforms can be a ligand-dependent driven process 
thought to occur as a result of the specific receptor conformations induced by specific 
compounds, having a working knowledge of the endogenous G protein expression in any 
given cell line allows for a better understanding of the mechanics that underlie potential 
ligand-induced differential signaling. Similar to PC12 cells (Li et al., 1995), it was 
observed that the expression of the Gαo isoform is up-regulated upon N27 cell 
differentiation, possibly suggesting that Gαo may be especially important for signaling in 
differentiated cells. 
There is little doubt that available lines have provided elegant and detailed 
information regarding GPCR activation and signal transduction mechanisms, yet protein 
expression and activity can vary substantially among cell models (for examples see Law 
et al., 1993a; Murray et al., 1998; Hussain et al., 1999). From our perspective, there is 
still a need for an important and stable clonal line that has many of the important 
characteristics of dopamine neurons. As noted earlier, MN9D cells were exquisitely 
useful in mirroring many functions of dopamine neurons, and their lack of endogenous 
dopamine receptors allowed one to study the role of the D2-like receptors in a suitable 
host system (Swarzenski et al., 1994; Tang et al., 1994b; O'Hara et al., 1996; Zhen et al., 
2001; Kilts et al., 2002). Indeed, the MN9D line recapitulated to a surprising degree the 
in vivo D2 functional selectivity of dihydrexidine and N-norpropyldihydrexidine, two 
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novel dopamine agonists (Kilts et al., 2002). It is unfortunate that this line lost the 
phenotypic characteristics that made it so useful. Such problems are one reason that stable 
non-neuronal lines such as PC12 cells have been used to study D2 receptor-mediated 
effects on dopaminergic systems (Dwyer et al., 1999; Nair et al., 2003; Stonehouse and 
Jones, 2005), despite important limitations. The current data suggest to us that the utility 
of N27 cells in this regard is limited, and also suggest caution when this line is used for 
other types of dopaminergic research (Prasad et al., 1998; Kaul et al., 2005; Peng et al., 
2005). 
 
  
CHAPTER 6. SUMMARY AND FUTURE DIRECTIONS 
SUMMARY OF THESE DATA 
Dopaminergic pathways of the central nervous system have been shown to be 
integral to the modulation of many important functions. The work described in this 
dissertation has direct relevance to understanding the mechanisms of action of drugs that 
are important in the treatment of schizophrenia and Parkinson’s disease, two of the most 
important psychiatric and neurological disorders. The fundamental goal of my 
dissertation was to increase the understanding of dopamine D2 receptor-mediated 
mechanisms that are critical to the actions of all antipsychotic drugs, whether typical or 
atypical. A second goal was to validate a novel physiologically relevant cell model that 
would be useful in modeling the actions of drugs on dopamine neurons.  
My results demonstrate that the antipsychotic drug aripiprazole is unique in its 
interaction with the D2 receptor and in its capacity to signal through this receptor as 
compared to other atypical APDs and typical D2 receptor agonists. This supports the 
hypothesis that compounds with mixed functional attributes through a single receptor 
isoform (i.e., functionally selective receptor ligands) may have unique therapeutic utility. 
Discovering new drugs with novel signaling profiles at the D2 receptor would be 
markedly aided by a cell line capturing the phenotype of dopamine neurons. 
Unfortunately, my research suggests that despite its initial promise, the N27-D2L cell line 
will not have the required characteristics to fulfill the criteria for a useful cell model. 
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Though the latter results were discouraging, it is anticipated that this work will help focus 
future research and development into such models by removing one potential pitfall. 
Another objective of Chapter 3 was to determine if several structurally-diverse 
drugs proposed to be atypical antipsychotics were actually functionally selective D2 
ligands. Historically, characterizing the ability of a compound to elicit receptor activation 
has been limited to studying the regulation of a single functional endpoint (e.g. adenylate 
cyclase). In light of the more recent evidence that some compounds may have 
functionally selective pharmacology through a single receptor (see Chapter 2 for review), 
it was hypothesized that some of the atypicals might have such properties. For 
heterologous in vitro studies, I chose to use the CHO-D2L cell line. This line previously 
had been used for experiments examining D2-mediated functional changes in adenylate 
cyclase. For my purposes, I also needed to establish other functional assays, and 
eventually developed experiments to measure D2-mediated phosphorylation of mitogen-
activating protein (MAP) kinase and the potentiation of arachidonic acid (AA) release, 
thus providing the needed tools for my research. 
As a group, the atypical APDs generally failed to provide any evidence of D2 
receptor stimulation, an observation consistent with prior reports that described their D2 
function as antagonistic. Aripiprazole was unique in this aspect since it demonstrated 
moderate intrinsic activity for both MAP kinase phosphorylation and AA release, 
observations that were consistent with previous reports on its capacity to inhibit adenylate 
cyclase through the D2 receptor (Lawler et al., 1999; Burris et al., 2002). What was 
interesting was that although aripiprazole showed similar partial intrinsic activities 
between the three functional endpoints, this compound was considerably less potent for 
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the activation of the MAP kinase pathway than either AA release or cyclase inhibition. 
This was in stark contrast to the consistent potencies observed with the typical full 
(quinpirole) and partial D2 (3PPP) agonists that were used as controls in the experiments. 
Previous studies have demonstrated D2 receptor functionally selective attributes for 
aripiprazole (Lawler et al., 1999; Shapiro et al., 2003), thus my data further support the 
notion that the unique pharmacology of this novel atypical APD may be in part 
responsible for its favorable clinical profile. 
Another function I investigated was ligand-induced internalization. Recent studies 
have shown that this is a ligand-dependent process that is likely driven by the 
conformational changes that are unique to each receptor-ligand unit, regardless of the 
intrinsic efficacy that had been associated with the ligand (Berry et al., 1996; Whistler et 
al., 1999; Ryman-Rasmussen et al., 2005). I observed that both aripiprazole and 3PPP fail 
to induce D2 receptor internalization in the HEK-hD2L cell model. Although the use of a 
non-neuronal line prevents direct extrapolation to the brain, these data provide additional 
evidence for the functionally selective properties of aripiprazole.  
The present data provide further evidence of the unique D2 receptor pharmacology 
of aripiprazole and highlight some of the differences between aripiprazole and other 
typical D2 partial agonists. Understanding how aripiprazole and other functionally 
selective ligands promote the specific activation of receptor pathways is imperative to the 
efficiency of future rational drug design and development. Indeed, prior studies have 
examined the repercussions of removing the active substituents of certain amino acids 
within the D2 receptor structure on D2 agonist activity, and have illustrated the 
significance of three particular serines within the putative receptor binding pocket (Cox et 
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al., 1992; Javitch et al., 1995a; Woodward et al., 1996; Wiens et al., 1998). It was within 
this framework that the specifics of the interactions between aripiprazole and these amino 
acids known to affect dopaminergic ligand activity within the D2 receptor pharmacophore 
became an important avenue of study.  
A group of serines within the fifth transmembrane helix (TM5) of adrenergic and 
dopaminergic receptors are required for binding and function of many agonist ligands 
(Cox et al., 1992; Javitch et al., 1995a; Woodward et al., 1996; Wiens et al., 1998). The 
experiments reported in Chapter 4 demonstrate the differential effect resulting from single 
point mutations of these three serines, S5.42A, S5.43A, and S5.46A, on the binding and 
function of aripiprazole and two typical D2 partial agonists, terguride and (-)3PPP. Aside 
from one exception, each point mutation resulted in a dramatic increase in intrinsic 
activity of the inhibition of adenylate cyclase for all three compounds (relative to the wild 
type D2 receptor activity). These observations provide insight into the receptor-ligand 
relationship shared by these low intrinsic activity compounds. The results suggest that 
these serines prevent the induction of ligand-receptor conformations that can efficiently 
couple to the inhibitory G proteins responsible for moderating cyclase activity. The 
exception was that the S5.42A mutant had the opposite effect on (-)3PPP at this effector, 
significantly decreasing (-)3PPP activity for cyclase inhibition. This exception, however, 
proved to be a consistent observation with all functional endpoints (including MAP 
kinase and AA release) examined for (-)3PPP in the presence of the S5.42A mutant. 
Combined with binding data that illustrate a loss of apparent affinity for the D2 in the 
presence of the S5.42A mutation, it is clear that this serine is required for all aspects of 
(-)3PPP pharmacology assessed in this study. 
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Overall, two other significant trends were observed in these mutational studies. 
First, D2 receptor-mediated MAP kinase phosphorylation was adversely affected by all 
three mutants for both terguride and (-)3PPP, as evidenced from either a decrease in 
intrinsic activity and/or a loss of ligand potency. This suggests that these serines are 
integral to the overall MAP kinase effector for the ligand-specific receptor conformations 
produced by both terguride and 3PPP; however it can not be determined from these 
studies alone whether or not a combination of these mutants would be enough to fully 
abrogate MAP kinase function. The second general observation made from these studies 
was that, aside from the increase in intrinsic activity for cyclase inhibition, the overall D2 
receptor pharmacology of aripiprazole is not affected by these three serine mutants. These 
data imply that at least no single one of these serines is required for the maintenance of 
D2 binding and activation of aripiprazole. This is not enough to elucidate the molecular 
interactions responsible for producing a functionally selective response through the D2 
receptor, however, as other D2 functionally selective compounds have been shown to be 
affected by these mutations [e.g. dihydrexidine (Wiens et al., 1998; Fowler et al., 2006c) 
and dinapsoline (Fowler et al., 2006c)]. Together, these studies support the idea that a 
receptor conformation resulting from the binding of a particular ligand will be unique to 
that compound. Subtle differences in ligand structure can lead to seemingly subtle 
changes in receptor conformation that can have differential physiological consequences. 
The present aripiprazole data suggest that one characteristic that may be desirable in 
future APDs is a limited D2 receptor functional profile that does not require an interaction 
with these specific receptor serines. 
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Although the CHO-hD2L cell line is an acceptable model for studying ligand-
specific functional differences in basic receptor-mediated biochemical responses, it fails 
to provide a platform with which to gain insight into the dopaminergically-related 
functions that are known to be affected by many psychotropic drugs. Therefore, a suitable 
dopaminergic cell model would be of great utility to study the effects of typical and 
unique APDs alike in order to elucidate possible physiologically relevant differences in 
their mechanisms of action. The work reported in Chapter 5 assesses the potential of the 
N27-hD2L cell line as a suitable model for such investigations. We were able to confirm 
previous reports that described certain dopaminergic characteristics of this cell line, such 
as the presence of dopamine and endogenous expression of dopamine transporter. After 
verifying the absence of any dopamine receptor expression, we established a stable N27-
hD2L transfectant and proved the functionality of the transfected receptor by studying its 
ability to inhibit endogenous adenylate cyclase. Unfortunately, the promise of measurable 
dopaminergic endpoints (such as D2 receptor-mediated inhibition of cellular dopamine 
release) was not realized using the diverse methodologies employed for this study.  
Whereas some aspects of N27 characterization were heuristically interesting (e.g. 
elevated Gαo isoform expression in differentiated versus undifferentiated N27 cells), the 
work reported in Chapter 5 illustrates some of the deficiencies that the field of 
dopaminergic research must deal with and overcome. Another dopaminergic cell line 
discussed in Chapter 5 as a potentially suitable model for these investigations (due in part 
to its origin from murine substantia nigra) is the SN4741 line (Son et al., 1999). Newer 
cell lines will certainly be developed as techniques in molecular biology become more 
advanced. The hope is that the present work will allow others to focus on alternate 
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potential models like the SN4741 without wasting valuable time or resources on the N27 
cell line. 
In summary, the present data provide further biochemical evidence for the unique 
D2 receptor pharmacology of aripiprazole, and an initial insight into the ligand-receptor 
molecular interactions that are responsible for its distinct D2 binding and functional 
profile. It is clear that aripiprazole is more than just a typical D2 partial agonist, and this 
drug appears to interact with the D2 receptor independent of the three TM5 serines 
thought to be integral to general receptor binding and activity. It is evident from this work 
that the employment of a number of diverse strategies will be necessary to more fully 
appreciate the molecular, biochemical, and physiological dimensions of atypical 
psychotropic drug activity. 
FUTURE DIRECTIONS 
The hypothesis central to this investigation is that drug-receptor interactions result 
in receptor conformations unique to each ligand, and in certain instances can produce an 
outcome in which receptor-coupled effectors are selectively activated instead of 
activating all or none of the functions as proposed by classic pharmacology. The major 
conclusions that can be drawn from this study are that 1) the D2 functionally selective 
profile of aripiprazole can be extended to its MAP kinase activity and possibly its 
inactivity regarding D2 receptor internalization, 2) D2 partial agonists interact with D2 
receptor TM5 serines differentially, supporting the overall idea that the species of ligand-
induced receptor conformational changes are unique to each compound regardless of 
activity, 3) the S5.42A, S5.43A, and S5.46A receptor mutations generally alleviate the 
restrictions on the cyclase intrinsic activities of the partial agonists studied, and 4) the 
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N27-D2L cell line is not an ideal model for investigating the D2 dopaminergic functional 
profile of functionally selective compounds. These conclusions raise a number of 
questions, though, the answers to which might be discovered through a number of diverse 
approaches. 
The proximal event responsible for activating many of the signaling pathways 
coupled to GPCRs is the binding and activation of a group of heterotrimeric guanine 
nucleotide binding proteins (G proteins). It has been hypothesized that for functional 
selectivity to occur, the differential or exclusive activation of a subset of the overall pool 
G proteins located within the proximity of the ligand-receptor complex is required 
(Mailman and Gay, 2004). A typical agonist is thought to promote a receptor 
conformation that is amenable to the activation of a number of analogous G protein 
isoforms; conversely, for a functionally selective compound to “select” among effectors it 
is necessary to induce a receptor conformation that only one or a few of those isoforms 
can regulate. The idea that a G protein isoform is either able (or unable) to perform in the 
same manner as an analogous G protein (e.g., Gαi1 versus Gαi2) has been demonstrated for 
functions such as the inhibition of adenylate cyclase (Watts et al., 1998) and GIRK 
channel activation (Leaney and Tinker, 2000). Although many of these observations are 
cell line specific, they still provide insight into ligand-dependent formation of 
conformationally-specific receptor-G protein complexes. 
There are a number of strategies that have been performed or proposed for 
studying these phenomena. Cordeaux et al., (2001) utilized reconstitution experiments, in 
combination with [35S]GTPγS binding, to demonstrate in the SF21 cell line that certain D2 
receptor agonists are able to activate specific G isoforms, whereas others are not. Most of 
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the downstream effects of GPCRs that couple to inhibitory G proteins (such as D2 
receptors) are mediated by Gαi/o proteins. These G protein isoforms contain a cysteine 
residue proximal to the C terminus that is sensitive to ADP-ribosylation by pertussis toxin 
(PTX), an action that uncouples G protein-GPCR interaction and thus prevents GPCR-
mediated activation of effectors regulated by these G proteins (Jones and Reed, 1987; 
Carty, 1994). The availability of PTX-resistant Gαi/o isoforms has allowed researchers to 
study and identify the specific G protein isoforms responsible for regulating certain 
functional pathways (Watts et al., 1998; Leaney and Tinker, 2000; Liu et al., 2003; Wu 
and Wong, 2005). This research can be extended to investigating the preferential D2L-G 
protein interactions that are hypothesized by functional selectivity to be ligand-
dependent. Another strategy is to use G protein specific antibodies in co-
immunoprecipitation experiments to parse out the specific G protein isoforms activated in 
[35S]GTPγS binding assays, for example, as applied to the D2L receptor (Gay et al., 2006). 
This method, however, relies on the availability of antibodies specific to every isoform, a 
deficiency that limits the projected outcomes of such studies. Yet another approach to 
solving this problem includes utilizing a more recent technology known as RNA 
interference (RNAi). This approach exploits the cellular process of targeted post-
transcription gene silencing by introducing short, double-stranded RNA sequences that 
are homologous to the transcription product of the gene of interest (see Hammond et al., 
2001 for review). Although use of this technology is on the rise, its application to study 
GPCR signaling is more limited (for examples, see Hislop et al., 2004; Kelley et al., 
2006). RNAi methodologies offer some exciting opportunities in this regard, however, as 
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this presents a possible strategy for elucidating the role of different βγ heterodimers in 
ligand-induced differential signaling (Jones et al., 2004). 
Another question raised in this work concerns the matter of low intrinsic activity 
D2 agonists and receptor internalization. Our studies indicate that both aripiprazole and 
the typical partial agonist (-)3PPP fail to promote D2 receptor internalization. Whether 
this is an attribute specific to these two ligands or rather a characteristic common among 
all low intrinsic activity D2 receptor ligands remains to be seen. Furthermore, there are 
recent reports that indicate novel signaling pathways associated with GPCR activation 
that are independent of G protein activation. For example, it has been illustrated that 
activation of β2 adrenergic and parathyroid receptors initiates phosphorylation of Erk 1/2 
kinases by two distinct mechanisms: a rapid transient mechanism moderated by G 
proteins, as well as a more sustained B-arrestin-dependent pathway that has a more 
gradual onset (Gesty-Palmer et al., 2006; Shenoy et al., 2006). Moreover, there is 
evidence that GPCRs play a role in the compartmentalization of certain Erk 1/2 activity 
by moderating the formation of “signalsomes” that function as scaffolds for Erk 1/2 
kinases (Luttrell, 2005; Jafri et al., 2006). These observations add an extra dimension of 
complexity to the MAP kinase pathway experiments conducted in the present study. 
Further investigation may help resolve the unique MAP kinase and internalization 
functional profile of aripiprazole. 
Finally, my serine mutation studies demonstrate how one small aspect of the D2 
receptor pharmacophore can be responsible (or not) for regulating ligand specific 
conformational changes and signaling. The data that I have provided in Chapter 4 now 
provides additional leads for exploring these critical issues. The target residues of 
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particular importance include F3.28, V3.33, F6.51, H6.55, Y7.35, T7.39, and Y7.43, all 
of which may affect the actions of one or more of the partial/functionally selective 
agonists that I have studied. In addition, a body of work over the past decade, has shown 
which amino acid residues of the D2 receptor binding pocket may be accessible to water, 
and therefore candidates for ligand interaction  (Javitch et al., 1995b). Interestingly, one 
of the amino acids this research excluded as being accessible was a threonine in the third 
transmembrane helix (T3.37). We have previously hypothesized that this threonine might 
be involved in stabilizing the binding of a number of probe ligands (Fowler et al., 2006b), 
and demonstrated that loss of this amino acid reduces the affinity of a number of ligands, 
and selectively abolishes their activity. Indeed, (-)3PPP lost all activity at the T3.37A 
mutant receptor. Based on the differences between prototypical partial agonists and the 
functionally selective drug aripiprazole that I found, the examination of T3.37A would be 
another potentially fruitful future direction.  
The concept of functional selectivity is now realized in a pharmacotherapeutically 
relevant compound aripiprazole, the prototype of a new generation of atypical APDs. In 
fact, it appears that aripiprazole will soon be accompanied by another atypical APD, 
bifeprunox, which is also reported to have partial D2 and 5-HT1A receptor activity (Bruins 
Slot et al., 2006). It will be interesting to see whether bifeprunox demonstrates the same 
efficacy and low propensity for side effects that has made aripiprazole an effective 
antipsychotic, and whether or not this compound also displays a functionally selective 
profile (Bardin et al., 2006). Regardless, the very idea of functional selectivity adds 
another layer of complexity to receptor pharmacology that is certain to affect a wide 
range of scientific arenas, from drug classification to re-evaluating the approaches taken 
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by industry when developing novel therapies (reviewed in Urban et al., 2006a). At the 
very least, compounds that are known to be functionally selective are themselves 
diagnostic tools that can be used by basic science to probe receptor pharmacophores in 
order to elucidate the chemical moieties that underlie the selective activation of specific 
pathways. By using these tools to study the therapeutic and side effects associated with 
activating one set of effectors over another, it will be possible to focus the efforts of drug 
development in order to generate novel therapeutics with enhanced efficacy and reduced 
adverse side effects. 
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